{"meta":{"query_hash":"dedd6f837dfb","filters":{"venue":"Hematological Oncology"},"cohort_total":189,"direct_labels_cover":0,"predictions_cover":189,"exported":189,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/dedd6f837dfb","api":"https://metacan.xera.ac/api/v1/cohort?venue=Hematological+Oncology"},"results":[{"id":"W1509594523","doi":"10.1002/hon.2165","title":"Use of non‐steroidal anti‐inflammatory drugs and risk of non‐Hodgkin lymphoma: a systematic review and meta‐analysis","year":2014,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Manitoba Health; Winnipeg Regional Health Authority","funders":"ExxonMobil Research and Engineering Company","keywords":"Medicine; Internal medicine; Odds ratio; Follicular lymphoma; Lymphoma; Epidemiology; Confidence interval; Meta-analysis; Oncology; Aspirin; Chronic lymphocytic leukemia; Relative risk; Leukemia","score_opus":0.060194367901718906,"score_gpt":0.35641511288956,"score_spread":0.2962207449878411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1509594523","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022873632,0.9934491,0.000027874346,0.000092633716,0.000030698437,0.003840973,0.00010606198,0.000024367262,0.00014092981],"genre_scores_gemma":[0.003658242,0.99385357,0.0010888434,0.00024450466,0.000014777044,0.0009807501,0.000057094214,0.00003387045,0.00006834994],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99427176,0.0014482394,0.0027649263,0.00079591054,0.00034553136,0.00037365488],"domain_scores_gemma":[0.99185616,0.0036632936,0.0030620175,0.0009149027,0.0001994728,0.0003041571],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0012183061,0.00076636364,0.026192414,0.00040510835,0.000055391505,0.0000146102675,0.0001877227,0.00088098424,0.0001021106],"category_scores_gemma":[0.00067233894,0.00040278665,0.0027660714,0.0005322049,0.00046345897,0.00005169186,0.00025275344,0.00021064274,0.00002204334],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017322502,0.00074254395,0.000858744,0.85194194,0.13809451,0.000260894,0.00003933963,1.17564525e-7,2.2457287e-7,0.00012621317,0.00013503445,0.007783086],"study_design_scores_gemma":[0.0010985673,0.00079856446,0.0004635251,0.04402433,0.9344133,0.0013006834,0.000012826855,0.000018675806,0.000004627309,0.000008215974,0.017551277,0.00030537948],"about_ca_topic_score_codex":0.000073129886,"about_ca_topic_score_gemma":0.000015467169,"teacher_disagreement_score":0.80791765,"about_ca_system_score_codex":0.00014421756,"about_ca_system_score_gemma":0.0002689379,"threshold_uncertainty_score":0.9998424},"labels":[],"label_agreement":null},{"id":"W1948948104","doi":"10.1002/hon.2176","title":"Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada","year":2014,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Université de Montréal","funders":"Lundbeck Canada","keywords":"Medicine; Arsenic trioxide; Adverse effect; Internal medicine; Cost effectiveness; Quality-adjusted life year; Cost-effectiveness analysis","score_opus":0.023086801594294836,"score_gpt":0.30402236607896094,"score_spread":0.2809355644846661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1948948104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748623,0.00056504575,0.0003923069,0.00009525766,0.000108644264,0.0005564572,0.000012944652,0.0000027486249,0.0007803829],"genre_scores_gemma":[0.9983923,0.00021615984,0.0009276362,0.000044354943,0.000042122454,0.00026946605,0.00006646011,0.000008781579,0.00003274422],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876624,0.0001819188,0.0004633513,0.0002838916,0.000097892516,0.00020672005],"domain_scores_gemma":[0.99918824,0.00020686124,0.00025269776,0.00020937981,0.000094203526,0.000048617923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033765726,0.0001325519,0.0005063216,0.000031644144,0.000016517406,0.0000016960106,0.00013517606,0.00020713189,0.000026972868],"category_scores_gemma":[0.00026420693,0.00010560268,0.00009228302,0.0000409412,0.000082980514,0.0000021320093,0.000025873043,0.000029580908,0.000001160318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030631393,0.0015772806,0.1091313,0.00063286,0.0007445678,0.00006349708,0.0002927086,0.009860635,0.7092374,0.005011696,0.0023032126,0.1580817],"study_design_scores_gemma":[0.009302307,0.0042239903,0.0046624327,0.000023853865,0.00024620665,0.00007532271,0.0001534497,0.006128554,0.96174043,0.0014919924,0.011697783,0.00025367827],"about_ca_topic_score_codex":0.014911932,"about_ca_topic_score_gemma":0.16420439,"teacher_disagreement_score":0.252503,"about_ca_system_score_codex":0.00063757773,"about_ca_system_score_gemma":0.0030008503,"threshold_uncertainty_score":0.99164784},"labels":[],"label_agreement":null},{"id":"W1958260647","doi":"10.1002/hon.2160","title":"PARP1 expression in mantle cell lymphoma: the utility of PARP1 immunohistochemistry and its relationship with markers of DNA damage","year":2014,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"PARP1; DNA damage; Cancer research; Biomarker; Immunohistochemistry; Poly ADP ribose polymerase; DNA repair; Biology; Real-time polymerase chain reaction; Medicine; Mantle cell lymphoma; Lymphoma; Pathology; Gene; DNA; Polymerase; Genetics","score_opus":0.030124478932331607,"score_gpt":0.3228460020073416,"score_spread":0.29272152307501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1958260647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97572786,0.0006351633,0.0001868477,0.0006904491,0.000028685034,0.00029299723,0.0000048500415,0.00001651816,0.02241661],"genre_scores_gemma":[0.99873084,0.000053570908,0.00087125564,0.00016554672,0.000012050346,0.000058162663,0.000007834885,0.000007553152,0.00009317342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987635,0.00027150582,0.00042317752,0.00022419417,0.00015224951,0.00016538185],"domain_scores_gemma":[0.99829817,0.0010118148,0.00027022895,0.0002891305,0.000069405505,0.00006123919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005276814,0.00011694955,0.0004890785,0.000038510156,0.00004323726,0.0000015885681,0.00009833421,0.00023743136,0.00023041024],"category_scores_gemma":[0.000248334,0.00006957994,0.000045290224,0.00013869927,0.00043544587,0.00002812287,0.000049462076,0.00018211135,0.000003052691],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010557313,0.002884115,0.39625615,0.001583247,0.00005511147,0.0001297438,0.00097187376,0.000006720579,0.578463,0.0034849271,0.0037976468,0.001810114],"study_design_scores_gemma":[0.009999303,0.0014367178,0.45256743,0.00039091718,0.000065014836,0.00035426326,0.0006006194,0.0006995248,0.52928126,0.0019133613,0.002507103,0.00018445111],"about_ca_topic_score_codex":0.000006426113,"about_ca_topic_score_gemma":0.0000024209685,"teacher_disagreement_score":0.056311294,"about_ca_system_score_codex":0.00005693084,"about_ca_system_score_gemma":0.00009806653,"threshold_uncertainty_score":0.28373876},"labels":[],"label_agreement":null},{"id":"W2002534044","doi":"10.1002/hon.743","title":"Radiation therapy for localized low-grade non-Hodgkin's lymphomas","year":2005,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Lymphoma; Medicine; MALT lymphoma; Radiation therapy; Follicular lymphoma; Helicobacter pylori; Marginal zone; Gastric lymphoma; Mucosa-associated lymphoid tissue; Stage (stratigraphy); Non-Hodgkin's lymphoma; Gastroenterology; Disease; Internal medicine; Pathology; Oncology; B cell; Immunology; Biology; Antibody","score_opus":0.08553989961677713,"score_gpt":0.42155492979817444,"score_spread":0.33601503018139733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002534044","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011039689,0.9908996,0.00012682733,0.0009797504,0.0004405929,0.0049044797,0.000046892084,0.00015281541,0.0023386031],"genre_scores_gemma":[0.00029841694,0.98909867,0.0027347319,0.0015472148,0.0006792368,0.0045362194,0.0007112319,0.000076308876,0.00031799581],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967795,0.00025873145,0.0011662381,0.00087072933,0.0002526442,0.0006721448],"domain_scores_gemma":[0.99669164,0.0017148367,0.00063370203,0.0005283505,0.00009241959,0.00033902295],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000299667,0.00072688056,0.0051061613,0.00020507303,0.0001197545,0.000022499331,0.00022649033,0.001735443,0.00054245105],"category_scores_gemma":[0.00019425261,0.0004336388,0.0015440027,0.00027091365,0.00017675929,0.00003890874,0.00006113255,0.00024856676,0.00040896854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021960484,0.003060925,0.000089415524,0.0029801496,0.00057378015,0.00045136397,0.000019679674,2.0428345e-7,2.8899362e-7,0.0018155595,0.010059547,0.98072946],"study_design_scores_gemma":[0.00974141,0.0026539096,0.0000917799,0.0018664214,0.0014210459,0.0018815001,0.000005854874,0.00002727802,0.00001769158,0.0001453359,0.98175555,0.00039222513],"about_ca_topic_score_codex":0.000010562206,"about_ca_topic_score_gemma":0.0000033383974,"teacher_disagreement_score":0.98033726,"about_ca_system_score_codex":0.0013770374,"about_ca_system_score_gemma":0.0011260158,"threshold_uncertainty_score":0.99981153},"labels":[],"label_agreement":null},{"id":"W2029325184","doi":"10.1002/hon.930","title":"Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program","year":2009,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Epidemiology; Incidence (geometry); Lymphoma; Chronic lymphocytic leukemia; Cohort; Multiple myeloma; Internal medicine; Surveillance, Epidemiology, and End Results; Oncology; Cancer; Demography; Leukemia; Cancer registry","score_opus":0.09203680189599868,"score_gpt":0.44985943269434053,"score_spread":0.35782263079834187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029325184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8137352,0.0007729262,0.000010813843,0.17870688,0.00014363547,0.0053682644,0.00002283661,0.000063991436,0.0011754588],"genre_scores_gemma":[0.9693423,0.00013259472,0.0016109686,0.027173366,0.00005227571,0.0015750987,0.00003875399,0.0000068068434,0.00006783278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967832,0.0010263704,0.0008471515,0.0005323464,0.00016139317,0.00064951694],"domain_scores_gemma":[0.9937445,0.0053546727,0.0002248802,0.00042418943,0.00006579049,0.00018596029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002441444,0.00025234005,0.0014724126,0.00006983185,0.00019315815,0.000014285995,0.00021105775,0.00016191068,0.000010295379],"category_scores_gemma":[0.0022003138,0.000107610795,0.00012608095,0.00022809848,0.00018433819,0.000017918397,0.000050906234,0.0001302609,0.00001828771],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013694428,0.007173019,0.9271225,0.000019949433,0.00007494946,0.00025845377,0.002081151,0.0000065575923,0.0000014217547,0.008471863,0.011281189,0.04213951],"study_design_scores_gemma":[0.007415847,0.01515152,0.92055935,0.000021498567,0.00003681022,0.00084317,0.0022072627,0.000037289166,0.0000042623906,0.0009058878,0.052711993,0.00010508826],"about_ca_topic_score_codex":0.00024171919,"about_ca_topic_score_gemma":0.0012814427,"teacher_disagreement_score":0.15560712,"about_ca_system_score_codex":0.0002153503,"about_ca_system_score_gemma":0.00019133162,"threshold_uncertainty_score":0.4388241},"labels":[],"label_agreement":null},{"id":"W2031242160","doi":"10.1002/hon.902","title":"Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy","year":2009,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Gastroenterology; Splenectomy; White blood cell; Blood transfusion; Anemia; Surgery; Bone marrow","score_opus":0.015490967396035928,"score_gpt":0.257920360962542,"score_spread":0.24242939356650609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031242160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99009156,0.00024928502,0.00008906368,0.0021429926,0.00008206262,0.001439297,0.0000045850497,0.00007093245,0.0058302376],"genre_scores_gemma":[0.99526995,0.0008115855,0.002738675,0.00080648216,0.000037149417,0.0001389464,0.00011822652,0.000017249304,0.00006173744],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980072,0.00023836517,0.00050570536,0.0005502768,0.00029879084,0.0003996623],"domain_scores_gemma":[0.9990547,0.00029371708,0.00017059989,0.00021885677,0.000104316445,0.00015784317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002237349,0.00029241535,0.0008420448,0.00011133253,0.00008956063,0.000012576143,0.00007606205,0.0003836583,0.00021734608],"category_scores_gemma":[0.000049411952,0.00018534808,0.000095389434,0.00021150439,0.00005497098,0.000081410675,0.00001864085,0.00032451493,0.00001031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003773834,0.009755543,0.94459224,0.000050912065,0.000047252168,0.00020900134,0.00031149935,0.000008308778,0.017486598,0.00012504679,0.000031271138,0.023608517],"study_design_scores_gemma":[0.016861267,0.011667659,0.9525262,0.00007779795,0.00009097637,0.00004584302,0.000036471938,0.00003827144,0.018177487,0.00008801003,0.0001812794,0.00020874394],"about_ca_topic_score_codex":0.000026332524,"about_ca_topic_score_gemma":0.000081360384,"teacher_disagreement_score":0.023399772,"about_ca_system_score_codex":0.00026674298,"about_ca_system_score_gemma":0.00011200158,"threshold_uncertainty_score":0.75582755},"labels":[],"label_agreement":null},{"id":"W2046069452","doi":"10.1002/hon.931","title":"The clinical relevance of <i>Wilms Tumour 1</i> (<i>WT1</i>) gene mutations in acute leukaemia","year":2009,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre","funders":"Medical Research Council; Research Councils UK; Cancer Research UK","keywords":"Wilms' tumor; Clinical significance; Oncology; Mutation; Karyotype; Medicine; Internal medicine; Gene; Gene mutation; Wilms tumour; Cancer research; Biology; Genetics; Chromosome","score_opus":0.04421241951846455,"score_gpt":0.392970906873712,"score_spread":0.34875848735524745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046069452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011339693,0.99510986,0.000067108725,0.00027802802,0.00044869076,0.0005967593,0.000027695589,0.00001564112,0.0023222486],"genre_scores_gemma":[0.00054105435,0.9973795,0.0007583721,0.00030105512,0.00017774785,0.0001341323,0.00017205584,0.000026753607,0.00050937664],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962163,0.0007647361,0.0017009255,0.00067145476,0.00016031954,0.00048626968],"domain_scores_gemma":[0.9977696,0.00064361526,0.0008720825,0.0004911319,0.00008949927,0.00013406595],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00068103353,0.00039677668,0.0020379485,0.00005867814,0.00010118899,0.000010937266,0.00068225147,0.001835701,0.000009320338],"category_scores_gemma":[0.00047465877,0.0002224733,0.0008307226,0.0003094219,0.00065679976,0.0000027057317,0.00018490946,0.000983879,0.0000386928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016474657,0.00033635268,0.000035880224,0.00065358495,0.0004381294,0.00039378722,0.0000075147846,0.000018189801,0.00028627345,0.00097455137,0.007219453,0.98947155],"study_design_scores_gemma":[0.00050598884,0.00094355625,0.000022247865,0.00067189266,0.0003711071,0.000892821,0.000007823153,0.0000028768889,0.0002801024,0.0005201635,0.99550754,0.0002739068],"about_ca_topic_score_codex":0.000004372503,"about_ca_topic_score_gemma":0.000032025666,"teacher_disagreement_score":0.9891976,"about_ca_system_score_codex":0.000082861356,"about_ca_system_score_gemma":0.000894868,"threshold_uncertainty_score":0.9994601},"labels":[],"label_agreement":null},{"id":"W2073588844","doi":"10.1002/hon.935","title":"Vav‐1 expression correlates with NFκB activation and CD40‐mediated cell death in diffuse large B‐cell lymphoma cell lines","year":2010,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University and Génome Québec Innovation Centre; Jewish General Hospital","funders":"","keywords":"Germinal center; Diffuse large B-cell lymphoma; Cancer research; Lymphoma; CD40; B cell; Biology; Gene expression profiling; Cell; Cell culture; Gene expression; Immunology; Antibody; Gene; Cytotoxic T cell; In vitro; Genetics","score_opus":0.013925940525976614,"score_gpt":0.2678761809839723,"score_spread":0.2539502404579957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073588844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917353,0.00026820856,0.00004234242,0.0006682891,0.00013174379,0.00054928806,0.000007150186,0.00009509339,0.0065026334],"genre_scores_gemma":[0.99640656,0.00022254983,0.0021661539,0.00070736767,0.00005876927,0.00013523657,0.000088969246,0.000024028932,0.00019035907],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984133,0.0001275831,0.00037415038,0.0004840787,0.00017303276,0.00042782963],"domain_scores_gemma":[0.99840796,0.0008313989,0.00019749823,0.00024926057,0.00006584527,0.00024805396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016811576,0.0002821496,0.0006597199,0.00011976823,0.00009085018,0.000016171649,0.00008243069,0.0005313401,0.00012684459],"category_scores_gemma":[0.00011166977,0.00016834607,0.00006111809,0.00015642485,0.00010786833,0.000077281235,0.00009672613,0.00026684406,0.000085798885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009099177,0.028853247,0.89328665,0.00015263101,0.000017464994,0.0020096123,0.00039945042,9.22028e-7,0.07232915,0.00031030006,0.00070392946,0.0010267119],"study_design_scores_gemma":[0.06708867,0.0030438004,0.5843744,0.00017043465,0.00015244549,0.0007071778,0.00035541173,0.00053017994,0.33457348,0.00021476996,0.008368769,0.0004204123],"about_ca_topic_score_codex":0.000035406356,"about_ca_topic_score_gemma":0.00006182064,"teacher_disagreement_score":0.30891222,"about_ca_system_score_codex":0.00011307865,"about_ca_system_score_gemma":0.00011814129,"threshold_uncertainty_score":0.68649536},"labels":[],"label_agreement":null},{"id":"W2090544453","doi":"10.1002/hon.890","title":"Involved field radiotherapy for limited stage Hodgkin lymphoma: balancing treatment efficacy against long‐term toxicities","year":2009,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Lymphoma; Stage (stratigraphy); Disease; Hodgkin lymphoma; Chemotherapy; Oncology; Modality (human–computer interaction); Intensive care medicine; Internal medicine","score_opus":0.09884274014293155,"score_gpt":0.3997563416836778,"score_spread":0.30091360154074626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090544453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005509829,0.98603505,0.00013611058,0.000832809,0.0003826326,0.0051160585,0.0000880038,0.0002802539,0.001619237],"genre_scores_gemma":[0.0009823911,0.9895456,0.0023958096,0.0026112592,0.00045516284,0.002011988,0.00089703465,0.00008255178,0.0010182066],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960616,0.00034193305,0.0013506269,0.0010687275,0.00025308153,0.0009239976],"domain_scores_gemma":[0.9945506,0.0035207325,0.00067544426,0.0007449833,0.0000891986,0.00041904455],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00021445144,0.00108534,0.0063726143,0.0002912041,0.00017962007,0.00004971334,0.00026507693,0.0016817063,0.00019198406],"category_scores_gemma":[0.00029106022,0.00065784185,0.0018438306,0.00026461025,0.00012804472,0.000043657645,0.000059060145,0.00021042948,0.000054297074],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044475286,0.006189518,0.00064846757,0.0038656553,0.0013787543,0.0028998163,0.00008401387,4.0623027e-7,0.0000021211943,0.0005066705,0.0021595692,0.9818202],"study_design_scores_gemma":[0.0126491925,0.013916964,0.00069783814,0.004841729,0.002314438,0.00076156325,0.00003377069,0.000012330545,0.000087007094,0.000019037947,0.96405196,0.0006141817],"about_ca_topic_score_codex":0.000017352926,"about_ca_topic_score_gemma":0.000034542398,"teacher_disagreement_score":0.98120606,"about_ca_system_score_codex":0.0032575647,"about_ca_system_score_gemma":0.001028571,"threshold_uncertainty_score":0.9996143},"labels":[],"label_agreement":null},{"id":"W2107886618","doi":"10.1002/hon.2048","title":"Successful treatment of non‐Hodgkin lymphoma associated immune thrombocytopenia with involved field radiotherapy","year":2013,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Thrombocytopenic purpura; Immune system; Chemotherapy; Radiation therapy; Immunology; Antibody; clone (Java method); Oncology; Internal medicine; Biology","score_opus":0.022743525150738575,"score_gpt":0.3064587636854287,"score_spread":0.2837152385346901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107886618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881282,0.0011885758,0.00005609021,0.004325492,0.00008307535,0.0012114636,0.0000043707496,0.0000741931,0.004928582],"genre_scores_gemma":[0.9946887,0.00078397465,0.0027059098,0.00095054973,0.000035818684,0.0005280031,0.0000389176,0.000020246149,0.00024790602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983523,0.00012493001,0.00053016364,0.00037714932,0.00020455441,0.0004108848],"domain_scores_gemma":[0.99833226,0.00067363295,0.00028550683,0.00037069406,0.00015149832,0.00018640226],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000078653255,0.00030258435,0.001666303,0.00007686154,0.00006894839,0.000014344116,0.000117281976,0.0004015377,0.0018797592],"category_scores_gemma":[0.00006394623,0.00016604595,0.0002166281,0.00021289338,0.0001881867,0.00006530402,0.000029421075,0.000057190373,0.000094857496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013941836,0.016985256,0.903945,0.00006126908,0.0016513882,0.0013220415,0.00051401637,0.0000024200003,0.0077673043,0.00084578624,0.0022460895,0.063265204],"study_design_scores_gemma":[0.028347377,0.04009485,0.84359515,0.00013178989,0.00041216516,0.00053378806,0.000337535,0.00021850452,0.08061916,0.00019522526,0.0052062953,0.00030814574],"about_ca_topic_score_codex":0.0011511315,"about_ca_topic_score_gemma":0.00012551888,"teacher_disagreement_score":0.07285185,"about_ca_system_score_codex":0.00069964724,"about_ca_system_score_gemma":0.00025383334,"threshold_uncertainty_score":0.9990327},"labels":[],"label_agreement":null},{"id":"W2128518863","doi":"10.1002/hon.2265","title":"Associations between statin use and non‐Hodgkin lymphoma (NHL) risk and survival: a meta‐analysis","year":2015,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba; Winnipeg Regional Health Authority","funders":"Research Manitoba","keywords":"Medicine; Internal medicine; Hazard ratio; Statin; Lymphoma; Odds ratio; Non-Hodgkin's lymphoma; Meta-analysis; Oncology; Incidence (geometry); Epidemiology; Confidence interval","score_opus":0.1279351761986888,"score_gpt":0.38888464512502957,"score_spread":0.26094946892634074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128518863","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012550901,0.9945299,0.00062832085,0.000055378197,0.0007176634,0.00058777566,0.0019186337,0.000028325221,0.00027892902],"genre_scores_gemma":[0.00030160233,0.99434096,0.0016439973,0.0001081258,0.0016193631,0.00020054054,0.0014429064,0.000042111344,0.00030039568],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99597275,0.0014480945,0.00091269193,0.0009708721,0.00021205035,0.00048355162],"domain_scores_gemma":[0.9972042,0.00084966817,0.0008920156,0.00049337896,0.00019633811,0.0003643885],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012320864,0.00056722685,0.0057176505,0.00019913011,0.00014299057,0.000068982146,0.00024815966,0.0014703653,0.0000352572],"category_scores_gemma":[0.0008606342,0.00040952218,0.0011372796,0.00040878681,0.00029849223,0.000008530989,0.00040013052,0.00030724067,0.000011710475],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000086494336,0.00058978406,0.007928316,0.0018997729,0.21541381,0.000015243653,0.00018843499,0.0000040096816,0.000011721009,0.00093202625,0.03277267,0.7401577],"study_design_scores_gemma":[0.0004728167,0.00022853735,0.000989405,0.000017689174,0.13904719,0.00003648775,0.00001646479,0.0000016882418,0.0000014852208,0.00011329221,0.8586899,0.00038502258],"about_ca_topic_score_codex":0.0003084246,"about_ca_topic_score_gemma":0.0006375838,"teacher_disagreement_score":0.82591724,"about_ca_system_score_codex":0.000073481584,"about_ca_system_score_gemma":0.0004889859,"threshold_uncertainty_score":0.99983567},"labels":[],"label_agreement":null},{"id":"W2130207527","doi":"10.1002/hon.802","title":"Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy","year":2006,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Risks and Factors","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Connaught Fund","keywords":"ABVD; Medicine; Pregnancy; Dacarbazine; Fertility; Vinblastine; Pregnancy rate; Chemotherapy regimen; Chemotherapy; Obstetrics; Gynecology; Pediatrics; Surgery; Cyclophosphamide; Population; Vincristine","score_opus":0.030237683259607413,"score_gpt":0.3238924048666322,"score_spread":0.29365472160702477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130207527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841135,0.0009823352,0.00047502483,0.0006817647,0.00040014283,0.00056959235,0.0000037025306,0.00025531868,0.01251862],"genre_scores_gemma":[0.9972662,0.000027487144,0.0011508337,0.0004843902,0.0001098277,0.000084515785,0.000023040087,0.000032693206,0.00082105264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768454,0.00014506734,0.0006448464,0.0006122491,0.0002770871,0.00063618383],"domain_scores_gemma":[0.99885315,0.0003210085,0.0002121226,0.00037804383,0.000058460588,0.00017723032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031437294,0.00029691652,0.0010439017,0.000081403385,0.00015494705,0.00002739637,0.00015250004,0.00050391676,0.00033069137],"category_scores_gemma":[0.00013226394,0.00022461785,0.0004020815,0.00027012787,0.00022501888,0.00011614152,0.000071803246,0.00023991932,0.00004965713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020314408,0.00073966116,0.978043,0.000081704435,0.000059420527,0.0007641846,0.00014945838,0.0000024579074,0.0007593892,0.00042412741,0.0002770857,0.01849634],"study_design_scores_gemma":[0.0031899654,0.0006313334,0.9869158,0.0001891588,0.00007056522,0.000103669394,0.00017552459,0.00007811812,0.0019251,0.00051709963,0.0059407987,0.0002628403],"about_ca_topic_score_codex":0.0016009412,"about_ca_topic_score_gemma":0.0009463233,"teacher_disagreement_score":0.018233499,"about_ca_system_score_codex":0.00033105796,"about_ca_system_score_gemma":0.00013627944,"threshold_uncertainty_score":0.915965},"labels":[],"label_agreement":null},{"id":"W2142220672","doi":"10.1002/hon.2266","title":"Non‐Hodgkin lymphoma in Romania: a single‐centre experience","year":2015,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Hodgkin lymphoma; Lymphoma; Medicine; Internal medicine","score_opus":0.06943261231885393,"score_gpt":0.3354643070766122,"score_spread":0.26603169475775823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142220672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94935966,0.00045370442,0.0000137649495,0.0038801287,0.00018893213,0.0003899709,0.0000013190039,0.000074018426,0.0456385],"genre_scores_gemma":[0.99605227,0.000022421602,0.0018048564,0.0016824685,0.000055074648,0.00013591588,0.000010515809,0.000011048098,0.00022544955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845004,0.00008054148,0.0003948759,0.00041546448,0.00021610994,0.00044294627],"domain_scores_gemma":[0.99903464,0.00018075305,0.00008903204,0.00025734212,0.000071158065,0.0003670903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013437057,0.0001989765,0.00072977116,0.00008517747,0.000029126992,0.000010939896,0.00010868977,0.00031288114,0.00021245606],"category_scores_gemma":[0.00027139988,0.00013661239,0.000096591146,0.00023389353,0.00015903084,0.00005236951,0.000101831356,0.000081055674,0.00040240554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009859959,0.013455395,0.9141741,0.000043116517,0.00006560051,0.023554794,0.0037658026,0.0000022410206,0.000770908,0.008740263,0.0095258355,0.024915995],"study_design_scores_gemma":[0.04318297,0.010051747,0.6351006,0.0003096215,0.0001926126,0.010305814,0.007086362,0.00047742785,0.013083869,0.0023013935,0.27711743,0.00079015625],"about_ca_topic_score_codex":0.0000737645,"about_ca_topic_score_gemma":0.00011498999,"teacher_disagreement_score":0.27907348,"about_ca_system_score_codex":0.0008590516,"about_ca_system_score_gemma":0.0002382214,"threshold_uncertainty_score":0.55708915},"labels":[],"label_agreement":null},{"id":"W2164571519","doi":"10.1002/hon.2251","title":"Concomitant high expression of Toll‐like receptor (TLR) and B‐cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma","year":2015,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Calgary Laboratory Services; University of Alberta; Alberta Cancer Foundation; University of Calgary","funders":"Alberta Cancer Foundation; Calgary Laboratory Services","keywords":"breakpoint cluster region; Cancer research; Syk; Biology; B-cell receptor; Mantle cell lymphoma; Toll-like receptor; Signal transduction; TLR7; Bruton's tyrosine kinase; TLR9; Receptor; Immunology; B cell; Gene expression; Cell biology; Innate immune system; Immune system; Gene; Lymphoma; Genetics; Tyrosine kinase; Antibody","score_opus":0.08521364045476884,"score_gpt":0.3416249336855472,"score_spread":0.2564112932307784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164571519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042296,0.0017019958,0.00013900826,0.0038882524,0.00022644085,0.00062369445,0.000025131956,0.000050175746,0.0029223158],"genre_scores_gemma":[0.9820789,0.0007447392,0.016132604,0.00061522453,0.000061349514,0.00015850407,0.00006105186,0.000018938272,0.00012868947],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99757516,0.00033490642,0.0009924083,0.00054989936,0.00019307104,0.0003545662],"domain_scores_gemma":[0.99764395,0.0011432427,0.0003401678,0.0003127962,0.00014229085,0.00041753697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004625045,0.00024167173,0.0011336945,0.00009676503,0.00006124521,0.000012655882,0.00013765866,0.0005357831,0.00016747709],"category_scores_gemma":[0.00025345525,0.00016923543,0.00014299556,0.00015571663,0.00037282938,0.000046408517,0.0001591116,0.00015752592,0.000104828054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041113687,0.03332616,0.7193285,0.00044476087,0.00014421853,0.0011332238,0.00095592387,0.000019538902,0.15339519,0.010807641,0.05957221,0.016761228],"study_design_scores_gemma":[0.07926635,0.01762091,0.16220824,0.0007994767,0.00057903427,0.0010064323,0.002030469,0.0003703533,0.5883537,0.0050028097,0.14155237,0.0012098463],"about_ca_topic_score_codex":0.000057683712,"about_ca_topic_score_gemma":0.000014028213,"teacher_disagreement_score":0.55712026,"about_ca_system_score_codex":0.00026630593,"about_ca_system_score_gemma":0.000391123,"threshold_uncertainty_score":0.690122},"labels":[],"label_agreement":null},{"id":"W2167849560","doi":"10.1002/hon.703","title":"Increasing incidence of non‐Hodgkin's lymphoma in Canada, 1970–1996: age–period–cohort analysis","year":2003,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Population and Public Health; Health Canada; University of Ottawa","funders":"","keywords":"Incidence (geometry); Medicine; Cohort; Lymphoma; Non-Hodgkin's lymphoma; Cohort effect; Cancer registry; Demography; Hodgkin lymphoma; Cohort study; Cancer; Pediatrics; Internal medicine","score_opus":0.017368339432354163,"score_gpt":0.29223887590384456,"score_spread":0.2748705364714904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167849560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868458,0.0005350412,0.000028768352,0.00043451064,0.000084104744,0.0003825481,0.000005955376,0.000017180215,0.011666083],"genre_scores_gemma":[0.9956422,0.00012138698,0.0032928456,0.00075573666,0.000012627408,0.000109505716,0.00002213144,0.000009807458,0.000033760807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763966,0.00033809405,0.0007455726,0.00047314735,0.00033700903,0.0004665025],"domain_scores_gemma":[0.9983339,0.00071358803,0.00023520549,0.00038054213,0.00008750982,0.0002492991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047580304,0.00023823687,0.0016120052,0.00023830742,0.00005133771,0.00000633467,0.00012657249,0.0002483781,0.00041714843],"category_scores_gemma":[0.00073919236,0.00017591758,0.00021788213,0.00095342926,0.0001611539,0.00003760988,0.00006098693,0.00011161805,0.000015272743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016384608,0.0009465832,0.9848946,0.000035858913,0.00046079504,0.009126955,0.00007887744,0.00002560346,0.00029471377,0.0010563093,0.00015318453,0.002762726],"study_design_scores_gemma":[0.0024581135,0.00043694986,0.99028265,0.000052233147,0.0007670244,0.0015954621,0.00022832978,0.00017800854,0.0021916525,0.00009696433,0.0015507791,0.00016182206],"about_ca_topic_score_codex":0.57453704,"about_ca_topic_score_gemma":0.67184395,"teacher_disagreement_score":0.09730691,"about_ca_system_score_codex":0.0020031452,"about_ca_system_score_gemma":0.0022069605,"threshold_uncertainty_score":0.71737105},"labels":[],"label_agreement":null},{"id":"W2168861745","doi":"10.1002/hon.2210","title":"I. Hodgkin lymphoma: special challenges and solutions","year":2015,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Foundation","keywords":"Hodgkin lymphoma; Lymphoma; Medicine; Immunology","score_opus":0.2753937735336374,"score_gpt":0.4161582098693922,"score_spread":0.1407644363357548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168861745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019143408,0.9295292,9.582941e-7,0.0011210161,0.00040752292,0.0009044446,0.000019757774,0.00008879603,0.067909166],"genre_scores_gemma":[0.00003917148,0.9972658,0.0005204957,0.00016767679,0.0011530421,0.0004958561,0.00008499688,0.000028989129,0.00024395784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976627,0.00031365402,0.00063527026,0.0006598014,0.00021747401,0.00051107106],"domain_scores_gemma":[0.99824554,0.00060109096,0.00026956527,0.0003544287,0.00008339523,0.00044596594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003313172,0.00048000948,0.004058341,0.0001449359,0.000086192376,0.00001140179,0.00011659674,0.0012199482,0.00025083366],"category_scores_gemma":[0.00022597173,0.0002890508,0.00043911033,0.00011324682,0.0003175969,0.000026123169,0.0002526659,0.0002026825,0.0006144091],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024741574,0.0014056601,0.000007579452,0.0028512334,0.00026548342,0.0023112954,0.00004576359,2.5434663e-9,6.026543e-9,0.026587382,0.011378591,0.95512223],"study_design_scores_gemma":[0.0019766125,0.0013190147,0.00013500251,0.0017423376,0.0019868999,0.013087927,0.000045207293,4.7104433e-7,1.00412464e-7,0.0008863621,0.9785734,0.0002466687],"about_ca_topic_score_codex":0.000004886501,"about_ca_topic_score_gemma":0.000017410479,"teacher_disagreement_score":0.9671948,"about_ca_system_score_codex":0.00080057356,"about_ca_system_score_gemma":0.0009455692,"threshold_uncertainty_score":0.9999562},"labels":[],"label_agreement":null},{"id":"W2411200550","doi":"10.1002/hon.2305","title":"<i>FCGR3A</i>/<i>2A</i> polymorphisms and diffuse large B‐cell lymphoma outcome treated with immunochemotherapy: a meta‐analysis on 1134 patients from two prospective cohorts","year":2016,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Fondation de France; National Cancer Institute; Fondation Philippe Wiener - Maurice Anspach","keywords":"Medicine; Internal medicine; Rituximab; Hazard ratio; Oncology; Single-nucleotide polymorphism; Lymphoma; Diffuse large B-cell lymphoma; Immunology; Genotype; Confidence interval; Biology; Gene; Genetics","score_opus":0.04268589500698621,"score_gpt":0.3397128301533769,"score_spread":0.29702693514639067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411200550","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024573598,0.9683638,0.000014511783,0.00028368307,0.00008298149,0.0035038746,0.00085973844,0.00018925336,0.0021285198],"genre_scores_gemma":[0.06189877,0.93279874,0.0004976818,0.0013851876,0.00008157529,0.0019699743,0.00071288756,0.00012592434,0.0005292716],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99477154,0.0006152137,0.0013862413,0.0017989498,0.0005410801,0.00088696904],"domain_scores_gemma":[0.99535096,0.0017544453,0.0011400987,0.0010809985,0.00017050233,0.00050300127],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0002081544,0.0014123168,0.012028414,0.00042639315,0.00017978626,0.000044485394,0.00026213742,0.0010111982,0.0006702726],"category_scores_gemma":[0.00006503501,0.0006445731,0.0025004933,0.0006948351,0.000338952,0.000059452042,0.00017398591,0.00030478038,0.00025106675],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002424206,0.058056936,0.38316813,0.0018930733,0.36112383,0.0065997113,0.00014793599,5.955762e-8,0.0000012568767,0.001366345,0.00048884406,0.18472965],"study_design_scores_gemma":[0.060894426,0.0072502987,0.018989868,0.0015469247,0.5741005,0.0005158825,0.000016898332,0.000002026271,0.00008660187,0.0001566922,0.3349839,0.001456031],"about_ca_topic_score_codex":0.00021784869,"about_ca_topic_score_gemma":0.00006589392,"teacher_disagreement_score":0.36417827,"about_ca_system_score_codex":0.001024136,"about_ca_system_score_gemma":0.00033659633,"threshold_uncertainty_score":0.9998627},"labels":[],"label_agreement":null},{"id":"W2513548018","doi":"10.1002/hon.2341","title":"Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF‐AML) – a single center analysis","year":2016,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Oncology; Chemotherapy; Reverse transcriptase; Single Center; Polymerase chain reaction; Leukemia; Gastroenterology; Gene; Biology","score_opus":0.02294623130666507,"score_gpt":0.3139093602436631,"score_spread":0.29096312893699805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513548018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393797,0.000017046252,0.0025724943,0.0014538461,0.000031456828,0.00081318856,0.00009475004,0.000055174194,0.0010240866],"genre_scores_gemma":[0.99655527,0.000047702346,0.0026635064,0.00037444313,0.000015158561,0.000049080903,0.00012966148,0.000027312912,0.00013788475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763614,0.00021318856,0.00059579423,0.0005572849,0.00046469257,0.0005328929],"domain_scores_gemma":[0.9982534,0.00046213856,0.00030713718,0.0004052023,0.00030962162,0.00026249647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019415081,0.00025817577,0.0010851733,0.0005525285,0.000048231763,0.0000061626974,0.00020479049,0.0004624074,0.0005044675],"category_scores_gemma":[0.0004339831,0.00014242681,0.00019142992,0.0010114346,0.0003540832,0.00009982861,0.00011855704,0.00034433152,0.000020316556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043059634,0.0011333661,0.88524985,0.000032295186,0.0013215757,0.00030765397,0.0002004191,0.000008969476,0.10445331,0.0002534197,0.00015429797,0.0025789023],"study_design_scores_gemma":[0.02364808,0.008775144,0.87302196,0.00040748363,0.0010221384,0.00017938188,0.00019866115,0.00060033327,0.09084437,0.0001914109,0.0006707788,0.00044023225],"about_ca_topic_score_codex":0.000024121045,"about_ca_topic_score_gemma":0.000008926714,"teacher_disagreement_score":0.019342115,"about_ca_system_score_codex":0.0018258417,"about_ca_system_score_gemma":0.000516037,"threshold_uncertainty_score":0.58079964},"labels":[],"label_agreement":null},{"id":"W2515380104","doi":"10.1002/hon.2339","title":"Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B‐cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group‐37 study","year":2016,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Cancer Research UK; National Cancer Institute; National Cancer Research Institute","keywords":"Medicine; Concordance; Positron emission tomography; Lymphoma; Nuclear medicine; Radiology; Radiation therapy; Interim; Clinical endpoint; Mediastinum; Clinical trial; Medical physics; Internal medicine","score_opus":0.11099691710297598,"score_gpt":0.3821411964883498,"score_spread":0.27114427938537383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515380104","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13297841,0.8585909,0.0000064836604,0.0011868109,0.00039300264,0.005922087,0.000016302398,0.00002354931,0.00088244525],"genre_scores_gemma":[0.3728907,0.62403125,0.00006300448,0.00082555145,0.00008514455,0.0020061126,0.000048399343,0.000023963461,0.000025826392],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9921024,0.0030104946,0.002446939,0.0009819538,0.0009083109,0.00054989295],"domain_scores_gemma":[0.9952372,0.0022763112,0.0012428967,0.0010302066,0.00009871222,0.00011471692],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024767222,0.00075032003,0.0042112065,0.00038910954,0.00011483967,0.000032018143,0.0014528523,0.0003553864,0.00013521],"category_scores_gemma":[0.00029481173,0.00027302743,0.0016034599,0.0013169636,0.00029147955,0.000072225375,0.00071167893,0.000365084,0.000007604808],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002880487,0.02959066,0.043601558,0.0031780722,0.0023662385,0.0011878149,0.004274722,9.836878e-8,0.000011101843,0.00002946087,0.00027882456,0.9151934],"study_design_scores_gemma":[0.025646076,0.012395309,0.66577923,0.07219043,0.019687502,0.002163377,0.015800517,0.00001794377,0.000013128589,0.000041874824,0.18507159,0.0011930214],"about_ca_topic_score_codex":0.00016036286,"about_ca_topic_score_gemma":0.00030357027,"teacher_disagreement_score":0.9140004,"about_ca_system_score_codex":0.0012276482,"about_ca_system_score_gemma":0.00043426512,"threshold_uncertainty_score":0.99997216},"labels":[],"label_agreement":null},{"id":"W2527713631","doi":"10.1002/hon.2351","title":"Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity","year":2016,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Mental Health Association of Westchester County","keywords":"Ixazomib; Bortezomib; Carfilzomib; Amyloidosis; Multiple myeloma; Proteasome inhibitor; Medicine; Proteasome; AL amyloidosis; Pharmacology; Oncology; Cancer research; Internal medicine; Immunoglobulin light chain; Immunology; Chemistry; Biochemistry","score_opus":0.07908604674415905,"score_gpt":0.4205617516177201,"score_spread":0.34147570487356105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527713631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03994451,0.95432884,0.000094837145,0.0010755814,0.0006370564,0.002970425,0.00008996476,0.00005187245,0.0008069315],"genre_scores_gemma":[0.06175319,0.93672454,0.00022040773,0.00018067467,0.00016363448,0.0008231428,0.000028953471,0.00004944569,0.00005599808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956906,0.0012809853,0.0011951322,0.0011454037,0.00019772255,0.0004901873],"domain_scores_gemma":[0.9973846,0.0007954403,0.001027999,0.00054614426,0.000050724237,0.00019507892],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0006642241,0.0006196283,0.0029535713,0.00019374251,0.000050765706,0.000009686297,0.0002994815,0.0022724916,0.0000447732],"category_scores_gemma":[0.00079231267,0.00039785646,0.00070904364,0.00015799944,0.00037811822,0.000007540312,0.00038136108,0.000577803,0.000051668925],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002510151,0.0017322166,0.0014000058,0.0010783982,0.0003677372,0.00009297564,0.00000473766,4.1472486e-8,0.00029089436,0.0017408751,0.0006310766,0.99241],"study_design_scores_gemma":[0.0029531491,0.007579444,0.00072797143,0.004360604,0.0006088716,0.0003780801,0.000022338112,0.0000012169066,0.006975684,0.0010836489,0.97436637,0.00094261504],"about_ca_topic_score_codex":0.000015716014,"about_ca_topic_score_gemma":0.00005779542,"teacher_disagreement_score":0.9914674,"about_ca_system_score_codex":0.00019678827,"about_ca_system_score_gemma":0.00032712138,"threshold_uncertainty_score":0.99984735},"labels":[],"label_agreement":null},{"id":"W2604118521","doi":"10.1002/hon.2411","title":"Follicular lymphoma: State‐of‐the‐art ICML workshop in Lugano 2015","year":2017,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Instituto de Ciencias del Mar y Limnología, Universidad Nacional Autónoma de México; European School of Oncology; Cancer Research UK; American Association for Cancer Research","keywords":"Follicular lymphoma; Epigenetics; Clinical Oncology; Lymphoma; Medicine; Oncology; Internal medicine; Cancer; Biology; Genetics; Gene","score_opus":0.12830900746607302,"score_gpt":0.43407985912802716,"score_spread":0.30577085166195417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604118521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00064348284,0.9883118,0.0000025723366,0.0012294985,0.0005345535,0.0018770628,0.000022482713,0.000039923973,0.007338581],"genre_scores_gemma":[0.001320502,0.995361,0.00026265663,0.00026678265,0.00007757861,0.0006715857,0.000056917394,0.000040152026,0.0019428328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966299,0.000452238,0.0013061948,0.0006892657,0.00033794405,0.0005844658],"domain_scores_gemma":[0.9963634,0.0010631416,0.0010320146,0.0012306224,0.00008442345,0.00022640245],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042206259,0.000577943,0.005419339,0.00017256175,0.00009533601,0.000017222557,0.0005572404,0.0011173594,0.00019114294],"category_scores_gemma":[0.0008605029,0.0002971988,0.0012163394,0.00028213108,0.0004410756,0.000035592024,0.0004017411,0.00035505794,0.00050743314],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059241785,0.002883419,0.0019315155,0.004558766,0.0003924655,0.004437742,0.0000307073,2.5569756e-7,9.916031e-8,0.00080897997,0.015421483,0.9694753],"study_design_scores_gemma":[0.002573323,0.0003798886,0.0014301626,0.008495941,0.0011072743,0.0027487145,0.000007616198,0.0000013910657,0.000006305912,0.00022354934,0.9827716,0.00025426634],"about_ca_topic_score_codex":0.000023801316,"about_ca_topic_score_gemma":0.00009244691,"teacher_disagreement_score":0.96922106,"about_ca_system_score_codex":0.00096239214,"about_ca_system_score_gemma":0.0014203162,"threshold_uncertainty_score":0.999948},"labels":[],"label_agreement":null},{"id":"W2621433260","doi":"10.1002/hon.2438_14","title":"PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND <scp>EZH</scp>2 MUTATION, IN <scp>NHL</scp> PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR <scp>DNA</scp>","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Simon Fraser University; McGill University Health Centre","funders":"","keywords":"Medicine; EZH2; Internal medicine; Cancer research; Oncology; Clinical endpoint; Mutation; Gene; Clinical trial; Genetics; Histone; Biology","score_opus":0.015951205664438677,"score_gpt":0.28139603628771,"score_spread":0.2654448306232713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621433260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939663,0.0011241504,0.0035122056,0.0000406373,0.0001261075,0.00079972757,0.000108223576,0.000011791433,0.00031090228],"genre_scores_gemma":[0.9968535,0.00021267816,0.002455344,0.00007663317,0.000036424943,0.000082732804,0.00021933937,0.000032274704,0.00003112672],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966697,0.0007296933,0.001165564,0.00066218234,0.00034479596,0.0004280334],"domain_scores_gemma":[0.9952963,0.0016777269,0.001813219,0.00058430084,0.00046731028,0.0001611491],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009057839,0.00031501474,0.0008143567,0.00020305385,0.00012244788,0.00002153751,0.00040947215,0.00036969446,0.0000030640604],"category_scores_gemma":[0.015474275,0.0002989384,0.00014495561,0.000166594,0.0005958712,0.000036682555,0.0004193215,0.00020926261,0.0000017108458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014682281,0.00040581313,0.14768344,0.00029900845,0.000050456933,0.00005918648,0.0006916785,0.00006234904,0.8498964,0.00012911894,0.000024614917,0.0005511355],"study_design_scores_gemma":[0.0010281603,0.003158067,0.4417954,0.00015911828,0.000052419757,0.000034817473,0.00018711117,0.0005047647,0.55169374,0.0011164824,0.00022703494,0.000042919088],"about_ca_topic_score_codex":0.000020926309,"about_ca_topic_score_gemma":0.000013675345,"teacher_disagreement_score":0.29820266,"about_ca_system_score_codex":0.000034738074,"about_ca_system_score_gemma":0.00020958862,"threshold_uncertainty_score":0.9999463},"labels":[],"label_agreement":null},{"id":"W2621545768","doi":"10.1002/hon.2439_20","title":"Analysis of preclinical and clinical samples after treatment with a <scp>CD37</scp> targeting antibody drug conjugate (<scp>AGS67E</scp>) support a high level of <scp>CD37</scp> expression in <scp>NHL</scp>","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; BC Cancer Agency","funders":"","keywords":"Antibody; Flow cytometry; Antibody-drug conjugate; Medicine; Cancer research; Monoclonal antibody; Molecular biology; Immunology; Biology","score_opus":0.12475944141595334,"score_gpt":0.42955576042117627,"score_spread":0.3047963190052229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621545768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912381,0.0015212921,0.0003190175,0.00045071286,0.00027478134,0.002271376,0.00033704162,0.00013344697,0.0034542056],"genre_scores_gemma":[0.98353815,0.0039044858,0.006915087,0.00044514838,0.00031010248,0.00042947815,0.00039281987,0.00013155321,0.003933166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98775095,0.0021675008,0.0039979587,0.0024840243,0.0014832458,0.0021163076],"domain_scores_gemma":[0.9635084,0.029735139,0.00252657,0.0021785728,0.000779566,0.0012717166],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004824197,0.0011828517,0.006799644,0.001045165,0.00036744404,0.00012268922,0.0010320378,0.001921386,0.00033433287],"category_scores_gemma":[0.019691987,0.0008224194,0.0013884598,0.0010198518,0.0033964082,0.00032635522,0.0011474601,0.0017849517,0.00006007312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063814636,0.0065764133,0.95005196,0.00046169607,0.0032159456,0.0024868718,0.0024423779,0.000022086655,0.027840052,0.00015612529,0.0031967016,0.0029116238],"study_design_scores_gemma":[0.019320065,0.014133758,0.884212,0.0006898261,0.004039995,0.00049581216,0.004784102,0.0010128167,0.036946703,0.00045058393,0.03374658,0.00016773187],"about_ca_topic_score_codex":0.00063733035,"about_ca_topic_score_gemma":0.00095706526,"teacher_disagreement_score":0.06583993,"about_ca_system_score_codex":0.00036410993,"about_ca_system_score_gemma":0.0010091288,"threshold_uncertainty_score":0.99942267},"labels":[],"label_agreement":null},{"id":"W2621632916","doi":"10.1002/hon.2437_86","title":"HIGHER MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Follicular lymphoma; Proportional hazards model; Oncology; Cohort; Gastroenterology; Lymphoma; Surgery","score_opus":0.052059824726519835,"score_gpt":0.37864398756473805,"score_spread":0.32658416283821823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621632916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800476,0.00026254106,0.0000025943066,0.011155949,0.00023364181,0.0006079748,0.000025209274,0.000057614223,0.0076068696],"genre_scores_gemma":[0.9971181,0.00012569787,0.00061539595,0.00047212193,0.00019922382,0.00028400056,0.000046982117,0.000015176428,0.0011232748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836844,0.000096036085,0.00040148175,0.00047259437,0.00021801294,0.00044342093],"domain_scores_gemma":[0.9984704,0.0004847271,0.00020895661,0.00052537286,0.00005477654,0.00025574403],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011548382,0.00028945398,0.0009428262,0.00008459638,0.00019508543,0.000041846073,0.00016067391,0.00034838406,0.00095068064],"category_scores_gemma":[0.00021017394,0.00014526819,0.00033329174,0.000044912194,0.00022648953,0.000068009416,0.00008190924,0.00006659362,0.00032369647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027712414,0.018643212,0.7628121,0.000052581596,0.0010573297,0.04427408,0.00039482626,0.000026192183,0.0019236532,0.015673198,0.00075765303,0.15161394],"study_design_scores_gemma":[0.018144565,0.0025694764,0.956699,0.000043192264,0.00017679684,0.0010760771,0.0000366919,0.000061474915,0.00516777,0.0005148307,0.015327798,0.00018230436],"about_ca_topic_score_codex":0.0008869795,"about_ca_topic_score_gemma":0.000076510565,"teacher_disagreement_score":0.19388692,"about_ca_system_score_codex":0.0012810763,"about_ca_system_score_gemma":0.00030244334,"threshold_uncertainty_score":0.99996257},"labels":[],"label_agreement":null},{"id":"W2621746631","doi":"10.1002/hon.2437_3","title":"INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Oncology; Clinical endpoint; Interim analysis; Ixazomib; Phases of clinical research; Adverse effect; EZH2; Surrogate endpoint; Pharmacology; Refractory (planetary science); Clinical trial; Lenalidomide; Multiple myeloma","score_opus":0.03091780164131205,"score_gpt":0.35164769038108107,"score_spread":0.32072988873976904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621746631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808496,0.000073169955,0.00023901681,0.000027110058,0.00020775486,0.0006523165,0.000020308566,0.00000850331,0.00068684516],"genre_scores_gemma":[0.9977568,0.000025463569,0.00172285,0.000054727523,0.00005920285,0.0000556043,0.00023177172,0.000022726968,0.00007084936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979926,0.00025657238,0.00067478576,0.0006237236,0.00018788663,0.00026444183],"domain_scores_gemma":[0.99801314,0.00006580142,0.00073632284,0.00089081767,0.00016882988,0.00012506142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029328745,0.00022475723,0.0005415939,0.0000635349,0.00009636719,0.000023143646,0.0003321107,0.00036894478,0.000070075315],"category_scores_gemma":[0.00040058276,0.00015663715,0.0000548075,0.000047047815,0.00017358027,0.000015425809,0.00024023787,0.00015758355,0.000003716997],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009051492,0.020840038,0.8527355,0.000024061856,0.00007524042,0.0007117746,0.00055475114,0.000012533129,0.10993983,0.0000024901824,0.00011075811,0.0059415046],"study_design_scores_gemma":[0.043725953,0.056160018,0.70419294,0.00005731578,0.00010202932,0.000011450775,0.00091125356,0.00014358759,0.1861034,0.000066016175,0.007953285,0.0005727664],"about_ca_topic_score_codex":0.00027844124,"about_ca_topic_score_gemma":0.00090750016,"teacher_disagreement_score":0.14854261,"about_ca_system_score_codex":0.00004601259,"about_ca_system_score_gemma":0.00013599313,"threshold_uncertainty_score":0.63874775},"labels":[],"label_agreement":null},{"id":"W2621758445","doi":"10.1002/hon.2437_99","title":"INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ibrutinib; Internal medicine; Chronic lymphocytic leukemia; IGHV@; Ofatumumab; Oncology; Chlorambucil; Leukemia; Univariate analysis; Bendamustine; Multivariate analysis; Chemotherapy; Cyclophosphamide","score_opus":0.02770539388624377,"score_gpt":0.2986521199294849,"score_spread":0.27094672604324116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621758445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951672,0.00020897575,0.00029737115,0.00007912133,0.00013492058,0.0022970675,0.00009932758,0.00035161618,0.0013643763],"genre_scores_gemma":[0.99671006,0.00013808373,0.0016121647,0.000118127646,0.000054079082,0.00025277745,0.00045933234,0.000110175155,0.0005451717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99347496,0.00050008536,0.0015141696,0.0015551823,0.0012605173,0.0016951041],"domain_scores_gemma":[0.991825,0.0020611356,0.0017769443,0.002428361,0.0010641884,0.00084436795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005654125,0.0010627265,0.0040709386,0.00071090774,0.0005719118,0.00010966358,0.0011997974,0.0010818185,0.0005110747],"category_scores_gemma":[0.0029159978,0.000592914,0.0005502039,0.0012526829,0.0024452598,0.00022379239,0.0004983172,0.0008918252,0.00012370992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004462988,0.00044078904,0.9837152,0.0004457118,0.005498058,0.0017759985,0.00017720045,0.0017868751,0.00006369422,0.00039746202,0.00011180242,0.001124227],"study_design_scores_gemma":[0.074540235,0.01207438,0.8761219,0.0004973137,0.007846694,0.00046075316,0.00021515274,0.023817446,0.0031313857,0.00008544291,0.00028819757,0.00092110544],"about_ca_topic_score_codex":0.018572126,"about_ca_topic_score_gemma":0.003710008,"teacher_disagreement_score":0.107593305,"about_ca_system_score_codex":0.17524049,"about_ca_system_score_gemma":0.070600174,"threshold_uncertainty_score":0.9996522},"labels":[],"label_agreement":null},{"id":"W2621834912","doi":"10.1002/hon.2439_120","title":"PROLONGED MOLECULAR AND CLINICAL REMISSIONS IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH HDT/ASCT AND COMBINATION IMMUNOTHERAPY WITH RITUXIMAB AND INTERFERON α","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Oncology; Follicular lymphoma; Minimal residual disease; Autologous stem-cell transplantation; Surgery; Bone marrow; Lymphoma","score_opus":0.021357904200114533,"score_gpt":0.3296958586988849,"score_spread":0.3083379544987704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621834912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99617493,0.0006451101,0.000013871184,0.0017794464,0.000015849462,0.00080751145,0.000002042393,0.000024829073,0.0005363991],"genre_scores_gemma":[0.99812454,0.00053492194,0.00087806745,0.0002980156,0.000005167125,0.00011335205,0.000019050369,0.000012859988,0.000014047253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988005,0.00015168417,0.00029897483,0.00042484901,0.00011696659,0.00020703179],"domain_scores_gemma":[0.99915004,0.0001801114,0.00018469301,0.00026237805,0.0000618909,0.00016090063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017421752,0.00019229054,0.00072484807,0.000054797878,0.00014603797,0.000033227818,0.000055467015,0.0002590936,0.000008611603],"category_scores_gemma":[0.00012041084,0.00010623083,0.00003292192,0.000040906645,0.00046535843,0.000065603985,0.0000704027,0.000104200175,0.0000014649568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031088179,0.0043490157,0.9537848,0.000025981388,0.00013906951,0.0011162489,0.000058727062,2.4793879e-8,0.0000716094,0.00056100765,0.000015035411,0.036769662],"study_design_scores_gemma":[0.043692872,0.013663871,0.94060934,0.00018862118,0.00013705941,0.0005712864,0.000030932293,0.00006710854,0.0003781633,0.00013177078,0.00040322085,0.0001257378],"about_ca_topic_score_codex":0.00007282849,"about_ca_topic_score_gemma":0.00007338274,"teacher_disagreement_score":0.040584054,"about_ca_system_score_codex":0.00009237292,"about_ca_system_score_gemma":0.00004875035,"threshold_uncertainty_score":0.43319675},"labels":[],"label_agreement":null},{"id":"W2621918247","doi":"10.1002/hon.2437_48","title":"OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B‐CELL LYMPHOMA TREATED WITH DOSE‐ADJUSTED EPOCH‐R THERAPY: a MULTICENTER RETROSPECTIVE ANALYSIS","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Epoch (astronomy); Single Center; Retrospective cohort study; Rituximab; Medical record; Pulmonary embolism; Surgery; Pediatrics; Lymphoma; Internal medicine","score_opus":0.016301857027294094,"score_gpt":0.27475590533467126,"score_spread":0.25845404830737717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621918247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99717975,0.00046900992,0.000021112037,0.0005197287,0.000017517807,0.0009411877,0.000031517924,0.00005215725,0.0007680106],"genre_scores_gemma":[0.9974067,0.0004104848,0.0016021706,0.00031725358,0.000020791835,0.00011208992,0.00007224982,0.000022450895,0.00003575881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99819946,0.00009767098,0.00040436827,0.0006167157,0.00031687078,0.00036493543],"domain_scores_gemma":[0.9982542,0.00013957045,0.0005640952,0.0006038338,0.00019677852,0.0002415413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000994973,0.00036200543,0.0017006915,0.00016311533,0.00014920907,0.000022864804,0.00015865907,0.00024183515,0.00007163517],"category_scores_gemma":[0.00007072259,0.00018591827,0.00019331896,0.00018971745,0.00063476723,0.000067046276,0.000095665106,0.000121529745,0.0000057821376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055998326,0.006004356,0.9766233,0.000053707096,0.0025088096,0.0007488942,0.00017002248,5.0477627e-7,0.000052528834,0.00004244932,0.00001737218,0.008178203],"study_design_scores_gemma":[0.031764023,0.004774829,0.9591382,0.00015359819,0.0022860803,0.0005008312,0.00008640348,0.000039300423,0.00104259,0.000005504848,0.000015590562,0.00019303877],"about_ca_topic_score_codex":0.00043208798,"about_ca_topic_score_gemma":0.00030297032,"teacher_disagreement_score":0.026164189,"about_ca_system_score_codex":0.00022931043,"about_ca_system_score_gemma":0.00011691952,"threshold_uncertainty_score":0.75815266},"labels":[],"label_agreement":null},{"id":"W2622107576","doi":"10.1002/hon.2438_75","title":"Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 <scp>DAWN</scp> study","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hatch (Canada)","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Lymphoma; Gastroenterology; Regimen; Phases of clinical research; Flow cytometry; Oncology; Immunology; Toxicity","score_opus":0.047056738369999844,"score_gpt":0.37735109612119744,"score_spread":0.3302943577511976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622107576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341714,0.00006399865,0.000031748197,0.00020248843,0.000015619902,0.001626622,0.000014762714,0.00002900372,0.004598641],"genre_scores_gemma":[0.99927706,0.000009367365,0.0001742192,0.00016366033,0.000012000566,0.00018472361,0.00006854094,0.000017698298,0.00009274415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997097,0.0004664282,0.00055307004,0.00056252116,0.0007558421,0.00056511385],"domain_scores_gemma":[0.9966273,0.0012296584,0.00042984457,0.0012805609,0.00025981368,0.00017282908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007567578,0.00027214963,0.0014317712,0.00034867437,0.00018638723,0.000033949236,0.0005715079,0.00026106584,0.000093908144],"category_scores_gemma":[0.0010552849,0.00012389317,0.00016664348,0.0009817147,0.0008004812,0.000071835966,0.00016447148,0.00019323501,0.00001598058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026079554,0.014289492,0.9717068,0.00004787145,0.0023678911,0.0054033217,0.0007609386,0.000007629499,0.000037629983,0.0001354605,0.00025479012,0.0023802416],"study_design_scores_gemma":[0.08634341,0.0106981,0.89618784,0.000037940732,0.0021723863,0.00019436247,0.0012102734,0.0018990155,0.00020018102,0.000013139143,0.0009593,0.00008405432],"about_ca_topic_score_codex":0.0005740712,"about_ca_topic_score_gemma":0.0005173381,"teacher_disagreement_score":0.08373545,"about_ca_system_score_codex":0.0016094783,"about_ca_system_score_gemma":0.0013462357,"threshold_uncertainty_score":0.50522166},"labels":[],"label_agreement":null},{"id":"W2622149297","doi":"10.1002/hon.2437_20","title":"PROGNOSTIC VALUE OF PET‐CT AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Alberta","funders":"","keywords":"Medicine; Follicular lymphoma; Bendamustine; Internal medicine; Rituximab; Population; PET-CT; Nuclear medicine; Prospective cohort study; Clinical endpoint; Lymphoma; Oncology; Positron emission tomography; Clinical trial","score_opus":0.03901549088674564,"score_gpt":0.37590643109384436,"score_spread":0.3368909402070987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622149297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99028885,0.00079804636,0.00006531995,0.004770704,0.00011343919,0.0034455343,0.000010557139,0.00002167601,0.0004858658],"genre_scores_gemma":[0.9955412,0.00015528765,0.00077393703,0.00077991677,0.000058817554,0.0026174611,0.000018960936,0.000015528634,0.000038897142],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998351,0.00013940169,0.0005617936,0.00037917044,0.00021472755,0.00035394836],"domain_scores_gemma":[0.99794436,0.00085978064,0.000296051,0.0007372109,0.0000854814,0.00007710872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050017197,0.0002355859,0.0009894451,0.000057040328,0.00017296066,0.000022982102,0.00031754945,0.0000726652,0.000085506836],"category_scores_gemma":[0.00044526148,0.00012560947,0.00026004013,0.000068379035,0.00022796358,0.000041614454,0.00007673848,0.000078625555,0.000015619162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007630019,0.070365526,0.8865317,0.00020383057,0.00053297466,0.01790508,0.0011196227,0.0000032399507,0.0001278265,0.003128413,0.00056292186,0.011888804],"study_design_scores_gemma":[0.092457235,0.021255156,0.8676814,0.00016905027,0.0006975842,0.0031617638,0.0006980596,0.00038885625,0.0015432974,0.0012442998,0.010443941,0.00025939848],"about_ca_topic_score_codex":0.00009218106,"about_ca_topic_score_gemma":0.000119803946,"teacher_disagreement_score":0.084827214,"about_ca_system_score_codex":0.0001436426,"about_ca_system_score_gemma":0.00013255967,"threshold_uncertainty_score":0.51222056},"labels":[],"label_agreement":null},{"id":"W2622171693","doi":"10.1002/hon.2438_45","title":"END OF TREATMENT <scp>PET‐CT</scp> PREDICTS PROGRESSION‐FREE SURVIVAL IN <scp>DLBCL</scp> AFTER FIRST‐LINE TREATMENT: RESULTS FROM THE PHASE III <scp>GOYA</scp> STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Alberta","funders":"","keywords":"Medicine; Nuclear medicine; Internal medicine; Clinical endpoint; Rituximab; PET-CT; Diffuse large B-cell lymphoma; Progression-free survival; CHOP; Phases of clinical research; Oncology; Clinical trial; Positron emission tomography; Lymphoma; Overall survival","score_opus":0.05398042620619866,"score_gpt":0.3550490730967307,"score_spread":0.3010686468905321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622171693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97798556,0.0030213762,0.0000054712323,0.0018777924,0.0007087689,0.0050288527,0.0010178869,0.00018349323,0.010170783],"genre_scores_gemma":[0.9919388,0.0018450689,0.00052585546,0.00027625734,0.00044822955,0.003034456,0.00046101306,0.0000770187,0.0013932728],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931125,0.0008095013,0.0020081424,0.0017566398,0.00089551165,0.0014176796],"domain_scores_gemma":[0.98158985,0.013136089,0.0013944468,0.002925404,0.00022628794,0.0007279118],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008459206,0.0011504089,0.0032415187,0.00021511302,0.0006143211,0.00011274294,0.00095262897,0.00043892354,0.000071713155],"category_scores_gemma":[0.006909384,0.0006193659,0.00065329915,0.00030102133,0.0010269829,0.00019557486,0.0006824121,0.00043037138,0.00014997787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012837647,0.095816374,0.8314591,0.000073490344,0.0020406016,0.040200613,0.006797931,0.000012964581,0.00008768127,0.0003911592,0.0072399443,0.014596401],"study_design_scores_gemma":[0.18817899,0.049899377,0.65056676,0.00054850033,0.002458412,0.0012496808,0.005119022,0.00024436344,0.006524437,0.0008218859,0.09423652,0.00015204785],"about_ca_topic_score_codex":0.0018780611,"about_ca_topic_score_gemma":0.0053953696,"teacher_disagreement_score":0.18689522,"about_ca_system_score_codex":0.00139364,"about_ca_system_score_gemma":0.000679615,"threshold_uncertainty_score":0.99962574},"labels":[],"label_agreement":null},{"id":"W2622353385","doi":"10.1002/hon.2438_80","title":"MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Bendamustine; Internal medicine; Minimal residual disease; Obinutuzumab; Population; Hazard ratio; Oncology; Gastroenterology; Follicular lymphoma; Surrogate endpoint; Bone marrow; Lymphoma; Confidence interval; Rituximab","score_opus":0.05161901287869262,"score_gpt":0.3889514008878156,"score_spread":0.33733238800912296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622353385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916311,0.0008330934,0.0000035956534,0.0050118286,0.00012308221,0.0015310786,0.000024914401,0.000022091202,0.0008192024],"genre_scores_gemma":[0.99844354,0.00031728944,0.00034709452,0.00039345425,0.00014358992,0.0001642153,0.00002330275,0.000019941428,0.00014759177],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99678475,0.00046971094,0.0009715587,0.0006285187,0.0005193274,0.00062615215],"domain_scores_gemma":[0.99636555,0.0020131413,0.0003819001,0.0008252182,0.00007747916,0.00033673487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014563737,0.00031059905,0.0015106493,0.00022128971,0.00016954655,0.000032211516,0.00040669035,0.0004410084,0.00009637802],"category_scores_gemma":[0.005654954,0.00019139759,0.00012669769,0.00014001493,0.0012954393,0.00008773942,0.0004349358,0.00046626283,0.000005473276],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7686394,0.019025385,0.10064366,0.0017613118,0.00045623555,0.062211245,0.0033159559,0.000012768693,0.0016264056,0.011049836,0.003006611,0.028251207],"study_design_scores_gemma":[0.8280876,0.011142251,0.15046602,0.00026022107,0.00029858554,0.0017243387,0.000678008,0.002839369,0.00021960102,0.0009097825,0.003019294,0.0003548871],"about_ca_topic_score_codex":0.00056218257,"about_ca_topic_score_gemma":0.00031629278,"teacher_disagreement_score":0.060486905,"about_ca_system_score_codex":0.0021488012,"about_ca_system_score_gemma":0.0035746985,"threshold_uncertainty_score":0.7804967},"labels":[],"label_agreement":null},{"id":"W2622354226","doi":"10.1002/hon.2437_76","title":"CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE‐AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR‐DLBCL) ‐ OUTCOME OF IBRUTINIB + R‐GDP","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Cancer Society","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Salvage therapy; Interim analysis; Oncology; Clinical endpoint; Gemcitabine; Febrile neutropenia; Diffuse large B-cell lymphoma; Population; Neutropenia; Ibrutinib; Chemotherapy regimen; Surgery; Chemotherapy; Randomized controlled trial; Lymphoma; Leukemia","score_opus":0.13571482489030035,"score_gpt":0.442831365213154,"score_spread":0.3071165403228537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622354226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850906,0.0026947455,0.00010039309,0.00085644046,0.00058746693,0.00824033,0.0002766891,0.00009532896,0.00205797],"genre_scores_gemma":[0.99542606,0.00071243616,0.00039521244,0.00059437234,0.00015311659,0.0015635148,0.000051095878,0.000086920634,0.0010172988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9888029,0.0034687314,0.0035168813,0.0013029757,0.0010766945,0.0018317982],"domain_scores_gemma":[0.98845714,0.0068110507,0.0019540985,0.0016124814,0.00026181122,0.0009034029],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0124857295,0.0007720394,0.0065993583,0.00054214895,0.00062177726,0.000052517324,0.0011383928,0.0012204834,0.0006919055],"category_scores_gemma":[0.0025637373,0.0005270367,0.0008379081,0.00029076813,0.00074819964,0.00013518936,0.0003109353,0.00095459,0.000024773784],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.60635006,0.22782081,0.04473223,0.0019086101,0.0021028041,0.019407738,0.025279876,0.00004072863,0.033647303,0.00083579577,0.0013406113,0.036533415],"study_design_scores_gemma":[0.9708825,0.012566488,0.0033189238,0.0002276483,0.0006569503,0.0004226367,0.0010054391,0.0066140736,0.0025889203,0.000060598275,0.0011017236,0.00055410585],"about_ca_topic_score_codex":0.0823807,"about_ca_topic_score_gemma":0.08154007,"teacher_disagreement_score":0.3645324,"about_ca_system_score_codex":0.010989406,"about_ca_system_score_gemma":0.011650395,"threshold_uncertainty_score":0.9997181},"labels":[],"label_agreement":null},{"id":"W2622499156","doi":"10.1002/hon.2437_25","title":"CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency","funders":"","keywords":"International Prognostic Index; Diffuse large B-cell lymphoma; Internal medicine; Medicine; Oncology; Proportional hazards model; Rituximab; Lymphoma","score_opus":0.011572009276033916,"score_gpt":0.28854556883869376,"score_spread":0.27697355956265984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622499156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997792,0.0000643523,0.00012024403,0.00044657264,0.00015939886,0.00079260615,0.0000605702,0.000020810743,0.000543455],"genre_scores_gemma":[0.9984536,0.00009323806,0.00097179326,0.00006893496,0.000024810526,0.00022736596,0.00009879468,0.000017244154,0.000044183213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99866813,0.00006266093,0.0005022332,0.00030283112,0.0002825549,0.00018160173],"domain_scores_gemma":[0.997999,0.00021523159,0.0009275012,0.0004346813,0.00034631297,0.0000772764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011464223,0.00018321343,0.00060912326,0.00008234172,0.00007588001,0.000016383117,0.00018582336,0.00018886616,0.00013276422],"category_scores_gemma":[0.00016542549,0.00010856667,0.00008173284,0.00005671278,0.0004428923,0.000086216125,0.00006339572,0.00013829644,0.000011129936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073348726,0.007397328,0.98044586,0.00006343317,0.00028022585,0.000108605964,0.00010659615,8.056095e-7,0.00044651944,0.00065026246,0.00007773969,0.0030877558],"study_design_scores_gemma":[0.015137996,0.006265281,0.96723866,0.000096668075,0.00024047562,0.000033801436,0.000033192468,0.0000320885,0.010412133,0.00022525292,0.00017360358,0.000110839275],"about_ca_topic_score_codex":0.000150219,"about_ca_topic_score_gemma":0.000031905707,"teacher_disagreement_score":0.013207187,"about_ca_system_score_codex":0.000110734465,"about_ca_system_score_gemma":0.00015282762,"threshold_uncertainty_score":0.44272205},"labels":[],"label_agreement":null},{"id":"W2622725967","doi":"10.1002/hon.2437_107","title":"COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Progressive disease; Gastroenterology; Rituximab; Lymphoma; Clinical endpoint; Refractory (planetary science); Phases of clinical research; Follicular lymphoma; Oncology; Surgery; Chemotherapy; Clinical trial","score_opus":0.03686729126405178,"score_gpt":0.3419778960514678,"score_spread":0.30511060478741603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622725967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726708,0.00011828046,0.000016664035,0.0007279583,0.00017282306,0.00095379626,0.0000046055884,0.00006752027,0.025267554],"genre_scores_gemma":[0.996682,0.00007111719,0.0010611092,0.00064384635,0.00007203804,0.00011038743,0.000026852773,0.000034069635,0.0012985832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730414,0.00018037,0.0005482129,0.00063745497,0.0005530239,0.0007767985],"domain_scores_gemma":[0.99749994,0.00052752893,0.0003319356,0.001109128,0.00016995183,0.00036148744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037397203,0.00028087373,0.0010150836,0.0001449312,0.00020054117,0.000035015164,0.0004907252,0.00058363576,0.00070817495],"category_scores_gemma":[0.001090852,0.00016583964,0.00008654912,0.00012981704,0.00071892864,0.0001358583,0.0003641471,0.00045166546,0.0003817583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06384883,0.024612358,0.8106879,0.0010775779,0.00022840282,0.0280037,0.00082314253,0.000009191113,0.0002807797,0.0014064226,0.015301437,0.053720288],"study_design_scores_gemma":[0.23215154,0.020988064,0.70525765,0.00040628226,0.000097683755,0.0009518988,0.00017389796,0.00050352205,0.0012971798,0.00013667229,0.03749312,0.0005425036],"about_ca_topic_score_codex":0.00020758605,"about_ca_topic_score_gemma":0.00019711272,"teacher_disagreement_score":0.1683027,"about_ca_system_score_codex":0.010330164,"about_ca_system_score_gemma":0.0064154943,"threshold_uncertainty_score":0.9992172},"labels":[],"label_agreement":null},{"id":"W2622731939","doi":"10.1002/hon.2438_53","title":"A PHASE 2B RANDOMIZED STUDY OF SINGLE AGENT <scp>S</scp>ELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE <scp>B</scp>‐CELL LYMPHOMA (<scp>DLBCL</scp>)","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Neutropenia; Medicine; Internal medicine; Nausea; Adverse effect; Diffuse large B-cell lymphoma; Phases of clinical research; Anemia; Refractory (planetary science); Gastroenterology; Vomiting; Lymphoma; Febrile neutropenia; Oncology; Toxicity; Biology","score_opus":0.02815762067654268,"score_gpt":0.3051412327820132,"score_spread":0.2769836121054705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622731939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98631656,0.0012369443,0.000044363547,0.00013235345,0.00048683782,0.0050722454,0.000081515114,0.00015232954,0.0064768293],"genre_scores_gemma":[0.9961194,0.00027970911,0.0005806387,0.00056831667,0.00011403401,0.0011488571,0.00015858344,0.000102022816,0.0009284327],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99337316,0.00097478443,0.0019494606,0.0013697784,0.00094717916,0.0013856386],"domain_scores_gemma":[0.9868798,0.008386288,0.0019008056,0.0016740618,0.00042408373,0.00073491334],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010682627,0.00093115395,0.0043891086,0.00042552126,0.00040011288,0.00008037901,0.00066188857,0.0008571832,0.000038191938],"category_scores_gemma":[0.0096168425,0.0006110336,0.00058895344,0.00032073393,0.000697091,0.00021332005,0.0005217386,0.0004721553,0.00016400889],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007782807,0.5439465,0.4238824,0.0002705138,0.0010426593,0.0057557444,0.0044013327,0.0000035196474,0.00036633926,0.0002815201,0.008292245,0.0039744396],"study_design_scores_gemma":[0.763921,0.022352682,0.18623747,0.00024970953,0.0012464302,0.00016751261,0.0033373109,0.00010848361,0.0021321217,0.00010902104,0.02001711,0.00012113205],"about_ca_topic_score_codex":0.00017963778,"about_ca_topic_score_gemma":0.00024115054,"teacher_disagreement_score":0.7561382,"about_ca_system_score_codex":0.00075358566,"about_ca_system_score_gemma":0.00039849224,"threshold_uncertainty_score":0.9996341},"labels":[],"label_agreement":null},{"id":"W2622897264","doi":"10.1002/hon.2437_57","title":"DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Cégep de l'Outaouais; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Refractory (planetary science); Gastroenterology; Clinical endpoint; Regimen; Lymphoma; Surgery; Oncology; Clinical trial","score_opus":0.08567979818774954,"score_gpt":0.4524975538175632,"score_spread":0.36681775562981367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2622897264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935776,0.000022476728,0.00004580255,0.0006035794,0.00014423976,0.002242478,0.0000043846226,0.000024685129,0.0033347742],"genre_scores_gemma":[0.9992801,0.000012512563,0.00029130196,0.00015246376,0.00006347299,0.00014745556,0.0000048090888,0.000019475652,0.000028419961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967024,0.0005496527,0.000916992,0.0005906924,0.0006719273,0.0005683666],"domain_scores_gemma":[0.9961205,0.0015120482,0.0007369809,0.0011690744,0.00022372567,0.00023763967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001823309,0.00025801177,0.0013205649,0.000096320655,0.00023795999,0.000029085191,0.00059672166,0.00042513077,0.00008437331],"category_scores_gemma":[0.001500435,0.00013783836,0.00014693287,0.0001546385,0.001222913,0.00012435218,0.00048210865,0.00070250593,0.000021759324],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021807851,0.033015024,0.8721244,0.000104785606,0.00022691455,0.0017682313,0.00054672995,0.0000033552017,0.000074035575,0.00013990894,0.00011523062,0.07007354],"study_design_scores_gemma":[0.16962445,0.019303758,0.8082384,0.00011860522,0.00010661701,0.0001489619,0.0004254373,0.0013849132,0.0002814768,0.000025026788,0.00018138604,0.0001609761],"about_ca_topic_score_codex":0.00053232344,"about_ca_topic_score_gemma":0.00053260656,"teacher_disagreement_score":0.1478166,"about_ca_system_score_codex":0.0027616955,"about_ca_system_score_gemma":0.004680143,"threshold_uncertainty_score":0.8302373},"labels":[],"label_agreement":null},{"id":"W2623105223","doi":"10.1002/hon.2437_46","title":"MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN‐FIXED, PARAFFIN‐EMBEDDED TISSUE SPECIMENS – AN LLMPP PROJECT","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; BC Cancer Agency","funders":"","keywords":"Lymphoma; Gene expression profiling; Medicine; Diffuse large B-cell lymphoma; Molecular diagnostics; Tissue microarray; Cancer research; Pathology; Computational biology; Gene; Gene expression; Immunohistochemistry; Bioinformatics; Biology","score_opus":0.09364401329832947,"score_gpt":0.3877165753220415,"score_spread":0.294072562023712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623105223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835442,0.00037167282,0.0007171084,0.0006487531,0.0001801372,0.00089618494,0.00002373781,0.00006423873,0.013553981],"genre_scores_gemma":[0.9840296,0.00007006279,0.015122197,0.00038464833,0.00010253974,0.00010924888,0.00011598859,0.000022629229,0.000043069143],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978889,0.00015333912,0.00061302667,0.0005057991,0.00032795398,0.0005109398],"domain_scores_gemma":[0.9979861,0.00017102093,0.0006590284,0.0007875957,0.00016871655,0.00022754636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032897096,0.00027834068,0.0010296304,0.00010480447,0.00023939044,0.000026494514,0.00027140195,0.00042915813,0.00010385372],"category_scores_gemma":[0.00018901976,0.00020362106,0.00016083887,0.000084581116,0.0002928459,0.00015005014,0.0001716295,0.00011168075,0.00004829957],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043802164,0.06441609,0.188834,0.0014070874,0.0005931652,0.01578212,0.0015193209,0.000015207458,0.6063588,0.060596716,0.0018440018,0.054253254],"study_design_scores_gemma":[0.031480264,0.008697637,0.50595605,0.00022374478,0.0010408785,0.0041691624,0.000625497,0.002894526,0.428228,0.00069294416,0.015292852,0.00069848093],"about_ca_topic_score_codex":0.000060187846,"about_ca_topic_score_gemma":0.0000241677,"teacher_disagreement_score":0.31712204,"about_ca_system_score_codex":0.00040264672,"about_ca_system_score_gemma":0.00055803295,"threshold_uncertainty_score":0.83034265},"labels":[],"label_agreement":null},{"id":"W2623197015","doi":"10.1002/hon.2440","title":"ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R‐CHOP VS PLACEBO/R‐CHOP IN UNTREATED ABC‐TYPE DIFFUSE LARGE B‐CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lenalidomide; Diffuse large B-cell lymphoma; Medicine; CHOP; Internal medicine; Rituximab; Oncology; Clinical endpoint; Lymphoma; Randomized controlled trial; Multiple myeloma","score_opus":0.08100994556227097,"score_gpt":0.37326443969028955,"score_spread":0.29225449412801857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623197015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944189,0.00069551717,0.000014668207,0.0001769452,0.000108165295,0.0029449498,0.000020096968,0.000024806455,0.0015959326],"genre_scores_gemma":[0.99881864,0.0004535753,0.0004352607,0.000052058935,0.000016447953,0.00012540864,0.0000138802325,0.000016882028,0.00006783538],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965403,0.0007194998,0.0014659652,0.00059118116,0.00026738815,0.0004156341],"domain_scores_gemma":[0.99558187,0.0019579842,0.0012426744,0.00077703287,0.00023729689,0.00020311933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001259229,0.00034469287,0.0036692757,0.00017590109,0.00010882311,0.000010611107,0.00023137005,0.00038775342,0.00013893719],"category_scores_gemma":[0.0011646568,0.00022810877,0.00023886809,0.00016938151,0.00055324694,0.00007388634,0.00021440553,0.00014393382,0.000005122829],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3137936,0.106566325,0.5724935,0.0005305335,0.00029214885,0.0009827359,0.0013837315,0.000005853209,0.00295915,0.0004781308,0.000074273616,0.00044002893],"study_design_scores_gemma":[0.9008578,0.0058489204,0.07525594,0.00016798616,0.0007426338,0.00009407082,0.000838117,0.0005678742,0.015245178,0.00013641245,0.00005304593,0.00019199563],"about_ca_topic_score_codex":0.0007632412,"about_ca_topic_score_gemma":0.00038378852,"teacher_disagreement_score":0.5870642,"about_ca_system_score_codex":0.00022638807,"about_ca_system_score_gemma":0.0002701665,"threshold_uncertainty_score":0.9302006},"labels":[],"label_agreement":null},{"id":"W2623202484","doi":"10.1002/hon.2437_130","title":"FIRST‐LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R‐CHOP/R‐CVP: RESULTS OF THE BRIGHT 5‐YEAR FOLLOW‐UP STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Rituximab; Vincristine; Prednisone; CHOP; Internal medicine; Hazard ratio; Gastroenterology; Mantle cell lymphoma; Cyclophosphamide; Confidence interval; Lymphoma; Surgery; Oncology; Chemotherapy","score_opus":0.06503796508252431,"score_gpt":0.3461452574412059,"score_spread":0.2811072923586816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623202484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993271,0.000061139865,0.0000016034533,0.00212217,0.00022210463,0.0018852385,0.00006698659,0.000022500808,0.0023472374],"genre_scores_gemma":[0.99786955,0.0001077729,0.00036385897,0.00010917867,0.00004044113,0.00018106792,0.000014775365,0.0000145216545,0.0012988542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981652,0.00012876045,0.00065731944,0.000421217,0.00033329517,0.00029421912],"domain_scores_gemma":[0.9974103,0.0005818656,0.0006605726,0.0010090717,0.00019927036,0.00013889857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000121491794,0.00026478726,0.0012379466,0.000044749944,0.00022080069,0.000009756603,0.00025485634,0.00020649737,0.00024167949],"category_scores_gemma":[0.00061418914,0.00009474866,0.00018346624,0.00010651173,0.00037530414,0.000040546398,0.00014296842,0.00007524456,0.000022883025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021248847,0.026174702,0.9449356,0.00005242431,0.0005610997,0.0005750452,0.00062921585,0.0000014228258,0.000006426736,0.00021732059,0.00090051873,0.004697348],"study_design_scores_gemma":[0.062017966,0.042569544,0.8833182,0.00013249839,0.0006116339,0.00009603779,0.00017098789,0.0000062779645,0.0014977574,0.00004457236,0.00941578,0.00011876402],"about_ca_topic_score_codex":0.00034036065,"about_ca_topic_score_gemma":0.0018000447,"teacher_disagreement_score":0.06161745,"about_ca_system_score_codex":0.00025148608,"about_ca_system_score_gemma":0.00026562126,"threshold_uncertainty_score":0.38637385},"labels":[],"label_agreement":null},{"id":"W2623319799","doi":"10.1002/hon.2439_17","title":"<i>BCL2</i><scp>mRNA</scp> or protein abundance is superior to gene rearrangement status in predicting clinical outcomes in patients with diffuse large <scp>B</scp>‐cell lymphoma","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; BC Cancer Agency; Queen's University","funders":"","keywords":"Fluorescence in situ hybridization; Immunohistochemistry; Messenger RNA; Biopsy; Biology; Molecular biology; Pathology; In situ hybridization; Diffuse large B-cell lymphoma; Lymphoma; Gene expression; Gene; Medicine; Immunology; Genetics","score_opus":0.03500791177400745,"score_gpt":0.3337833299450458,"score_spread":0.2987754181710383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623319799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307865,0.00020117126,0.000013073206,0.0008637655,0.00026079867,0.0033600333,0.000101202226,0.00009313515,0.0020281882],"genre_scores_gemma":[0.99110514,0.00017871245,0.0037398378,0.0027606029,0.000076547825,0.0011961968,0.000045005792,0.00005300663,0.000844963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99515635,0.00031124058,0.0013579476,0.0011531585,0.0005924719,0.0014288528],"domain_scores_gemma":[0.9959494,0.0015810947,0.00056189887,0.0010352499,0.00016177434,0.00071058894],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006657914,0.00055189454,0.0020458617,0.00019142995,0.00025750278,0.00007822532,0.00042642365,0.0006177642,0.00005587247],"category_scores_gemma":[0.003982973,0.00033855182,0.00022485793,0.0002213645,0.00026788795,0.0001588366,0.00048144755,0.00035497398,0.00018064695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000557253,0.026594622,0.96526545,0.00010589156,0.00013584987,0.0026690979,0.0008221626,7.2736805e-7,0.0000494045,0.00006175861,0.0012995424,0.002438228],"study_design_scores_gemma":[0.050816115,0.0067307106,0.9207529,0.00025647186,0.00010487353,0.00004588343,0.00048528987,0.000026334787,0.0012791267,0.000024045712,0.019368455,0.00010982555],"about_ca_topic_score_codex":0.00036796264,"about_ca_topic_score_gemma":0.0011465931,"teacher_disagreement_score":0.05025886,"about_ca_system_score_codex":0.00078771723,"about_ca_system_score_gemma":0.0004604702,"threshold_uncertainty_score":0.99990666},"labels":[],"label_agreement":null},{"id":"W2623329013","doi":"10.1002/hon.2438_50","title":"PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE <scp>B</scp>‐CELL LYMPHOMA (<scp>RRPMBCL</scp>): UPDATED RESULTS FROM THE <scp>KEYNOTE</scp>‐013 TRIAL","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Internal medicine; Pembrolizumab; Regimen; Adverse effect; Population; Cohort; Refractory (planetary science); Surgery; Oncology; Gastroenterology; Toxicity; Cancer; Immunotherapy","score_opus":0.026721705012862557,"score_gpt":0.30302441348129183,"score_spread":0.2763027084684293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623329013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860274,0.0007392065,0.000019993768,0.00025259517,0.0010886514,0.003613667,0.00039564265,0.0001349645,0.007727851],"genre_scores_gemma":[0.99630946,0.0001955031,0.00024901927,0.0011990069,0.00037380523,0.0002492566,0.00072485994,0.000079760895,0.00061935745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992979,0.0011256974,0.0021028162,0.0013338136,0.0011849754,0.0012737212],"domain_scores_gemma":[0.987651,0.0074480763,0.0022916484,0.0018133566,0.00038914164,0.000406801],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015888186,0.00078628375,0.0023749296,0.00025167287,0.0005317579,0.00007771721,0.0012231531,0.0010892458,0.000057381418],"category_scores_gemma":[0.006228133,0.0004874528,0.00035657003,0.00045129293,0.0010062193,0.00027322437,0.0004897537,0.0010946124,0.00006583129],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30392435,0.2751453,0.24619499,0.00031771485,0.0025233212,0.0051956773,0.018272994,0.0000056342483,0.0037922051,0.00011748073,0.1285859,0.015924452],"study_design_scores_gemma":[0.56098384,0.03447393,0.3450088,0.00017355819,0.00044074064,0.00008236734,0.003688765,0.000039941468,0.00085425196,0.00006117423,0.054093447,0.000099176825],"about_ca_topic_score_codex":0.00045644323,"about_ca_topic_score_gemma":0.00038414213,"teacher_disagreement_score":0.2570595,"about_ca_system_score_codex":0.00056471274,"about_ca_system_score_gemma":0.00096005003,"threshold_uncertainty_score":0.9997577},"labels":[],"label_agreement":null},{"id":"W2623453597","doi":"10.1002/hon.2439_188","title":"IBRUTINIB IN ASSOCIATION WITH R‐DHAP/OX FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE BIBLOS PHASE IB LYSA STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Internal medicine; DHAP; Gastroenterology; Neutropenia; Mantle cell lymphoma; Febrile neutropenia; Nausea; Mucositis; Cytarabine; Rash; Ibrutinib; Rituximab; Surgery; Oncology; Lymphoma; Toxicity; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.03194529137704255,"score_gpt":0.35223566715245574,"score_spread":0.3202903757754132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623453597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916354,0.000050481107,0.0000116747715,0.0010498532,0.000119716286,0.0034749003,0.00003735207,0.00003116985,0.0035894425],"genre_scores_gemma":[0.9982385,0.000012163754,0.0005031399,0.000121355115,0.000047749112,0.0003237003,0.00002751761,0.000027903965,0.0006979761],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971183,0.0003271419,0.00069962227,0.00055807596,0.00073129905,0.00056558655],"domain_scores_gemma":[0.99548864,0.0019168133,0.0010304318,0.000993383,0.00042409927,0.0001466472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009927842,0.00024229813,0.0009206338,0.000157469,0.00023483405,0.000020022886,0.00048791897,0.00042979696,0.00002279008],"category_scores_gemma":[0.0033889597,0.00012657196,0.00010437585,0.00027207244,0.00038500762,0.00011168986,0.0002656292,0.000328982,0.000011453695],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11310019,0.057644922,0.81593305,0.00044424305,0.00030998394,0.0010042238,0.0015046758,0.000011409369,0.00016339865,0.00011502695,0.006012364,0.003756541],"study_design_scores_gemma":[0.4856425,0.08683607,0.41858494,0.0003065042,0.0003858814,0.00015724111,0.0007129452,0.00079308066,0.0022701253,0.00008480003,0.003918332,0.00030759405],"about_ca_topic_score_codex":0.00020383182,"about_ca_topic_score_gemma":0.00017154875,"teacher_disagreement_score":0.39734808,"about_ca_system_score_codex":0.0057902327,"about_ca_system_score_gemma":0.0034727987,"threshold_uncertainty_score":0.9980264},"labels":[],"label_agreement":null},{"id":"W2623570352","doi":"10.1002/hon.2437_22","title":"NON‐MEDIASTINAL CASES OF GREY ZONE LYMPHOMA: A PATHOLOGICAL AND CLINICAL SERIES OF 17 CASES FROM THE LYSA","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Immunophenotyping; Lymphoma; Pathological; Immunohistochemistry; Fluorescence in situ hybridization; Pathology; Phenotype; Fibrosis; In situ hybridization; Antigen; Gene; Immunology; Gene expression; Biology","score_opus":0.10199596551042601,"score_gpt":0.3850008084535151,"score_spread":0.2830048429430891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623570352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937534,0.0012059773,0.000009016055,0.003440086,0.00018349213,0.00033798415,0.000074548494,0.000021802327,0.00097374397],"genre_scores_gemma":[0.9969013,0.00097459473,0.0014212847,0.00041921582,0.00015972601,0.00004926213,0.000024757544,0.0000084031135,0.000041470797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828815,0.00018736956,0.00071703456,0.00037740558,0.00018061418,0.00024941127],"domain_scores_gemma":[0.99442655,0.004200699,0.0005389706,0.00054065365,0.00011896414,0.00017418871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036838333,0.00020434379,0.001312577,0.000024657857,0.00018240506,0.000013096451,0.00019920123,0.00031390475,0.000233792],"category_scores_gemma":[0.0028677282,0.000100163015,0.00022145078,0.000039879065,0.001905732,0.00005335327,0.0002676985,0.00016337687,0.0000095168925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015968366,0.002459527,0.97166836,0.00003288376,0.00014698577,0.0163034,0.00008567692,6.173467e-8,0.000029075301,0.0010372046,0.0011477073,0.005492252],"study_design_scores_gemma":[0.0039595244,0.0079509225,0.97277325,0.00011357235,0.00042928196,0.012446781,0.00027990903,0.0000099925255,0.0006060099,0.0004409842,0.00089258753,0.00009716049],"about_ca_topic_score_codex":0.00042414613,"about_ca_topic_score_gemma":0.00023760305,"teacher_disagreement_score":0.005491395,"about_ca_system_score_codex":0.000023726527,"about_ca_system_score_gemma":0.00012574861,"threshold_uncertainty_score":0.7021749},"labels":[],"label_agreement":null},{"id":"W2623711786","doi":"10.1002/hon.2437_11","title":"CVP OR R‐CVP GIVEN AFTER INVOLVED‐FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I‐II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Vincristine; Randomized controlled trial; Progression-free survival; Follicular lymphoma; Internal medicine; Surgery; Radiation therapy; Stage (stratigraphy); Gastroenterology; Cyclophosphamide; Lymphoma; Chemotherapy","score_opus":0.03600107695463218,"score_gpt":0.37193222761093775,"score_spread":0.3359311506563056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623711786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878326,0.00038460773,0.00001890168,0.006591246,0.0007782313,0.002106488,0.000035944246,0.000040712843,0.0022112583],"genre_scores_gemma":[0.99329984,0.0004749353,0.0043608206,0.00042390445,0.00023848159,0.00083989,0.000047705777,0.000016430447,0.00029798513],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99736404,0.0004595102,0.0009347123,0.00052768545,0.00038652297,0.0003275486],"domain_scores_gemma":[0.99705124,0.0012216383,0.00062785204,0.0008170568,0.00010838098,0.00017381615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011313825,0.0002646461,0.0017313437,0.00012235642,0.00011497605,0.000033016408,0.00044243794,0.00050010544,0.00027053338],"category_scores_gemma":[0.0032114326,0.00014663201,0.00032830823,0.000057943318,0.00037281084,0.00016428638,0.00025618568,0.00012974025,0.0000041517496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9544434,0.0071672746,0.014143849,0.000043271706,0.0003231889,0.0029544819,0.00027003573,3.7747884e-7,0.00054201076,0.00096412585,0.00025730973,0.01889066],"study_design_scores_gemma":[0.95855325,0.009633274,0.019025413,0.00015818478,0.00012020895,0.00008586933,0.00007378455,0.0003267578,0.004734243,0.0004379646,0.006668829,0.00018223995],"about_ca_topic_score_codex":0.0003428344,"about_ca_topic_score_gemma":0.00040460934,"teacher_disagreement_score":0.01870842,"about_ca_system_score_codex":0.0002580826,"about_ca_system_score_gemma":0.00027286244,"threshold_uncertainty_score":0.59794796},"labels":[],"label_agreement":null},{"id":"W2623923854","doi":"10.1002/hon.2439_189","title":"ENGAGING ADMINISTRATIVE DATA TO DETERMINE TIME TO DIAGNOSIS AND TREATMENT OF LYMPHOMA: A POPULATION BASED STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Cancer registry; Referral; Cumulative incidence; Population; Incidence (geometry); Cohort; Diagnosis code; Pediatrics; Cancer; Internal medicine; Family medicine","score_opus":0.22143945473183244,"score_gpt":0.427478478394114,"score_spread":0.20603902366228158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2623923854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262965,0.00007431963,0.000008357953,0.004841287,0.000038191178,0.0016647301,0.00005394865,0.000027577094,0.00066194066],"genre_scores_gemma":[0.99543154,0.000013423762,0.0034439059,0.0003685359,0.00003670842,0.0005691186,0.000061308616,0.000009324813,0.00006613208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986539,0.000121850506,0.00034490408,0.0005225753,0.00014336836,0.00021339895],"domain_scores_gemma":[0.9979702,0.00064115477,0.00017004422,0.00088465307,0.00005178306,0.00028214246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016065246,0.00019311214,0.00084393995,0.00007816753,0.00018560608,0.000023768376,0.0001712344,0.0001013093,0.00018581447],"category_scores_gemma":[0.0006471448,0.00012739714,0.00005054687,0.000054378976,0.000048187885,0.000056079527,0.0002025037,0.000023304465,0.00007086577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005390525,0.008959306,0.8795564,0.000014355698,0.00012198882,0.0010314595,0.00025591702,7.551654e-7,0.00007595329,0.000035864286,0.0002220352,0.10918691],"study_design_scores_gemma":[0.006138282,0.016768733,0.9711984,0.000053463977,0.0003140123,0.000101740574,0.00012766647,0.00017839344,0.0012161769,0.000011002738,0.0037745337,0.000117641386],"about_ca_topic_score_codex":0.00024976654,"about_ca_topic_score_gemma":0.00023027303,"teacher_disagreement_score":0.109069265,"about_ca_system_score_codex":0.00027603575,"about_ca_system_score_gemma":0.00011239132,"threshold_uncertainty_score":0.51951045},"labels":[],"label_agreement":null},{"id":"W2624153561","doi":"10.1002/hon.2437_10","title":"OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF <sup>18</sup>F‐FDG PET‐CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Follicular lymphoma; Radiation therapy; Stage (stratigraphy); Nuclear medicine; Multivariate analysis; Proportional hazards model; International Prognostic Index; Retrospective cohort study; Internal medicine; Radiology; Lymphoma; Oncology; Rituximab","score_opus":0.07821086845207646,"score_gpt":0.42442757323974944,"score_spread":0.34621670478767297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624153561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937094,0.00010720332,0.00005556122,0.0026117607,0.00007819157,0.0022169643,0.00008950318,0.000009463319,0.0011219573],"genre_scores_gemma":[0.99773645,0.000052560852,0.0012766519,0.00037631422,0.000027805287,0.00047725564,0.000027026445,0.000011590423,0.000014343639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800074,0.00034878557,0.0007602951,0.00034305232,0.00034229213,0.00020485332],"domain_scores_gemma":[0.9973467,0.0010799799,0.00063620874,0.00055287307,0.00031551498,0.00006870264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052176235,0.00021349202,0.0011999505,0.000090937174,0.00008214456,0.000012402523,0.0004048918,0.0000725725,0.000082469254],"category_scores_gemma":[0.0005369078,0.00012047174,0.0001863668,0.000111126246,0.00040201875,0.00008963199,0.000050296745,0.00009895595,0.0000012399473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027195953,0.017646074,0.9557252,0.00005163939,0.0006434105,0.0012417508,0.0041991426,0.000072853996,0.00014306481,0.013702239,0.00016490844,0.0036901333],"study_design_scores_gemma":[0.033175096,0.023417464,0.92014974,0.0001355453,0.00027738351,0.00025084658,0.012224662,0.0014706112,0.0062248777,0.0005065426,0.0019700378,0.00019720604],"about_ca_topic_score_codex":0.00015989617,"about_ca_topic_score_gemma":0.000052514257,"teacher_disagreement_score":0.03557546,"about_ca_system_score_codex":0.0002949222,"about_ca_system_score_gemma":0.00023490674,"threshold_uncertainty_score":0.49126953},"labels":[],"label_agreement":null},{"id":"W2624207812","doi":"10.1002/hon.2438_72","title":"PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Leukapheresis; Mantle cell lymphoma; Autologous stem-cell transplantation; Internal medicine; Vaccination; Rash; Minimal residual disease; Adverse effect; Peripheral blood mononuclear cell; Oncology; Gastroenterology; Immunology; Lymphoma; CD34; Bone marrow; Stem cell","score_opus":0.043524360428083414,"score_gpt":0.38495610131224156,"score_spread":0.3414317408841582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624207812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464494,0.00005054115,0.000017616638,0.00026726897,0.00019316834,0.0019098677,0.000048355538,0.0000243704,0.0028438538],"genre_scores_gemma":[0.9985562,0.00003636137,0.0003524089,0.00008801849,0.00004375112,0.00005373742,0.000082180784,0.00003612828,0.0007512427],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996612,0.0004899463,0.0013820746,0.00055031234,0.00044872504,0.00051690475],"domain_scores_gemma":[0.99764025,0.0004714473,0.00047194026,0.00092982384,0.00020560849,0.00028091905],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009364089,0.00027681715,0.0019686958,0.00013474388,0.00010045139,0.0000090636995,0.00049146224,0.0004884821,0.0011695251],"category_scores_gemma":[0.00018416908,0.00019046327,0.00027490317,0.00016156975,0.00040980938,0.00010432892,0.00013598826,0.00044227904,0.00001527692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29730025,0.08091693,0.008981935,0.00014507803,0.00007647132,0.0003242724,0.0001085993,5.2764756e-7,0.6048338,0.000008800189,0.00047262828,0.0068307123],"study_design_scores_gemma":[0.39424312,0.07639873,0.0073948274,0.00004377659,0.00008520785,0.000011812357,0.000052041694,0.000037840273,0.5185124,0.000012809569,0.003049517,0.00015790328],"about_ca_topic_score_codex":0.00008299757,"about_ca_topic_score_gemma":0.000021104786,"teacher_disagreement_score":0.09694286,"about_ca_system_score_codex":0.00009904312,"about_ca_system_score_gemma":0.00029508932,"threshold_uncertainty_score":0.9997435},"labels":[],"label_agreement":null},{"id":"W2624425537","doi":"10.1002/hon.2437_13","title":"DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST‐AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12‐YEAR FOLLOW‐UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Rituximab; Medicine; Autologous stem-cell transplantation; Follicular lymphoma; Maintenance therapy; Internal medicine; Surgery; Oncology; Lymphoma; Salvage therapy; Chemotherapy; Progression-free survival","score_opus":0.022196431573017688,"score_gpt":0.2645807255552944,"score_spread":0.2423842939822767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624425537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99332845,0.00017622119,0.000004120201,0.0013252046,0.0004512068,0.0014976271,0.000017727336,0.000028082775,0.003171363],"genre_scores_gemma":[0.9985594,0.000053382446,0.00070210866,0.00025794675,0.000035031066,0.00020279089,0.000019369383,0.000024008847,0.00014591873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742144,0.00015393473,0.00085406506,0.00052574376,0.0004828433,0.00056195364],"domain_scores_gemma":[0.99732786,0.00036747768,0.0009417689,0.0009876982,0.00022863237,0.0001465748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033139123,0.00032336506,0.0016007217,0.00008862089,0.0002144875,0.000018887235,0.00044255445,0.00043943245,0.000071983115],"category_scores_gemma":[0.00071401487,0.00017209233,0.00039486995,0.00017277173,0.00054281787,0.00008001231,0.00024532757,0.00010761136,0.000015008587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03250066,0.009030201,0.9455956,0.00006953313,0.00024500236,0.00030526635,0.00013434651,0.0000024894955,0.000039964685,0.0049325614,0.0002152477,0.0069290763],"study_design_scores_gemma":[0.24892756,0.00338749,0.743795,0.00042641108,0.00022931788,0.000067489935,0.00007729559,0.000017050586,0.0013009458,0.0004121907,0.0012001325,0.00015915386],"about_ca_topic_score_codex":0.00036002434,"about_ca_topic_score_gemma":0.00026847632,"teacher_disagreement_score":0.21642691,"about_ca_system_score_codex":0.0004102876,"about_ca_system_score_gemma":0.00035676177,"threshold_uncertainty_score":0.70177215},"labels":[],"label_agreement":null},{"id":"W2624535566","doi":"10.1002/hon.2437_81","title":"THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"ABVD; Medicine; Oncology; Clinical endpoint; Lymphoma; Internal medicine; Context (archaeology); Stage (stratigraphy); Interim analysis; Dacarbazine; Surrogate endpoint; Clinical trial; Nuclear medicine; Chemotherapy; Biology; Cyclophosphamide","score_opus":0.0370597856809882,"score_gpt":0.3473945094879564,"score_spread":0.3103347238069682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624535566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799646,0.00020890898,0.00003856674,0.015353048,0.00084505184,0.0016409238,0.00009306923,0.000050603045,0.001805235],"genre_scores_gemma":[0.9941209,0.000168523,0.0011657316,0.0018207538,0.00022942857,0.00202881,0.000058245805,0.000023438377,0.0003841616],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.995728,0.0011485214,0.0011019703,0.0008153468,0.0004735372,0.0007325795],"domain_scores_gemma":[0.9951399,0.0027722586,0.00050205016,0.0013194794,0.00006643927,0.00019987943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001546838,0.0004116951,0.0010974532,0.000116144445,0.00030407193,0.00014111304,0.000762777,0.000403246,0.00007331849],"category_scores_gemma":[0.002472809,0.00017147536,0.00028705664,0.00011551285,0.0007047793,0.00013878042,0.00037338753,0.0003779964,0.000039266997],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6011412,0.028626455,0.22294274,0.00014673467,0.00030823186,0.057378773,0.001555716,0.000022177393,0.012887701,0.0021516504,0.0046968567,0.06814175],"study_design_scores_gemma":[0.21543784,0.009510658,0.68662316,0.00054501963,0.00014169473,0.0007784921,0.0004912306,0.0005876212,0.04961932,0.00037042593,0.035381325,0.0005132036],"about_ca_topic_score_codex":0.0000850274,"about_ca_topic_score_gemma":0.0013624891,"teacher_disagreement_score":0.46368042,"about_ca_system_score_codex":0.0006754313,"about_ca_system_score_gemma":0.0003167783,"threshold_uncertainty_score":0.6992562},"labels":[],"label_agreement":null},{"id":"W2624634583","doi":"10.1002/hon.2438_64","title":"FREQUENCY OF PERFORATION &amp; IMPACT OF BOWEL REST IN AGGRESSIVE NON‐HODGKIN LYMPHOMA WITH GASTROINTESTINAL INVOLVEMENT: AN INTERNATIONAL, MULTI‐CENTER RETROSPECTIVE STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Perforation; Retrospective cohort study; Chemotherapy; Lymphoma; Internal medicine; Univariate analysis; Surgery; Peritonitis; Bowel obstruction; Gastrointestinal perforation; Multivariate analysis; Gastroenterology","score_opus":0.06494795422468139,"score_gpt":0.39566113440297185,"score_spread":0.33071318017829043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624634583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99614316,0.000019064384,0.00017174854,0.00014976213,0.00007564662,0.00074093376,0.00003426336,0.00001269659,0.0026527073],"genre_scores_gemma":[0.99337375,0.000021173251,0.006326674,0.00006494591,0.00003967785,0.00005442925,0.00007462816,0.0000120607065,0.00003265334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984442,0.00012441263,0.0005551334,0.00038853684,0.00024878324,0.00023895755],"domain_scores_gemma":[0.99799895,0.00006394746,0.00096763676,0.0005089194,0.0003432307,0.00011728715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002866726,0.00019185117,0.000737457,0.00015838555,0.000075192285,0.000013313524,0.00029423417,0.00011230945,0.00032719615],"category_scores_gemma":[0.0005462417,0.00012964968,0.00010128786,0.0000694111,0.0003918798,0.00026972068,0.00009574742,0.00021558457,0.0000047214517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022143896,0.0051112706,0.9851622,0.000039028044,0.00011506399,0.0006475938,0.0009973401,0.000015266407,0.004862369,0.000109356566,0.000028865543,0.0006972302],"study_design_scores_gemma":[0.012135351,0.009858567,0.97557247,0.00022419117,0.000037941685,0.0005592846,0.0005862091,0.0005095302,0.00034747308,0.000051676263,0.0000101059995,0.00010723153],"about_ca_topic_score_codex":0.0010352021,"about_ca_topic_score_gemma":0.0033301518,"teacher_disagreement_score":0.009920962,"about_ca_system_score_codex":0.0006398574,"about_ca_system_score_gemma":0.00043003648,"threshold_uncertainty_score":0.528696},"labels":[],"label_agreement":null},{"id":"W2800810996","doi":"10.1002/hon.2513","title":"Management of newly diagnosed high‐risk and intermediate‐risk follicular lymphoma with <sup>90</sup>Y ibritumomab tiuxetan in a phase II study","year":2018,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Spectrum Pharmaceuticals","keywords":"Medicine; Ibritumomab tiuxetan; Follicular lymphoma; Internal medicine; Rituximab; International Prognostic Index; Oncology; Gastroenterology; Immunotherapy; Vincristine; Lymphoma; Cyclophosphamide; Radioimmunotherapy; Surgery; Immunology; Chemotherapy; Cancer; Antibody","score_opus":0.014193834309545334,"score_gpt":0.2984657552718471,"score_spread":0.28427192096230175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800810996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956792,0.00051760185,0.000047327132,0.00035452275,0.00006572044,0.0019528084,0.000023501309,0.00006888645,0.0012904577],"genre_scores_gemma":[0.9965134,0.0007257891,0.001900539,0.00019041263,0.00006140778,0.00052393536,0.000021987727,0.000024817442,0.000037665242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973522,0.00033917456,0.000744693,0.00073734863,0.00032374467,0.0005028518],"domain_scores_gemma":[0.99840105,0.00039792736,0.0003457856,0.00048779507,0.00009812524,0.00026933308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035822054,0.00037220918,0.0014229629,0.00019277414,0.00014049132,0.000013480155,0.00015854229,0.0002351166,0.00016634588],"category_scores_gemma":[0.00011097004,0.00023503772,0.00011415665,0.00037187105,0.00052220066,0.000063319334,0.00028365737,0.00014386234,0.000036955487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004180615,0.040374294,0.78033626,0.00012911021,0.0010598911,0.025871223,0.0020388432,0.000005846893,0.0000105362415,0.00198115,0.00036999898,0.14364225],"study_design_scores_gemma":[0.10621288,0.085134536,0.79664063,0.00033072653,0.0016314213,0.0009258951,0.0039515314,0.0004660581,0.0006647287,0.0006091103,0.0030630697,0.00036938844],"about_ca_topic_score_codex":0.000497376,"about_ca_topic_score_gemma":0.00032479636,"teacher_disagreement_score":0.14327286,"about_ca_system_score_codex":0.00026549364,"about_ca_system_score_gemma":0.00010662194,"threshold_uncertainty_score":0.958456},"labels":[],"label_agreement":null},{"id":"W2891861976","doi":"10.1002/hon.2560","title":"Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin","year":2018,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Refractory (planetary science); Anaplastic large-cell lymphoma; Internal medicine; Salvage therapy; Surgery; Gastroenterology; Lymphoma; Chemotherapy; Oncology; CD30","score_opus":0.023676171663027976,"score_gpt":0.3013416210523374,"score_spread":0.2776654493893094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891861976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990899,0.000095167234,0.00007286422,0.00028397137,0.0001673485,0.00063698797,0.0000416079,0.00006551404,0.0077375197],"genre_scores_gemma":[0.9970659,0.000021262123,0.0012979798,0.0007906722,0.000059373877,0.00008270919,0.0000655703,0.000024816954,0.0005917052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785477,0.00014243582,0.0006778017,0.00048584703,0.00032919462,0.00050993706],"domain_scores_gemma":[0.99805933,0.0006477459,0.00036449012,0.00039995805,0.00027515015,0.00025332996],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013768443,0.00029517052,0.0012529154,0.00010962591,0.00009494453,0.0000067406827,0.00013352213,0.00037470585,0.0011547381],"category_scores_gemma":[0.0003230452,0.00015801197,0.0001379427,0.00017994485,0.0003537213,0.000052109783,0.000107495915,0.00011507208,0.00023250005],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061686547,0.017157529,0.970431,0.00012606227,0.00012707239,0.00072196615,0.00015980423,1.1204154e-7,0.0000151109,0.00045969957,0.0026217098,0.0020112246],"study_design_scores_gemma":[0.045915253,0.025443602,0.90216404,0.000102228005,0.0003119927,0.0000918808,0.00013386883,0.00006498853,0.0015835935,0.000035030633,0.023932448,0.00022108165],"about_ca_topic_score_codex":0.000018941362,"about_ca_topic_score_gemma":0.00012087461,"teacher_disagreement_score":0.068267025,"about_ca_system_score_codex":0.0003532847,"about_ca_system_score_gemma":0.00022723102,"threshold_uncertainty_score":0.99975836},"labels":[],"label_agreement":null},{"id":"W2949376168","doi":"10.1002/hon.131_2631","title":"PRIMARY PANCREATIC LYMPHOMA: CLINICAL PRESENTATION, DIAGNOSIS, TREATMENT AND OUTCOME IN A MULTICENTRIC ITALIAN EXPERIENCE","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Hematology; Lymphoma; Medical record; International Prognostic Index; Gastroenterology; Radiation therapy; Oncology; Diffuse large B-cell lymphoma","score_opus":0.06891196737359159,"score_gpt":0.4040591967374352,"score_spread":0.33514722936384356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949376168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148804,0.0017626587,0.0000022614136,0.002018249,0.00020020506,0.0014181876,0.000004246863,0.00005463019,0.0030514987],"genre_scores_gemma":[0.99412644,0.0019617898,0.0012026251,0.0014070863,0.000040869632,0.0009418923,0.00002803623,0.000012407276,0.00027888216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776995,0.00024093955,0.00084073876,0.0005958202,0.00015643949,0.00039608436],"domain_scores_gemma":[0.99758637,0.0016306743,0.00016484004,0.00030391474,0.000040202263,0.0002739844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018375689,0.00024738838,0.0012055786,0.00010317529,0.00004097247,0.000015245949,0.00007433813,0.00029874893,0.000313921],"category_scores_gemma":[0.00031043298,0.00015877107,0.00015480592,0.000192083,0.00018936342,0.00007558995,0.00008188649,0.00007696519,0.0002444223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032606345,0.0060437312,0.9702308,0.00007071526,0.000071889226,0.0011716443,0.0004652515,6.663101e-7,0.000013928253,0.00052617927,0.0001071012,0.020972027],"study_design_scores_gemma":[0.01248337,0.0027173634,0.9730502,0.00005435037,0.00014430242,0.00058156316,0.00035509828,0.00008808091,0.00015369397,0.00005373569,0.010164347,0.0001539175],"about_ca_topic_score_codex":0.00014808234,"about_ca_topic_score_gemma":0.000030962718,"teacher_disagreement_score":0.020818109,"about_ca_system_score_codex":0.0006906343,"about_ca_system_score_gemma":0.00015381878,"threshold_uncertainty_score":0.6474496},"labels":[],"label_agreement":null},{"id":"W2949542758","doi":"10.1002/hon.36_2630","title":"RESULTS OF A MULTICENTER PHASE2 TRIAL OF INVOLVED FIELD RADIOTHERAPY ALONE FOR LOCALIZED NON‐GASTRIC MARGINAL ZONE LYMPHOMA: TROG 05.02","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Marginal zone B-cell lymphoma; Lymphoma; Splenic marginal zone lymphoma; Gastroenterology; Internal medicine; Radiation therapy; Population; Mantle cell lymphoma; Stage (stratigraphy); Surgery; Marginal zone; B cell; Splenectomy; Spleen; Antibody; Immunology","score_opus":0.02820743010664234,"score_gpt":0.329768612454491,"score_spread":0.3015611823478487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949542758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990997,0.00053947855,0.0015527551,0.002566153,0.00041372987,0.0029353644,0.000048728594,0.000031407086,0.00091535464],"genre_scores_gemma":[0.9850926,0.00023801914,0.012973855,0.000940028,0.00010986773,0.00032034752,0.000071898685,0.000017180228,0.00023623486],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99782836,0.0001304444,0.000979361,0.00043478384,0.00024060134,0.00038642672],"domain_scores_gemma":[0.99697876,0.0018263424,0.0004887016,0.0003864709,0.0001620401,0.00015768183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003231659,0.00024785445,0.001779591,0.00013298573,0.00002710837,0.0000040796094,0.0001376108,0.00041777059,0.0002627312],"category_scores_gemma":[0.0003425527,0.00016508132,0.0004314843,0.00018853343,0.00015060691,0.000034221885,0.00004191641,0.00008111771,0.000018374814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85569346,0.035571016,0.024724972,0.00066054304,0.0011711129,0.0005710451,0.00033563637,0.0000061771734,0.010536039,0.0013568561,0.014437351,0.054935794],"study_design_scores_gemma":[0.84523594,0.060745977,0.0050559756,0.00019349318,0.00050012884,0.00026229175,0.00014540016,0.0013852007,0.052904543,0.00009017608,0.033248365,0.00023249077],"about_ca_topic_score_codex":0.00010012087,"about_ca_topic_score_gemma":0.000015780157,"teacher_disagreement_score":0.054703306,"about_ca_system_score_codex":0.00021766775,"about_ca_system_score_gemma":0.00023319386,"threshold_uncertainty_score":0.6731821},"labels":[],"label_agreement":null},{"id":"W2949614109","doi":"10.1002/hon.106_2630","title":"PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF &gt;4 YEARS OF FOLLOW‐UP","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Pembrolizumab; Autologous stem-cell transplantation; Oncology; Cohort; Population; Lymphoma; Progression-free survival; Surgery; Chemotherapy; Hodgkin lymphoma; Cancer; Immunotherapy","score_opus":0.01381244760435406,"score_gpt":0.28203078677181476,"score_spread":0.2682183391674607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949614109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973922,0.00010927781,0.0000014844418,0.00016679376,0.000116722695,0.0015633506,0.00004417628,0.000017455757,0.00058856135],"genre_scores_gemma":[0.9993392,0.000011772957,0.00032415768,0.00007444459,0.000009807335,0.00013150388,0.00004181752,0.000018683528,0.000048573187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99745244,0.00022634369,0.0010323902,0.00048641424,0.00045889837,0.0003435246],"domain_scores_gemma":[0.9981755,0.00045002485,0.0005648598,0.00050732435,0.00018373845,0.000118578006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018667855,0.00024830442,0.0016118508,0.00021042873,0.000010970658,0.0000029055757,0.00014828313,0.0002831141,0.00012712757],"category_scores_gemma":[0.00016323122,0.000169396,0.00015412515,0.0003557929,0.00018276408,0.00004900662,0.0001113603,0.0001063125,0.000029394696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040975824,0.10418581,0.837823,0.00016963064,0.0003108359,0.00052274246,0.0010496464,0.0000033107797,0.00013630177,0.00015407654,0.0003349304,0.014333894],"study_design_scores_gemma":[0.22507262,0.040961333,0.73143876,0.0001799886,0.00020299795,0.000034358753,0.00035395962,0.000017460843,0.0010772832,0.000023105427,0.00050753646,0.00013058662],"about_ca_topic_score_codex":0.0001137584,"about_ca_topic_score_gemma":0.00015551102,"teacher_disagreement_score":0.1840968,"about_ca_system_score_codex":0.00023444241,"about_ca_system_score_gemma":0.0002221968,"threshold_uncertainty_score":0.69077677},"labels":[],"label_agreement":null},{"id":"W2949669062","doi":"10.1002/hon.99_2629","title":"CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B‐CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; Spinal Cord Injury BC","funders":"","keywords":"Subtyping; Immunohistochemistry; Concordance; Diffuse large B-cell lymphoma; Medicine; Oncology; Internal medicine; Lymphoma; Germinal center; Pathology; B cell; Immunology; Antibody","score_opus":0.03413755928242088,"score_gpt":0.3608417598344579,"score_spread":0.32670420055203697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949669062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994773,0.0014213865,0.00010831367,0.0004646536,0.00012575583,0.002189383,0.00002417356,0.000031273514,0.0008620859],"genre_scores_gemma":[0.9963691,0.000093631985,0.0020384998,0.000492822,0.00012498614,0.000702365,0.00009920021,0.00001241573,0.000066976456],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985359,0.00011209369,0.0004354971,0.00040910344,0.00013277377,0.00037466915],"domain_scores_gemma":[0.99824315,0.0011705013,0.00017666482,0.00028294127,0.000037101374,0.00008964498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037942204,0.0001925729,0.00073897565,0.00003515852,0.00008958216,0.000013204091,0.00012147419,0.00028836657,0.000035999972],"category_scores_gemma":[0.00016733122,0.00011297779,0.00012182005,0.00007970339,0.000080814076,0.00003534398,0.00007234788,0.00011715732,0.00001643213],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.086070865,0.055946138,0.35168445,0.0011640969,0.00018312097,0.0013886527,0.0018079722,5.2074466e-7,0.48333558,0.0020738724,0.0014343782,0.014910347],"study_design_scores_gemma":[0.60149413,0.005667874,0.0065460084,0.0001563129,0.00018896276,0.00040343477,0.00061001244,0.00010660251,0.37514848,0.00029026906,0.009108561,0.000279381],"about_ca_topic_score_codex":0.000006252984,"about_ca_topic_score_gemma":6.7187676e-7,"teacher_disagreement_score":0.51542324,"about_ca_system_score_codex":0.00020134095,"about_ca_system_score_gemma":0.00014213733,"threshold_uncertainty_score":0.46071005},"labels":[],"label_agreement":null},{"id":"W2949706248","doi":"10.1002/hon.103_2629","title":"STAGE I‐II NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA IN THE MODERN ERA: A MULTI‐INSTITUTIONAL EXPERIENCE OF ADULT PATIENTS BY ILROG","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Stage (stratigraphy); Rituximab; CD20; Internal medicine; Oncology; Lymphoma; Hodgkin lymphoma; Radiation therapy; Chemotherapy; Progression-free survival; Overall survival; Retrospective cohort study","score_opus":0.01791784213219566,"score_gpt":0.2938603189074094,"score_spread":0.2759424767752137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949706248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551845,0.00059523,0.000078464276,0.00064166373,0.00016157232,0.0010852161,0.00005029056,0.000026071573,0.001843063],"genre_scores_gemma":[0.9961242,0.00017103954,0.0013365835,0.0017037087,0.000014563238,0.00038590588,0.000078289835,0.000010331989,0.00017538588],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788254,0.00017754633,0.00061086525,0.0004950554,0.00041566067,0.0004183169],"domain_scores_gemma":[0.9987824,0.00033696243,0.00021481434,0.0004057196,0.00014416821,0.00011595184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001584128,0.0002691527,0.00086309476,0.000059289625,0.000096300355,0.0000074639406,0.00024907826,0.0003085566,0.0002833718],"category_scores_gemma":[0.00023808774,0.00014419216,0.00017863997,0.00019629094,0.00033307102,0.0000707156,0.00014551007,0.0001036755,0.000094873576],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017619466,0.02590349,0.9259745,0.00017836186,0.00012930443,0.0012320653,0.004959781,0.000041879488,0.0024229276,0.011206948,0.0011175404,0.025071288],"study_design_scores_gemma":[0.094517075,0.010428761,0.81478894,0.0005072266,0.00021239746,0.0013330246,0.002163235,0.009636605,0.025645772,0.00046236848,0.039488073,0.000816526],"about_ca_topic_score_codex":0.0002514195,"about_ca_topic_score_gemma":0.000039784834,"teacher_disagreement_score":0.11118553,"about_ca_system_score_codex":0.0005941834,"about_ca_system_score_gemma":0.00031510272,"threshold_uncertainty_score":0.58799857},"labels":[],"label_agreement":null},{"id":"W2949728827","doi":"10.1002/hon.228_2631","title":"FUNCTIONAL PREDICTORS OF CHEMOTHERAPY TOXICITY IN ELDERLY LYMPHOMA PATIENTS – A PROSPECTIVE PILOT STUDY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemotherapy; Febrile neutropenia; Internal medicine; Neutropenia; Geriatric oncology; Toxicity; Chemotherapy regimen; Grip strength; Surgery; Cancer","score_opus":0.025320815363330085,"score_gpt":0.29119575744946385,"score_spread":0.26587494208613377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949728827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914605,0.00002550468,0.000017929642,0.00050873525,0.0003535908,0.0022834572,0.0000058690707,0.000064493826,0.0052799056],"genre_scores_gemma":[0.9987743,0.0000052008554,0.00022482409,0.00041973876,0.000041702533,0.00013222119,0.000013506574,0.000015317015,0.00037321297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998196,0.00014728303,0.0005511079,0.00044304895,0.000359717,0.00030284107],"domain_scores_gemma":[0.99892396,0.0003376959,0.00018057042,0.00026955176,0.00018234143,0.0001058756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002111212,0.00018946345,0.00085474923,0.00012951693,0.000020402045,0.0000029865098,0.000113430004,0.0001814466,0.0008743727],"category_scores_gemma":[0.0003091886,0.0001408283,0.000069568225,0.0002911707,0.0001474405,0.0000554295,0.00006633546,0.00020734082,0.000117042655],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033307911,0.020644583,0.97197115,0.00005819441,0.00009332043,0.00006178229,0.00045161147,0.0000029017565,0.0005985441,0.00025879513,0.0006615898,0.0018667491],"study_design_scores_gemma":[0.017850403,0.05255747,0.92748964,0.000043328495,0.000025807745,0.00006992981,0.00028989193,0.000025603298,0.0009602763,0.00027707632,0.0002976144,0.00011294177],"about_ca_topic_score_codex":0.000043854165,"about_ca_topic_score_gemma":0.00008329758,"teacher_disagreement_score":0.04448148,"about_ca_system_score_codex":0.0003546962,"about_ca_system_score_gemma":0.00016780203,"threshold_uncertainty_score":0.9573768},"labels":[],"label_agreement":null},{"id":"W2949744877","doi":"10.1002/hon.211_2631","title":"PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Mycosis fungoides; Refractory (planetary science); Adverse effect; Peripheral T-cell lymphoma; Brentuximab vedotin; Oncology; Cutaneous T-cell lymphoma; Clinical endpoint; Phases of clinical research; Gastroenterology; T cell; Chemotherapy; Clinical trial; Immunology; Hodgkin lymphoma; Immune system","score_opus":0.017398915298579,"score_gpt":0.29152571588674026,"score_spread":0.27412680058816125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949744877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97228956,0.0019023842,0.000024564491,0.00064411643,0.000101879414,0.001500539,0.000039012066,0.00004914553,0.023448786],"genre_scores_gemma":[0.9938827,0.0005854005,0.0017347393,0.0004588851,0.00003789723,0.00006752295,0.00003380635,0.00005120069,0.0031478244],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963684,0.0002894377,0.0010440885,0.00103487,0.00045199413,0.00081119145],"domain_scores_gemma":[0.9971706,0.0013995795,0.000338511,0.0005248809,0.00019407911,0.0003723051],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045646683,0.00045484022,0.0016484436,0.00032218016,0.000090254165,0.000022881886,0.0002248473,0.0007814791,0.00018947749],"category_scores_gemma":[0.00047997118,0.00037458967,0.00014523377,0.00035789487,0.00084531575,0.00006501687,0.00037801795,0.00035501085,0.00006448283],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13764463,0.039990705,0.19287902,0.004726318,0.0002854731,0.017843928,0.008175299,0.0000885863,0.5617014,0.0006134905,0.0022022205,0.03384893],"study_design_scores_gemma":[0.31854245,0.14005575,0.1487301,0.0013676983,0.0005892978,0.19470584,0.0122046545,0.03960532,0.114595175,0.0011107334,0.025209194,0.00328377],"about_ca_topic_score_codex":0.0001486523,"about_ca_topic_score_gemma":0.000052847547,"teacher_disagreement_score":0.4471062,"about_ca_system_score_codex":0.00045865274,"about_ca_system_score_gemma":0.0007076403,"threshold_uncertainty_score":0.9998706},"labels":[],"label_agreement":null},{"id":"W2949786431","doi":"10.1002/hon.113_2629","title":"OUTCOME OF PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA IN THE RITUXIMAB ERA: IMPACT OF A PET‐GUIDED APPROACH","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Rituximab; Lymphoma; Diffuse large B-cell lymphoma; Pericardial effusion; CHOP; Nuclear medicine; Internal medicine; Radiology; Oncology","score_opus":0.0446453396361501,"score_gpt":0.34547408597828105,"score_spread":0.30082874634213097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949786431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592441,0.0004981174,0.000016667062,0.00047411452,0.00005717656,0.0007774754,0.000018394852,0.000017065327,0.03889691],"genre_scores_gemma":[0.9968955,0.00004985119,0.0021773686,0.00065155356,0.00002227997,0.00009743178,0.000043755645,0.000010185161,0.00005210544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794203,0.00025432973,0.00078180176,0.00031370125,0.0003154425,0.0003927215],"domain_scores_gemma":[0.99827,0.00086856703,0.0002943822,0.0003930144,0.00007885095,0.00009519102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005683227,0.00021680222,0.0014994282,0.00011260773,0.000020234464,0.0000032218427,0.00021023102,0.00020404332,0.00028444114],"category_scores_gemma":[0.00013209334,0.00010722752,0.0003843383,0.00025666875,0.0001519968,0.000031997854,0.00010178914,0.00015089421,0.00006656378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061693205,0.027142478,0.9656298,0.00036794302,0.00009288652,0.00085475727,0.00035206246,0.000003297481,0.00038732705,0.0027964073,0.00093679805,0.00081928796],"study_design_scores_gemma":[0.027691666,0.003445236,0.9631866,0.000044416338,0.00014007968,0.0038819872,0.00027544194,0.00018618545,0.00041530194,0.00015061263,0.00046487365,0.00011756647],"about_ca_topic_score_codex":0.00010353803,"about_ca_topic_score_gemma":0.0000072738217,"teacher_disagreement_score":0.038844805,"about_ca_system_score_codex":0.00037355477,"about_ca_system_score_gemma":0.0003535217,"threshold_uncertainty_score":0.43726113},"labels":[],"label_agreement":null},{"id":"W2949814266","doi":"10.1002/hon.118_2630","title":"CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University","funders":"","keywords":"Cytokine release syndrome; Medicine; Internal medicine; Refractory (planetary science); Gastroenterology; Clinical endpoint; Lymphoma; Diffuse large B-cell lymphoma; Phases of clinical research; Cytokine; Peripheral T-cell lymphoma; Clinical trial; Immunotherapy; Immunology; T cell; Immune system; Cancer; Biology","score_opus":0.03648638014391697,"score_gpt":0.33761168354361193,"score_spread":0.30112530339969495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949814266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949792,0.00031993078,0.000009088615,0.00017543219,0.00009799022,0.0010939562,0.000023668923,0.000054589655,0.0032461702],"genre_scores_gemma":[0.99769706,0.0002615998,0.000115372175,0.0004323085,0.000010830584,0.000045855748,0.000074819414,0.000029746605,0.0013323888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967701,0.0007265485,0.00075665285,0.000683933,0.00043341503,0.00062935223],"domain_scores_gemma":[0.9976528,0.0011834506,0.00028648955,0.00041979222,0.00014863534,0.00030880788],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035893294,0.00031073176,0.0014263025,0.0003188635,0.000042837233,0.000003738064,0.00018336152,0.0006616547,0.002201002],"category_scores_gemma":[0.0005287587,0.00022353535,0.00017402548,0.0005175185,0.0002544988,0.000076771044,0.00026254644,0.0005756715,0.00018055651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044807415,0.016233364,0.9585636,0.00014138802,0.00008777887,0.0020001198,0.00012804527,0.0000023681532,0.016436933,0.00010155013,0.0000900702,0.0017340278],"study_design_scores_gemma":[0.033957448,0.011849665,0.94838566,0.00007151147,0.00010091249,0.00059442304,0.00006695381,0.0007371784,0.0019192132,0.00018094225,0.0019021706,0.00023395257],"about_ca_topic_score_codex":0.000056069257,"about_ca_topic_score_gemma":0.000013870248,"teacher_disagreement_score":0.029476708,"about_ca_system_score_codex":0.00020251084,"about_ca_system_score_gemma":0.00012080874,"threshold_uncertainty_score":0.9987111},"labels":[],"label_agreement":null},{"id":"W2949885403","doi":"10.1002/hon.98_2630","title":"CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH HODGKIN'S LYMPHOMA OLDER THAN 60 YEARS TREATED IN SWITZERLAND OVER THE LAST 17 YEARS","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"WiLAN (Canada)","funders":"","keywords":"Medicine; Internal medicine; ABVD; Stage (stratigraphy); Chemotherapy; Population; Surgery; Radiation therapy; Gastroenterology; Chemotherapy regimen; Cyclophosphamide; Vincristine","score_opus":0.02222822920117366,"score_gpt":0.3169711645304888,"score_spread":0.2947429353293151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949885403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99851596,0.00006018297,7.0806493e-7,0.00019873686,0.00008773821,0.00059445057,0.000017104818,0.000016000604,0.00050910766],"genre_scores_gemma":[0.99911386,0.00005429294,0.00011167896,0.0005420411,0.000019948799,0.000030921008,0.000036536858,0.000011553861,0.000079171834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99868506,0.00012331906,0.0005081168,0.0002903434,0.00016538905,0.00022776605],"domain_scores_gemma":[0.99884456,0.0005500289,0.00020908931,0.00024505606,0.000051215124,0.00010006755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018163297,0.0001489887,0.00085040636,0.000052969663,0.000014908273,0.000006746898,0.000073688,0.00025336724,0.00017033338],"category_scores_gemma":[0.00009691274,0.0000771222,0.00007579098,0.0001322443,0.00021307259,0.0000241117,0.000071860675,0.00010999099,0.000038252547],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056372944,0.0019879977,0.98844135,0.000024727331,0.000080521364,0.00060730183,0.00007922477,1.229221e-7,0.0000018423507,0.00017653673,0.00019093089,0.007845703],"study_design_scores_gemma":[0.010837039,0.0021425323,0.9845905,0.000057671754,0.00009943085,0.000058783116,0.000032463788,0.000010351497,0.00000599968,0.000013923684,0.0020626506,0.00008867038],"about_ca_topic_score_codex":0.00004558479,"about_ca_topic_score_gemma":0.00005567531,"teacher_disagreement_score":0.010273309,"about_ca_system_score_codex":0.00007888572,"about_ca_system_score_gemma":0.00005326114,"threshold_uncertainty_score":0.31449518},"labels":[],"label_agreement":null},{"id":"W2949969572","doi":"10.1002/hon.4_2629","title":"IDENTIFYING MUTATIONS ENRICHED IN RELAPSED‐REFRACTORY DLBCL TO DERIVE GENETIC FACTORS UNDERLYING TREATMENT RESISTANCE","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; McGill University; Queen's University; Genome British Columbia; Princess Margaret Cancer Centre; Simon Fraser University","funders":"","keywords":"Oncology; Diffuse large B-cell lymphoma; Internal medicine; Exome sequencing; Population; Exome; Medicine; Lymphoma; Germline mutation; Cohort; Mutation; Biology; Gene; Genetics","score_opus":0.08466862076756414,"score_gpt":0.3714651027956474,"score_spread":0.2867964820280832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949969572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910204,0.0010929194,0.00009536367,0.0013444114,0.0002121119,0.0010904832,0.0000045042384,0.000075291,0.0050645145],"genre_scores_gemma":[0.9936584,0.00014571953,0.0045212107,0.00054201356,0.000017249726,0.00028903846,0.00002792931,0.000018811028,0.00077961973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982198,0.00013984046,0.0004816317,0.0005358662,0.00018787303,0.00043499187],"domain_scores_gemma":[0.99847496,0.00079252315,0.00012607551,0.00031421552,0.000050217503,0.00024203911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000804023,0.00024978849,0.00079655,0.00019255537,0.00007436772,0.000015868625,0.00008750919,0.0002655382,0.0003875704],"category_scores_gemma":[0.0001582227,0.00017574597,0.00015037066,0.00030016777,0.0000600476,0.00003808856,0.00004928708,0.00012976705,0.0005645068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035936123,0.0042333174,0.97877324,0.00008204425,0.00017004716,0.0022767435,0.0022440178,0.000042912357,0.0037724436,0.003218748,0.00020767756,0.004619431],"study_design_scores_gemma":[0.0062647285,0.0022497296,0.9796093,0.00009738757,0.000121014666,0.00014521781,0.0015018855,0.000019985771,0.0011453956,0.0008865784,0.007745525,0.00021321897],"about_ca_topic_score_codex":0.00007459424,"about_ca_topic_score_gemma":0.00044766907,"teacher_disagreement_score":0.0075378474,"about_ca_system_score_codex":0.0016314852,"about_ca_system_score_gemma":0.00022260196,"threshold_uncertainty_score":0.72557807},"labels":[],"label_agreement":null},{"id":"W2950210042","doi":"10.1002/hon.119_2630","title":"MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL)","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Dosing; Cytokine release syndrome; Adverse effect; Gastroenterology; Chills; Internal medicine; Refractory (planetary science); Toxicity; Lymphoma; Neurotoxicity; Anesthesia; Immunotherapy; Cancer; Chimeric antigen receptor","score_opus":0.021715764776681783,"score_gpt":0.2974048794280057,"score_spread":0.2756891146513239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950210042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98779213,0.0003565152,0.00010267809,0.0006676169,0.0001087851,0.0014409273,0.0000045085326,0.00006319625,0.009463629],"genre_scores_gemma":[0.99652475,0.00025058177,0.000995503,0.0005046201,0.000022510194,0.000061973326,0.000009011689,0.000047621783,0.001583456],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99715203,0.00034671836,0.00066286273,0.0007160889,0.0004533451,0.0006689559],"domain_scores_gemma":[0.9979835,0.0008085261,0.00025953157,0.00056334963,0.000099182114,0.0002859196],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005556806,0.00031989967,0.0013894498,0.00034460457,0.00004989278,0.000013226493,0.00021139669,0.00044133601,0.0011343606],"category_scores_gemma":[0.00012642257,0.0002398691,0.000105801715,0.0005001218,0.00041392603,0.0000785731,0.00022653468,0.0006581138,0.00006194666],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029130308,0.005345892,0.3195799,0.003075826,0.00023452398,0.025953721,0.00087228615,0.00011957026,0.54675037,0.0009212164,0.00043456696,0.06758181],"study_design_scores_gemma":[0.13426478,0.09467867,0.5313249,0.0028453723,0.0005350563,0.056699384,0.0029306419,0.029755624,0.11103548,0.0014215476,0.031886097,0.0026224053],"about_ca_topic_score_codex":0.00015928531,"about_ca_topic_score_gemma":0.000047783797,"teacher_disagreement_score":0.4357149,"about_ca_system_score_codex":0.00038021026,"about_ca_system_score_gemma":0.00029513382,"threshold_uncertainty_score":0.99977875},"labels":[],"label_agreement":null},{"id":"W2950234208","doi":"10.1002/hon.106_2629","title":"COST‐EFFECTIVENESS AND COST‐UTILITY ANALYSIS OF MULTIPLE TREATMENT STRATEGIES USING ABVD AND/OR BEACOPP IN THE TREATMENT OF ADVANCED‐STAGE HODGKIN LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre","funders":"Karolinska Institutet","keywords":"Medicine; ABVD; Incremental cost-effectiveness ratio; Quality-adjusted life year; Life expectancy; Cost effectiveness; Brentuximab vedotin; Oncology; Hodgkin lymphoma; Internal medicine; Lymphoma; Population; Risk analysis (engineering); Environmental health; Chemotherapy","score_opus":0.09515614530214744,"score_gpt":0.397217687607386,"score_spread":0.3020615423052386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950234208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565965,0.0016205438,0.000046647576,0.00010174011,0.000034744146,0.0021782946,0.000058148296,0.000012448727,0.00028776252],"genre_scores_gemma":[0.99747765,0.0013863506,0.0007191762,0.000038355854,0.000005542372,0.00032061685,0.000029906101,0.0000068336517,0.000015540902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99834377,0.00038009512,0.00045184905,0.00042319103,0.00014184685,0.00025925305],"domain_scores_gemma":[0.9971652,0.0021653143,0.00021600309,0.00031793574,0.00005463999,0.000080882746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021679414,0.00025275,0.001586136,0.00016547422,0.00003981785,0.000010406986,0.000054839184,0.00019315934,0.0000499365],"category_scores_gemma":[0.00005549695,0.00012356271,0.00019004916,0.00038108372,0.00023389136,0.00006814391,0.000027144528,0.000031842308,0.0000011762826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030401815,0.008965249,0.9152976,0.00014394164,0.0010573472,0.00040810718,0.0010888035,0.00019765411,0.001208793,0.0008579782,7.835309e-7,0.06773351],"study_design_scores_gemma":[0.014849096,0.00999995,0.960526,0.0000622684,0.0014525302,0.00014473908,0.0033899688,0.002332605,0.0061497088,0.000053574026,0.00092650426,0.00011308265],"about_ca_topic_score_codex":0.0007259316,"about_ca_topic_score_gemma":0.0007523389,"teacher_disagreement_score":0.067620434,"about_ca_system_score_codex":0.00052039465,"about_ca_system_score_gemma":0.00019201843,"threshold_uncertainty_score":0.5038741},"labels":[],"label_agreement":null},{"id":"W2950771228","doi":"10.1002/hon.42_2629","title":"CRYPTIC <i>MYC</i> AND <i>BCL2</i> REARRANGEMENTS ARE AMONG A RANGE OF GENETIC MECHANISMS UNDERLYING THE DOUBLE HIT SIGNATURE IN NON‐DOUBLE HIT DIFFUSE LARGE B‐CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Simon Fraser University","funders":"","keywords":"Biology; BCL6; Breakpoint; Gene rearrangement; Diffuse large B-cell lymphoma; Locus (genetics); Genetics; Population; Germline; Gene; Indel; Chromosomal translocation; Cancer research; Single-nucleotide polymorphism; B cell; Medicine; Germinal center","score_opus":0.024663027561924115,"score_gpt":0.2806197764140144,"score_spread":0.2559567488520903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950771228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904321,0.0018354504,0.000057971913,0.0011416556,0.0001707522,0.0018731857,0.000009420615,0.000044843542,0.0044346116],"genre_scores_gemma":[0.99672276,0.0003840323,0.0007383711,0.0014101353,0.00001558995,0.00031998483,0.000013376449,0.00002935419,0.00036637817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779516,0.00012943706,0.00057693967,0.00057137787,0.00032711797,0.00059998484],"domain_scores_gemma":[0.9985806,0.00036758202,0.0003346948,0.0004625212,0.00007252951,0.00018211974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002942998,0.00033045365,0.0011215392,0.000112380076,0.00009427011,0.000021402353,0.00020242708,0.0005347818,0.00023527611],"category_scores_gemma":[0.000023023904,0.00020191341,0.00016833734,0.00027476143,0.00015194749,0.00006306319,0.00021028392,0.00022450446,0.00008990687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026702774,0.017148554,0.9592452,0.00087399024,0.00030410584,0.00262739,0.0013843718,0.000009766621,0.0061723967,0.0055794143,0.0014424932,0.0025420133],"study_design_scores_gemma":[0.13248087,0.0028596197,0.85233355,0.00049867725,0.0005781928,0.0005135763,0.0019625633,0.00052835594,0.003324681,0.0018740741,0.0025468692,0.0004989514],"about_ca_topic_score_codex":0.000146931,"about_ca_topic_score_gemma":0.00019036676,"teacher_disagreement_score":0.1298106,"about_ca_system_score_codex":0.00025939714,"about_ca_system_score_gemma":0.000095325275,"threshold_uncertainty_score":0.823379},"labels":[],"label_agreement":null},{"id":"W2950978058","doi":"10.1002/hon.43_2629","title":"FUNCTIONAL CHARACTERIZATION OF <i>NFKBIZ</i> 3′ UTR MUTATIONS IN DIFFUSE LARGE B‐CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Genome British Columbia; Spinal Cord Injury BC; Simon Fraser University","funders":"","keywords":"Untranslated region; Diffuse large B-cell lymphoma; Biology; Three prime untranslated region; Signal transduction; Mutation; Gene; Genetics; Cancer research; Molecular biology; Messenger RNA","score_opus":0.019070139544184263,"score_gpt":0.27324969611325584,"score_spread":0.2541795565690716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950978058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990671,0.00007933876,0.00007757315,0.0010709825,0.00017792091,0.00045706704,0.00002151041,0.000033100427,0.00741151],"genre_scores_gemma":[0.9978981,0.0000654564,0.00024853923,0.00089319586,0.000026287416,0.00010454168,0.00029809965,0.000008630967,0.00045716058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891454,0.000071935414,0.0003888223,0.00025022935,0.00014728478,0.00022717347],"domain_scores_gemma":[0.9992967,0.0002393494,0.00014696442,0.00016735095,0.00006669656,0.000082928775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010057487,0.00012304212,0.0005264877,0.00010334409,0.000024105824,0.0000034985192,0.000044272605,0.00022051275,0.0007490643],"category_scores_gemma":[0.000045949393,0.000090038106,0.00009947917,0.00019478632,0.000052494972,0.00004918029,0.00004068456,0.00005970793,0.00040006186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005222579,0.041384287,0.9073983,0.00015474457,0.000052652995,0.00039282558,0.00019648967,0.0000017574357,0.030701617,0.016253473,0.00036425245,0.0025773768],"study_design_scores_gemma":[0.027578602,0.0010168232,0.94492805,0.000045790737,0.00006337628,0.00027930696,0.00009494918,0.00018174198,0.014029599,0.00022244066,0.011449979,0.000109330285],"about_ca_topic_score_codex":0.0000093303515,"about_ca_topic_score_gemma":0.000008279998,"teacher_disagreement_score":0.040367465,"about_ca_system_score_codex":0.00018824101,"about_ca_system_score_gemma":0.00015064854,"threshold_uncertainty_score":0.8201729},"labels":[],"label_agreement":null},{"id":"W2951473081","doi":"10.1002/hon.127_2629","title":"HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Chemoimmunotherapy; Fludarabine; Internal medicine; Lymphoma; Cyclophosphamide; Gastroenterology; Immunotherapy; Oncology; Rituximab; Immunology; Surgery; Chemotherapy; Cancer","score_opus":0.025236009386087662,"score_gpt":0.31089935114862133,"score_spread":0.28566334176253366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951473081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886222,0.0009476544,0.00002697024,0.0013953836,0.00016669223,0.00091965473,0.0000051295606,0.000040661882,0.007875661],"genre_scores_gemma":[0.9919688,0.00043667425,0.0011690648,0.0010598483,0.000034258188,0.00008574766,0.00001951454,0.000030899642,0.00519518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976568,0.00045400913,0.00062888465,0.0004558406,0.0002633243,0.00054110814],"domain_scores_gemma":[0.9984639,0.0005552584,0.00015883186,0.0005498828,0.00011824542,0.00015385287],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006781083,0.00022275234,0.001232239,0.00017780568,0.000025164974,0.000006754823,0.00020261807,0.00047443752,0.013545003],"category_scores_gemma":[0.000073960975,0.00015969125,0.0002126388,0.00034527146,0.00018209635,0.000041157324,0.000106835585,0.00031527545,0.00033965803],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006236092,0.0010469196,0.03299004,0.0002265551,0.000052073072,0.0011736489,0.00016632915,0.00000964568,0.95387304,0.00070504827,0.00044051697,0.003080071],"study_design_scores_gemma":[0.038821984,0.008409007,0.15078737,0.0004194185,0.00006850138,0.0013595863,0.00042215505,0.00070079305,0.50163347,0.0032747914,0.29338396,0.0007189706],"about_ca_topic_score_codex":0.0002027899,"about_ca_topic_score_gemma":0.000013107808,"teacher_disagreement_score":0.4522396,"about_ca_system_score_codex":0.00030152616,"about_ca_system_score_gemma":0.00021219478,"threshold_uncertainty_score":0.9873567},"labels":[],"label_agreement":null},{"id":"W2951482915","doi":"10.1002/hon.99_2630","title":"EXPLORATORY BIOMARKER ANALYSIS IN THE PH 3 ECHELON‐1 STUDY: WORSE OUTCOME WITH ABVD IN PATIENTS WITH ELEVATED BASELINE LEVELS OF SCD30 AND TARC","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Dacarbazine; Oncology; ABVD; Biomarker; Post-hoc analysis; Progression-free survival; Gastroenterology; Lymphoma; Overall survival; CD30; Vincristine; Chemotherapy; Cyclophosphamide","score_opus":0.045777632030831635,"score_gpt":0.3204171451610274,"score_spread":0.27463951313019574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951482915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99786645,0.00008583989,0.000012363857,0.0005717242,0.000014700408,0.001249728,0.000010619887,0.000013327875,0.00017523642],"genre_scores_gemma":[0.99897385,0.000007750874,0.00033981484,0.0004926326,0.0000031214624,0.00013456077,0.000024507031,0.000008392889,0.000015353075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99815387,0.0004153932,0.00051087333,0.00038658016,0.0002805088,0.00025277634],"domain_scores_gemma":[0.9987097,0.0006098424,0.00018008109,0.0003302485,0.00010001697,0.000070123744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000639475,0.00019881749,0.0010931663,0.00028697235,0.000019852254,0.000006831055,0.000092443566,0.00014023225,0.00016066205],"category_scores_gemma":[0.00010271921,0.000088926245,0.000056026016,0.0009997287,0.00013241971,0.00006199215,0.000050279617,0.00014207157,0.000010795261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015832974,0.0074557806,0.98839456,0.000032824522,0.00042899765,0.0005860046,0.0005203451,0.000007807586,0.000016958154,0.000077696925,0.00001230523,0.00088342826],"study_design_scores_gemma":[0.013983253,0.004207605,0.97988725,0.00004312096,0.0004885931,0.000019354004,0.0010678192,0.000071567185,0.00006507709,0.0000144231635,0.000044868062,0.00010705982],"about_ca_topic_score_codex":0.00007799021,"about_ca_topic_score_gemma":0.00068936276,"teacher_disagreement_score":0.012399956,"about_ca_system_score_codex":0.00012771411,"about_ca_system_score_gemma":0.0000831002,"threshold_uncertainty_score":0.3626307},"labels":[],"label_agreement":null},{"id":"W2951527270","doi":"10.1002/hon.112_2631","title":"EFFICIENCY AND SAFETY OF STEM CELL MOBILIZATION FOLLOWING GDP SALVAGE IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Plerixafor; Apheresis; Leukapheresis; Etoposide; Granulocyte colony-stimulating factor; Neutropenia; Internal medicine; Gemcitabine; Regimen; Surgery; Urology; Chemotherapy; CD34; Stem cell; CXCR4","score_opus":0.01176025195940498,"score_gpt":0.2661096031595577,"score_spread":0.2543493512001527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951527270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281913,0.00008765581,0.000096792406,0.00006301512,0.00012945978,0.00067372987,0.0000022818244,0.000026208378,0.0061017363],"genre_scores_gemma":[0.9992845,0.000029503433,0.00018149256,0.00016946312,0.0000059217305,0.000024281966,0.000007731162,0.000009767017,0.00028732285],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99902564,0.0000923045,0.00032405122,0.0002499163,0.00013418013,0.00017390803],"domain_scores_gemma":[0.9993631,0.00023319306,0.00012874414,0.00016091394,0.00004849714,0.00006553345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012582085,0.00010549347,0.00050637085,0.000079438556,0.000030497045,0.0000025192398,0.000044405228,0.00017670523,0.00014029322],"category_scores_gemma":[0.000021232754,0.0000642229,0.000043225158,0.00024275685,0.00006894549,0.000052895313,0.00003523509,0.000110109075,0.000015612828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002742617,0.0014696809,0.99053407,0.00015008671,0.000017296989,0.000071227885,0.00017296907,0.000019472885,0.00097117736,0.00034102626,0.000039411676,0.0034709957],"study_design_scores_gemma":[0.019143378,0.010598172,0.96401733,0.00018934374,0.00009407742,0.000069365014,0.00039232723,0.00006704956,0.0013836864,0.000022623039,0.003845219,0.00017743831],"about_ca_topic_score_codex":0.000010236821,"about_ca_topic_score_gemma":0.0000208375,"teacher_disagreement_score":0.026516719,"about_ca_system_score_codex":0.00014883056,"about_ca_system_score_gemma":0.00014626919,"threshold_uncertainty_score":0.2618934},"labels":[],"label_agreement":null},{"id":"W2951720456","doi":"10.1002/hon.5_2629","title":"ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R<sup>2</sup>‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Lenalidomide; Medicine; Diffuse large B-cell lymphoma; CHOP; Internal medicine; Rituximab; Clinical endpoint; Placebo; Gastroenterology; Lymphoma; Vincristine; Oncology; Pathology; Randomized controlled trial; Chemotherapy; Cyclophosphamide; Multiple myeloma","score_opus":0.02707653928937821,"score_gpt":0.3086064026914633,"score_spread":0.2815298634020851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951720456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98722863,0.0010700005,0.000016921127,0.0005330084,0.00020028622,0.0070582605,0.000017676595,0.00010543924,0.0037697959],"genre_scores_gemma":[0.99721795,0.00062326354,0.0004166573,0.00026562618,0.00004625481,0.00066339265,0.00008769361,0.000049476217,0.0006297039],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99364567,0.0009912757,0.002835555,0.0010769382,0.0005930879,0.0008574745],"domain_scores_gemma":[0.99364066,0.0032213796,0.0013233656,0.0010845858,0.00036539708,0.0003646097],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016692047,0.00064214476,0.0055809156,0.00037480536,0.000083174586,0.000013646471,0.00031425597,0.00071286765,0.0011396095],"category_scores_gemma":[0.0014592063,0.00042824252,0.00056756433,0.0006901387,0.0002791995,0.000098038574,0.00025045415,0.0002763182,0.00013360966],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4576057,0.21609351,0.29472205,0.0008437205,0.0015034642,0.020377578,0.004807062,0.0003922936,0.00028873878,0.0006269808,0.0020817905,0.0006571189],"study_design_scores_gemma":[0.97018635,0.011970374,0.0057555805,0.00037085317,0.0013326746,0.0021989406,0.001625575,0.00264818,0.001349704,0.000067718654,0.0020742728,0.00041976012],"about_ca_topic_score_codex":0.00061125465,"about_ca_topic_score_gemma":0.00022945434,"teacher_disagreement_score":0.5125807,"about_ca_system_score_codex":0.00057645864,"about_ca_system_score_gemma":0.0005019684,"threshold_uncertainty_score":0.99981695},"labels":[],"label_agreement":null},{"id":"W2951924370","doi":"10.1002/hon.47_2630","title":"PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Ibrutinib; Rituximab; Medicine; Waldenstrom macroglobulinemia; Internal medicine; Oncology; Placebo; Lymphoma; Leukemia; Chronic lymphocytic leukemia; Pathology","score_opus":0.028252088364664883,"score_gpt":0.3390303575365446,"score_spread":0.31077826917187973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951924370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893356,0.00004090171,9.069756e-7,0.001022444,0.00008750453,0.004171365,0.000004147463,0.000073421674,0.0052637383],"genre_scores_gemma":[0.9979996,0.0000075843072,0.00017100754,0.0012153822,0.000014039074,0.00034030888,0.000051563693,0.000027606198,0.00017289155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995876,0.00050820847,0.0011661003,0.0007706978,0.00081155536,0.0008673949],"domain_scores_gemma":[0.9977691,0.0008035039,0.00028611292,0.00077409076,0.00023700805,0.00013015345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070796534,0.000365212,0.0014324725,0.00029042506,0.000049738668,0.000022724531,0.00031834104,0.000396546,0.0003428749],"category_scores_gemma":[0.00066727516,0.00018688873,0.00008885276,0.0013536272,0.00024917218,0.00007167317,0.00022747734,0.00089057174,0.00025241773],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022597634,0.010666235,0.97334397,0.00007117471,0.000088143745,0.010232817,0.0009055067,0.000004844429,0.0000306719,0.00015259664,0.00020994163,0.0020343428],"study_design_scores_gemma":[0.118656114,0.01217951,0.8623111,0.00011608193,0.000076570956,0.0019415251,0.0026006002,0.000434379,0.00016499104,0.000080246,0.0011002107,0.00033864685],"about_ca_topic_score_codex":0.00062602106,"about_ca_topic_score_gemma":0.00039438903,"teacher_disagreement_score":0.116396345,"about_ca_system_score_codex":0.0040842695,"about_ca_system_score_gemma":0.0016619655,"threshold_uncertainty_score":0.9997389},"labels":[],"label_agreement":null},{"id":"W2951994857","doi":"10.1002/hon.52_2629","title":"FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Capital District Health Authority","funders":"Università degli Studi di Perugia; Hospital de Clínicas de Porto Alegre; Monash University; F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Gastroenterology; Minimal residual disease; Obinutuzumab; Hazard ratio; Clinical endpoint; Population; Surrogate endpoint; Oncology; Venetoclax; Progression-free survival; Confidence interval; Surgery; Chronic lymphocytic leukemia; Randomized controlled trial; Bone marrow; Leukemia; Chemotherapy","score_opus":0.013142738743973956,"score_gpt":0.27572653323056384,"score_spread":0.26258379448658986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951994857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972025,0.0003407798,0.000003372804,0.00034249062,0.000039057744,0.0014410522,0.000013433793,0.000044455937,0.0005728288],"genre_scores_gemma":[0.99895114,0.00006881585,0.0002974967,0.00019782128,0.000028883946,0.00008288411,0.00007875223,0.000015723199,0.00027849528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982436,0.00021772113,0.00034852806,0.0004782594,0.00028256496,0.000429327],"domain_scores_gemma":[0.9986765,0.0005926122,0.000118003874,0.00023923631,0.000095172356,0.00027848917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020631513,0.0002038936,0.000672265,0.00009414181,0.00005218883,0.000022246544,0.00006964411,0.00023662337,0.00009018316],"category_scores_gemma":[0.00039791645,0.00013718072,0.000026563477,0.00014063831,0.00045932323,0.00011398238,0.00015331665,0.00027862104,0.000020615982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.038000867,0.0005790634,0.94757164,0.0018989922,0.00017463976,0.0022125293,0.0016017207,0.000075128555,0.00050141464,0.0025369397,0.0012714452,0.003575636],"study_design_scores_gemma":[0.06327177,0.010859543,0.9082426,0.00031448164,0.00013271726,0.00038072714,0.00032518807,0.014582472,0.0003624656,0.0004270184,0.00073672953,0.00036428048],"about_ca_topic_score_codex":0.0003480812,"about_ca_topic_score_gemma":0.000179025,"teacher_disagreement_score":0.039329015,"about_ca_system_score_codex":0.010767219,"about_ca_system_score_gemma":0.0064574024,"threshold_uncertainty_score":0.9991751},"labels":[],"label_agreement":null},{"id":"W2952476145","doi":"10.1002/hon.35_2630","title":"SYSTEMIC THERAPY AFTER RADIATION THERAPY IN STAGE I‐II FOLLICULAR LYMPHOMA: FINAL RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL TROG 99.03","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Vincristine; Randomized controlled trial; Radiation therapy; Progression-free survival; Internal medicine; Surgery; Cyclophosphamide; Stage (stratigraphy); Lymphoma; Chemotherapy","score_opus":0.03015826436044576,"score_gpt":0.3268272183137123,"score_spread":0.29666895395326653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952476145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916652,0.0018669565,0.000005784938,0.0009469913,0.0005209562,0.0029928093,0.000023541566,0.000037330974,0.001940422],"genre_scores_gemma":[0.99589634,0.0019655456,0.00030322853,0.0005185647,0.000115982664,0.00085871055,0.00011905763,0.000013015168,0.0002095754],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974048,0.00062674953,0.0009636861,0.00043771238,0.00030997398,0.00025706008],"domain_scores_gemma":[0.9983296,0.0007632167,0.00038935902,0.00032389883,0.00009546165,0.00009846522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087385875,0.00022229886,0.0015028208,0.00016504493,0.000024924295,0.000010085848,0.00014098563,0.00036488616,0.00044430146],"category_scores_gemma":[0.00023798479,0.00013464286,0.0003405598,0.0001318981,0.000108773085,0.000096585594,0.000035145473,0.000089523906,0.00004804145],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9534393,0.006182272,0.017534113,0.000021293217,0.00029373894,0.0005698543,0.0003872679,0.000011121704,0.00032308084,0.0022717672,0.00006131981,0.018904865],"study_design_scores_gemma":[0.95906645,0.007708034,0.024691032,0.00006624665,0.000042967476,0.00025677984,0.00005859933,0.0003684964,0.002246188,0.00015894632,0.005203067,0.00013319867],"about_ca_topic_score_codex":0.000098958015,"about_ca_topic_score_gemma":0.000009942076,"teacher_disagreement_score":0.018771667,"about_ca_system_score_codex":0.00036907542,"about_ca_system_score_gemma":0.00022584053,"threshold_uncertainty_score":0.54905766},"labels":[],"label_agreement":null},{"id":"W2952794489","doi":"10.1002/hon.232_2631","title":"QUALITY OF LIFE AND CAREGIVER BURDEN IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS UNDERGOING OUTPATIENT AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS INPATIENT TRANSPLANTATION","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Caregiver burden; Multiple myeloma; Transplantation; Autologous stem-cell transplantation; Distress; Population; Physical therapy; Internal medicine; Clinical psychology; Disease; Nursing","score_opus":0.04702925078614812,"score_gpt":0.3144274004288685,"score_spread":0.2673981496427204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952794489","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733657,0.0002732113,0.00006344651,0.00011453869,0.00011438627,0.0010762484,0.00004149738,0.000026457497,0.00095363904],"genre_scores_gemma":[0.9987288,0.00053604617,0.00046230847,0.00004647272,0.0000073534043,0.000050660045,0.00013798889,0.000011039977,0.000019322862],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807256,0.0003347713,0.00057465467,0.00040446644,0.00029970036,0.00031386784],"domain_scores_gemma":[0.9979736,0.0013754,0.00020456457,0.00014059477,0.000093151546,0.00021267262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017448048,0.00018806852,0.00069023663,0.00015079371,0.000045855766,0.0000062960885,0.00005366149,0.000283478,0.000027263737],"category_scores_gemma":[0.00010077603,0.0001479062,0.00005759114,0.00011627343,0.00013852559,0.000079312325,0.00003326358,0.00013296638,0.000012725648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011584902,0.00084215397,0.9566183,0.0013693202,0.000060076818,0.00014714416,0.0032612267,0.000020865504,0.00037493432,0.00018788969,0.0000037416219,0.025529431],"study_design_scores_gemma":[0.036398344,0.0046746037,0.9560036,0.00008492982,0.000049777533,0.000033069005,0.0010417005,0.00063054374,0.0008899022,0.000024375946,0.000031162537,0.00013797553],"about_ca_topic_score_codex":0.00022308061,"about_ca_topic_score_gemma":0.0003539339,"teacher_disagreement_score":0.025391456,"about_ca_system_score_codex":0.00018285509,"about_ca_system_score_gemma":0.00014939986,"threshold_uncertainty_score":0.603144},"labels":[],"label_agreement":null},{"id":"W2953047243","doi":"10.1002/hon.108_2629","title":"DECIPHERING THE CONTRIBUTION OF MACROPHAGES TO FOLLICULAR LYMPHOMA PATHOGENESIS: NEW INSIGHTS INTO THERAPY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"CD163; Follicular lymphoma; Follicular dendritic cells; Cancer research; In vivo; M2 Macrophage; CD68; Tumor microenvironment; Cell culture; CD20; Lymphoma; Tumor-associated macrophage; Chemistry; Molecular biology; Macrophage; Medicine; Immunology; Biology; Immunohistochemistry; In vitro; T cell; Immune system; Antigen-presenting cell; Tumor cells","score_opus":0.01941334795268278,"score_gpt":0.29901533824970034,"score_spread":0.27960199029701754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953047243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874697,0.0069641336,0.00022314028,0.0034648068,0.00016895587,0.00095784845,6.963362e-7,0.00004232483,0.0007083976],"genre_scores_gemma":[0.9956931,0.0006693733,0.001179685,0.0021849845,0.00005779184,0.00011930759,0.000008113399,0.000010411517,0.00007723972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987958,0.00012206333,0.00035128163,0.00029389688,0.00019046552,0.00024651358],"domain_scores_gemma":[0.9989029,0.00036790172,0.000119124394,0.00033188495,0.00010150494,0.00017664797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001283842,0.00016983457,0.0006803654,0.000043679167,0.000058698803,0.000007658869,0.0001285053,0.00021458017,0.00022044983],"category_scores_gemma":[0.00011791052,0.00008498629,0.0001773749,0.00020533454,0.000060431918,0.000025177995,0.000076728575,0.00004475227,0.00023464861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029349818,0.0043099886,0.5359756,0.00007128293,0.00079509645,0.0016267013,0.0017202008,0.000048111444,0.13053894,0.04611532,0.0023616834,0.2735021],"study_design_scores_gemma":[0.012612204,0.0055148466,0.6377778,0.00012012568,0.00015773207,0.0005767567,0.00022426702,0.00006283155,0.18343374,0.0020709387,0.15721647,0.00023229812],"about_ca_topic_score_codex":0.000086748885,"about_ca_topic_score_gemma":0.000024596276,"teacher_disagreement_score":0.2732698,"about_ca_system_score_codex":0.0002174254,"about_ca_system_score_gemma":0.00019681851,"threshold_uncertainty_score":0.34656405},"labels":[],"label_agreement":null},{"id":"W2953165127","doi":"10.1002/hon.11_2630","title":"REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Diffuse large B-cell lymphoma; Gene expression profiling; Immunohistochemistry; Germinal center; Concordance; Lymphoma; Gene expression; Biology; Pathology; Medicine; B cell; Gene; Internal medicine; Genetics; Antibody","score_opus":0.06360683452695104,"score_gpt":0.3626921888921254,"score_spread":0.29908535436517436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953165127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98441344,0.00021054503,0.0011705029,0.0015448572,0.00017422548,0.0035625864,0.00007157764,0.000035988916,0.008816298],"genre_scores_gemma":[0.9881156,0.00007290975,0.006069175,0.0006938256,0.000081414655,0.00059050554,0.00021328157,0.000038662936,0.0041246247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761814,0.00011477445,0.0008010561,0.0005438747,0.00036762262,0.0005545383],"domain_scores_gemma":[0.9974323,0.0010348274,0.0004626653,0.0005247865,0.00038953242,0.00015591255],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006976001,0.00023726371,0.0010825095,0.00015192623,0.000054380427,0.0000062967392,0.0002347628,0.00051325036,0.0012137529],"category_scores_gemma":[0.000073206065,0.00017156068,0.00031649997,0.00016842326,0.00014145735,0.000048336697,0.00011819234,0.00017653462,0.000038645107],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012567155,0.008465374,0.011394452,0.000940981,0.000062784384,0.000018578588,0.00030316453,0.000001168595,0.9565849,0.003267984,0.005491365,0.0009021053],"study_design_scores_gemma":[0.051648516,0.007786456,0.005133038,0.00013874784,0.00014436987,0.00003410202,0.00045730485,0.0012415595,0.8533162,0.0005024673,0.07934052,0.00025671057],"about_ca_topic_score_codex":0.000015464648,"about_ca_topic_score_gemma":0.000011195181,"teacher_disagreement_score":0.10326868,"about_ca_system_score_codex":0.00025965978,"about_ca_system_score_gemma":0.00023156348,"threshold_uncertainty_score":0.9996993},"labels":[],"label_agreement":null},{"id":"W2953229874","doi":"10.1002/hon.95_2629","title":"IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Clinical endpoint; Diffuse large B-cell lymphoma; CHOP; Rituximab; Ven; Oncology; Gastroenterology; Venetoclax; Regimen; Lymphoma; Randomized controlled trial; Chronic lymphocytic leukemia; Leukemia","score_opus":0.022662026207577096,"score_gpt":0.32456376199109754,"score_spread":0.3019017357835204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953229874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161637,0.000067001376,0.000011496529,0.0005433025,0.00009890963,0.005188043,0.00017379483,0.0000967611,0.0022043453],"genre_scores_gemma":[0.9960421,0.000019261268,0.00013981694,0.00081338227,0.000048349197,0.00028721403,0.00025665681,0.000058595535,0.0023346685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596125,0.0007715587,0.00073970197,0.000993094,0.00063578674,0.00089863397],"domain_scores_gemma":[0.9961664,0.0019826551,0.0003126234,0.00093808456,0.0003120726,0.00028818607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052547955,0.0004790247,0.0015965564,0.00013246662,0.00011620513,0.000032401604,0.0003902879,0.00039402462,0.0005268992],"category_scores_gemma":[0.00031050303,0.00023594401,0.00013330743,0.00046931702,0.00026607665,0.00008081422,0.00020900073,0.00063102413,0.0001488588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093153566,0.05865432,0.8368514,0.000030179077,0.0005931229,0.0022353104,0.0032418258,0.0000065897493,0.0017517131,0.000025510291,0.0002591807,0.003197251],"study_design_scores_gemma":[0.44500273,0.050093085,0.49615955,0.00010425742,0.00027514723,0.000070120186,0.0025756732,0.000855826,0.001582255,0.000014972679,0.0027946378,0.00047170898],"about_ca_topic_score_codex":0.001384025,"about_ca_topic_score_gemma":0.0013999891,"teacher_disagreement_score":0.35184917,"about_ca_system_score_codex":0.0013022717,"about_ca_system_score_gemma":0.0005548764,"threshold_uncertainty_score":0.96215177},"labels":[],"label_agreement":null},{"id":"W2968968970","doi":"10.1002/hon.2666","title":"Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis","year":2019,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"Cancer Research UK; European Hematology Association","keywords":"Rituximab; Medicine; Primary central nervous system lymphoma; Internal medicine; Oncology; Lymphoma; Randomized controlled trial; Clinical trial; Meta-analysis; Diffuse large B-cell lymphoma","score_opus":0.09136588791526158,"score_gpt":0.368136584382143,"score_spread":0.2767706964668814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968968970","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009944105,0.9896645,0.000005755039,0.000352336,0.000081541926,0.007830736,0.00006551132,0.0001058262,0.0018838275],"genre_scores_gemma":[0.0002581754,0.9941172,0.0002794577,0.0012549185,0.000021654836,0.0035124894,0.00028542252,0.00004968016,0.00022102591],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9939478,0.001359886,0.0024756442,0.0011148967,0.0003586957,0.0007430716],"domain_scores_gemma":[0.9958427,0.0016213576,0.0011103278,0.0009898054,0.00007586091,0.00035997637],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0007106985,0.0009174029,0.03569552,0.0004950864,0.00004986781,0.000026108022,0.00026570252,0.0010565533,0.00020353045],"category_scores_gemma":[0.00018510684,0.00049750955,0.0039754496,0.001060748,0.0001293748,0.00004017174,0.00023443492,0.00031249246,0.00037880836],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010624641,0.0016250305,0.00002765314,0.89122754,0.089532666,0.00325868,0.00000798284,7.223619e-8,2.6715676e-9,0.000805378,0.0001500395,0.013354335],"study_design_scores_gemma":[0.0013112553,0.00030730004,0.00016805429,0.0903454,0.85469234,0.008897902,0.000014511489,0.000004135412,3.2174853e-8,0.0000031121237,0.043892566,0.0003634177],"about_ca_topic_score_codex":0.00004495459,"about_ca_topic_score_gemma":0.000018965327,"teacher_disagreement_score":0.80088216,"about_ca_system_score_codex":0.0020281042,"about_ca_system_score_gemma":0.00063746143,"threshold_uncertainty_score":0.99974763},"labels":[],"label_agreement":null},{"id":"W2996879561","doi":"10.1002/hon.2708","title":"Radiotherapy in mantle cell lymphoma: A literature review","year":2019,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Mantle cell lymphoma; Radiation therapy; Lymphoma; Malignancy; Stage (stratigraphy); Disease; Oncology; Internal medicine; Systemic therapy; Cancer","score_opus":0.06253466837350785,"score_gpt":0.3986835428973755,"score_spread":0.33614887452386766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996879561","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001076264,0.9831043,0.0000012561178,0.00118201,0.00027445535,0.0031072572,0.000024333722,0.0000620688,0.01223358],"genre_scores_gemma":[0.000007202039,0.9930258,0.0007787047,0.0035036625,0.00011724466,0.0009616486,0.00030897214,0.000050781964,0.0012460082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996826,0.00047596594,0.0011105062,0.0008281767,0.00022048676,0.0005388493],"domain_scores_gemma":[0.9978907,0.00071982684,0.00045038635,0.0006797272,0.00005264738,0.0002066718],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002920041,0.0006559047,0.0069926344,0.0002225684,0.000026298405,0.000016177268,0.00024058462,0.0014307719,0.00061611057],"category_scores_gemma":[0.000091107686,0.00036963564,0.0010997659,0.0006212691,0.00008159624,0.0000319126,0.00009157279,0.00041523014,0.0009976615],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034589004,0.0033445251,0.00009948699,0.16374111,0.00015642696,0.011356174,0.00001750873,9.16069e-9,8.593163e-8,0.00069837726,0.016588213,0.8039635],"study_design_scores_gemma":[0.0031350483,0.00083696493,0.000031413118,0.122673675,0.0011666629,0.00897189,0.0000019809966,7.3453134e-7,6.815945e-7,0.00002286282,0.8628798,0.00027827485],"about_ca_topic_score_codex":0.000004035747,"about_ca_topic_score_gemma":0.0000022882882,"teacher_disagreement_score":0.8462916,"about_ca_system_score_codex":0.001224086,"about_ca_system_score_gemma":0.0008037782,"threshold_uncertainty_score":0.99987555},"labels":[],"label_agreement":null},{"id":"W3006286575","doi":"10.1002/hon.2723","title":"Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma","year":2020,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Carfilzomib; Ibrutinib; Medicine; Dexamethasone; Refractory (planetary science); Multiple myeloma; Oncology; Internal medicine; Lenalidomide; Leukemia; Materials science","score_opus":0.06631480899877269,"score_gpt":0.35118968776323356,"score_spread":0.2848748787644609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006286575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976181,0.000043092594,0.00005774191,0.0002513623,0.000011335374,0.0016534036,0.000047920686,0.000032824148,0.00028422097],"genre_scores_gemma":[0.9977885,0.0000056765743,0.001799947,0.00011269859,0.000007412089,0.000111591944,0.00014376671,0.000017400345,0.000013014826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973365,0.00039336053,0.0007299866,0.00053794775,0.0005896975,0.00041248376],"domain_scores_gemma":[0.9977365,0.00086216204,0.00039435615,0.00035737996,0.0002905045,0.00035908594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019061584,0.00026512207,0.0020294073,0.0003716269,0.00003672243,0.0000035299731,0.00016307957,0.00019337582,0.00028156178],"category_scores_gemma":[0.0007222465,0.00015794046,0.00013136174,0.001598396,0.00029835105,0.000053458454,0.00009804327,0.00038865977,0.000006821278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06776069,0.030930454,0.8942095,0.000096602176,0.00225868,0.0011767606,0.00097574806,0.00004037723,0.00023941003,0.000021900458,0.00002636183,0.0022634983],"study_design_scores_gemma":[0.09147003,0.095970094,0.80860233,0.000039363527,0.0011330544,0.000008841667,0.0007990496,0.0013965821,0.00039872923,0.0000024624705,0.000048940015,0.0001305125],"about_ca_topic_score_codex":0.00015444595,"about_ca_topic_score_gemma":0.00038796154,"teacher_disagreement_score":0.085607186,"about_ca_system_score_codex":0.00011098976,"about_ca_system_score_gemma":0.00020421723,"threshold_uncertainty_score":0.6440625},"labels":[],"label_agreement":null},{"id":"W3022359034","doi":"10.1002/hon.2437_133","title":"IBRUTINIB VS TEMSIROLIMUS: THREE‐YEAR FOLLOW‐UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN‐LABEL RAY STUDY","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Mantle cell lymphoma; Temsirolimus; Refractory (planetary science); Ibrutinib; Progression-free survival; Gastroenterology; Phases of clinical research; Neutropenia; Tolerability; Toxicity; Surgery; Adverse effect; Lymphoma; Chemotherapy; Leukemia","score_opus":0.06600161204894871,"score_gpt":0.3834560218168101,"score_spread":0.3174544097678614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022359034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841034,0.00014588983,0.00006579013,0.0009912435,0.00028055764,0.005293955,0.000056925288,0.00004406146,0.009018178],"genre_scores_gemma":[0.9976208,0.0000815401,0.0005879513,0.00030555387,0.00008879159,0.00042766458,0.000119360215,0.00003483535,0.00073345454],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967495,0.00054655486,0.0008335612,0.0006533283,0.0007100745,0.0005069343],"domain_scores_gemma":[0.99510485,0.0021939664,0.0007547239,0.0013327642,0.0003938552,0.00021981812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010922628,0.0003208357,0.0018905007,0.00006620314,0.00029570982,0.00010195412,0.0016497385,0.00028968006,0.0008116254],"category_scores_gemma":[0.0018227638,0.00015933481,0.00016556714,0.000109379784,0.0010063209,0.00014707026,0.001010556,0.00026151305,0.00013200649],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67617923,0.03393851,0.27226767,0.00009490934,0.0018421058,0.0015609391,0.0013907665,0.0000015225902,0.00010190149,0.0005688004,0.006256857,0.0057967617],"study_design_scores_gemma":[0.972795,0.0067372834,0.014968602,0.000114620954,0.00056108,0.00005203043,0.00030495264,0.0010252829,0.0003941544,0.00024796426,0.0025953092,0.0002037355],"about_ca_topic_score_codex":0.0019608978,"about_ca_topic_score_gemma":0.00039851197,"teacher_disagreement_score":0.29661572,"about_ca_system_score_codex":0.0016569074,"about_ca_system_score_gemma":0.0018796714,"threshold_uncertainty_score":0.8886729},"labels":[],"label_agreement":null},{"id":"W3032984305","doi":"10.1002/hon.2759","title":"Risk factors for high‐dose methotrexate associated acute kidney injury in patients with hematological malignancies","year":2020,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Methotrexate; Internal medicine; Creatinine; Acute kidney injury; Univariate analysis; Gastroenterology; Confidence interval; Adverse effect; Renal function; Hazard ratio; Surgery; Multivariate analysis","score_opus":0.03139114837398717,"score_gpt":0.3225171573876341,"score_spread":0.29112600901364694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032984305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899768,0.000015041367,0.001292381,0.00561788,0.00010366053,0.0019101315,0.00044168456,0.00023884547,0.00040356113],"genre_scores_gemma":[0.98646164,0.000035238685,0.008287667,0.0043241982,0.00004353838,0.00026096107,0.00046260425,0.00004994684,0.00007423157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607754,0.0005564394,0.0008303835,0.0008921989,0.00057940686,0.0010640598],"domain_scores_gemma":[0.99624693,0.0017602396,0.0004101105,0.00030339978,0.00035355426,0.0009257516],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045827933,0.00046472988,0.0019610834,0.00015840886,0.0001325174,0.000020776803,0.00034213645,0.0009148203,0.0003663582],"category_scores_gemma":[0.010249443,0.00028016264,0.00020209611,0.0007291423,0.00046707992,0.00010088705,0.00026966407,0.00084281305,0.00008291879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014129072,0.0025813626,0.9574769,0.00019640128,0.00072739396,0.0013414373,0.00049138453,0.000004677161,0.0005753173,0.0030112811,0.018910693,0.0005540704],"study_design_scores_gemma":[0.04830051,0.03298555,0.89967144,0.00022443007,0.0010717902,0.00015304703,0.00027483064,0.0015357309,0.0068042264,0.0021555016,0.005743769,0.0010792091],"about_ca_topic_score_codex":0.00004159916,"about_ca_topic_score_gemma":0.0000041830153,"teacher_disagreement_score":0.0578055,"about_ca_system_score_codex":0.00083679636,"about_ca_system_score_gemma":0.0007989,"threshold_uncertainty_score":0.9999651},"labels":[],"label_agreement":null},{"id":"W3092926650","doi":"10.1002/hon.2818","title":"Clinical trial risk in leukemia: Biomarkers and trial design","year":2020,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Celiac Association; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Clinical trial; Oncology; Chronic lymphocytic leukemia; Biomarker; Internal medicine; Drug; Leukemia; Pharmacology","score_opus":0.3097116344433638,"score_gpt":0.5104696459623587,"score_spread":0.20075801151899486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092926650","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006735187,0.9856913,0.00015430035,0.00029517306,0.0009878533,0.010097122,0.000015025706,0.00012827055,0.0019574494],"genre_scores_gemma":[0.00009143902,0.9939377,0.0033812348,0.00023127144,0.0011261405,0.0010056999,0.000048784495,0.00007424449,0.00010348695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98760486,0.0059257154,0.0033381877,0.0016193757,0.0005515755,0.00096031756],"domain_scores_gemma":[0.98134875,0.01608906,0.0009611418,0.00067875034,0.000065380525,0.00085692306],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004882868,0.0007293712,0.009334393,0.0003548952,0.00007769452,0.000031031574,0.00047624737,0.004167879,0.0003224396],"category_scores_gemma":[0.015530647,0.0004766327,0.0011775008,0.0007943183,0.001102291,0.00004039117,0.00060282403,0.0035761301,0.0004267722],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.29394937,0.00061091327,0.0000054668603,0.0034635954,0.0004783128,0.009912625,0.000013800144,9.882188e-8,2.5833797e-8,0.00015100325,0.0046350695,0.68677974],"study_design_scores_gemma":[0.40757546,0.013522018,9.254043e-7,0.0013232349,0.0010856568,0.0024925086,0.000011562387,0.00021065482,1.11113486e-7,0.00014548659,0.5733775,0.00025487604],"about_ca_topic_score_codex":0.00008267043,"about_ca_topic_score_gemma":0.000015753516,"teacher_disagreement_score":0.6865248,"about_ca_system_score_codex":0.016687473,"about_ca_system_score_gemma":0.04239848,"threshold_uncertainty_score":0.99976856},"labels":[],"label_agreement":null},{"id":"W3109601420","doi":"10.1002/hon.2828","title":"Obinutuzumab‐related adverse events: A systematic review and meta‐analysis","year":2020,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Obinutuzumab; Medicine; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Adverse effect; Relative risk; Oncology; Meta-analysis; Hazard ratio; Follicular lymphoma; Lymphoma; Leukemia; Confidence interval","score_opus":0.11802474173356127,"score_gpt":0.4309193846730987,"score_spread":0.31289464293953745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109601420","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[4.1391817e-7,0.98947144,0.000021768674,0.0009871715,0.00003936444,0.0074523604,0.000037686063,0.00017085292,0.0018189294],"genre_scores_gemma":[0.000014574049,0.99384487,0.00039412273,0.0018425075,0.000022605383,0.002252979,0.00018242064,0.00006186556,0.0013840391],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99248993,0.0021782243,0.0027647472,0.001240945,0.00061522744,0.00071090326],"domain_scores_gemma":[0.99442416,0.0024265791,0.0011713059,0.0010605186,0.00016922825,0.0007481881],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0012175175,0.0008758367,0.030488553,0.00040145896,0.00008026772,0.0000073739657,0.0004898679,0.0014316953,0.0029551734],"category_scores_gemma":[0.0027059147,0.0004793421,0.0052637598,0.0023139897,0.00032513886,0.000045871675,0.0005522206,0.0013568797,0.0013523608],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000011784002,0.00009203313,8.8137675e-8,0.7877951,0.20653313,0.004042532,0.000014510374,1.2468827e-7,7.3396733e-9,0.00058407173,0.00041530316,0.00051129865],"study_design_scores_gemma":[0.0012283792,0.00040644372,3.2326508e-8,0.03969701,0.7434517,0.012968896,0.000011652091,0.00007072331,2.8489819e-8,0.000047408324,0.20181891,0.00029880123],"about_ca_topic_score_codex":0.000025343637,"about_ca_topic_score_gemma":0.0000058376363,"teacher_disagreement_score":0.7480981,"about_ca_system_score_codex":0.013194664,"about_ca_system_score_gemma":0.009900045,"threshold_uncertainty_score":0.99986464},"labels":[],"label_agreement":null},{"id":"W3111005279","doi":"10.1002/hon.2830","title":"Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland","year":2020,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"WiLAN (Canada)","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Confidence interval; Population; Retrospective cohort study; Lymphoma; Surgery","score_opus":0.05213350040243925,"score_gpt":0.3476552728913584,"score_spread":0.29552177248891914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111005279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998302,0.00006804848,0.0000031146346,0.0007574711,0.00003302861,0.0003383981,0.000017354947,0.000022356631,0.00045824458],"genre_scores_gemma":[0.9978771,0.00009034729,0.00047822556,0.0014514528,0.000023671104,0.000024287609,0.000035785193,0.000009169582,0.000009923634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869365,0.00009804901,0.00060463627,0.00029391187,0.00012475587,0.0001849923],"domain_scores_gemma":[0.99913067,0.00032984072,0.00018318964,0.000112439695,0.000041301635,0.00020257477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009363359,0.00013821239,0.0009932371,0.000038061455,0.00001147976,0.0000037193122,0.0000446214,0.00023536578,0.00009603477],"category_scores_gemma":[0.00023803693,0.00008492904,0.000067086716,0.0001230557,0.00017358315,0.000019857698,0.0000547099,0.000086294895,0.000016225858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014701315,0.0020660337,0.97894406,0.00004927066,0.00006113594,0.002415306,0.00007474659,6.558109e-8,0.0000055728383,0.00016976507,0.00011265561,0.014631245],"study_design_scores_gemma":[0.0119796945,0.004965074,0.98059386,0.00003303274,0.00010414135,0.000056886834,0.000017941655,0.000043521726,0.000032800115,0.00001219112,0.0020756463,0.000085181455],"about_ca_topic_score_codex":0.000026682184,"about_ca_topic_score_gemma":0.000014471772,"teacher_disagreement_score":0.014546064,"about_ca_system_score_codex":0.00006610753,"about_ca_system_score_gemma":0.0000479319,"threshold_uncertainty_score":0.34633055},"labels":[],"label_agreement":null},{"id":"W3125135564","doi":"10.1002/hon.2838","title":"Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Spinal Cord Injury BC; BC Cancer Agency","funders":"Takeda Oncology","keywords":"Medicine; Dacarbazine; ABVD; Internal medicine; Neutropenia; Brentuximab vedotin; Hazard ratio; Vinblastine; Gastroenterology; Population; Febrile neutropenia; Subgroup analysis; Adverse effect; Surgery; Lymphoma; Oncology; Confidence interval; Chemotherapy; Vincristine; Hodgkin lymphoma; Cyclophosphamide","score_opus":0.013377878726427905,"score_gpt":0.26856359267082425,"score_spread":0.2551857139443963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125135564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974364,0.00041010795,0.000030047075,0.00046240067,0.000086484186,0.0011216974,0.00017517735,0.000032623037,0.00024507954],"genre_scores_gemma":[0.9979759,0.00012910202,0.0009423158,0.00027986369,0.00002288806,0.00018070081,0.00041968576,0.000019370513,0.000030177878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968079,0.0005832513,0.00083174923,0.0008473505,0.000517333,0.00041242232],"domain_scores_gemma":[0.9966564,0.0018562824,0.00044023595,0.0005710644,0.0002897727,0.00018623246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001865193,0.00035875538,0.00186421,0.0001580925,0.00008816543,0.000018162918,0.00015659959,0.00025594156,0.0002037854],"category_scores_gemma":[0.00055809907,0.00019824535,0.00016531674,0.001036199,0.0002585772,0.000057991216,0.00027518914,0.0002241853,0.000006784645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037511056,0.021091454,0.96156466,0.00001723558,0.0015062076,0.00054376514,0.0003976571,0.000048776663,0.000010002903,0.00027015217,0.00012879413,0.0106702],"study_design_scores_gemma":[0.04238446,0.0056883134,0.9479214,0.00005395979,0.0024194259,0.0000064328974,0.00043416835,0.00021398482,0.0002145636,0.000044566135,0.000435139,0.00018356681],"about_ca_topic_score_codex":0.00047778804,"about_ca_topic_score_gemma":0.0020968278,"teacher_disagreement_score":0.038633358,"about_ca_system_score_codex":0.00041383118,"about_ca_system_score_gemma":0.0002091673,"threshold_uncertainty_score":0.8084211},"labels":[],"label_agreement":null},{"id":"W3158953552","doi":"10.1002/hon.2875","title":"Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta‐analysis","year":2021,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Western University","funders":"Ottawa Hospital Anesthesia Alternate Funds Association; Ottawa Hospital; University of Ottawa; Terry Fox Research Institute; Cancer Research Society; American Society of Hematology","keywords":"Medicine; Adverse effect; Internal medicine; Clinical trial; Vaccination; Oncology; Meta-analysis; Immunology","score_opus":0.045633990717050876,"score_gpt":0.33394017103951046,"score_spread":0.2883061803224596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158953552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007980446,0.99648386,0.000030230816,0.00026052754,0.00008749781,0.0027366984,0.00009418094,0.00006422562,0.00016297934],"genre_scores_gemma":[0.00033481745,0.9972442,0.0001571019,0.00038984118,0.0000027281817,0.00057116983,0.0001983863,0.000036016794,0.0010657515],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98874104,0.0060925875,0.0033279578,0.0010613968,0.000072498835,0.0007044953],"domain_scores_gemma":[0.9900233,0.0069862967,0.0019028301,0.00090261875,0.0001314025,0.000053559837],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016357371,0.0009633084,0.025769057,0.000632302,0.00014130934,0.000017546306,0.0005676189,0.001980665,0.0008772633],"category_scores_gemma":[0.0012177099,0.0005889431,0.001934494,0.0013388768,0.00063868915,0.00006340969,0.00048015203,0.0009488281,0.00007166144],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013995457,0.0009474994,0.0000073622637,0.897536,0.096980385,0.00043645292,0.00015917898,4.4217222e-7,0.00006015429,0.0014448507,0.00017342431,0.0021143116],"study_design_scores_gemma":[0.0014888587,0.0008087808,0.000016972514,0.037721936,0.74820155,0.0072524133,0.00015667171,4.1379707e-7,0.000059265927,0.00003654334,0.20334777,0.0009088294],"about_ca_topic_score_codex":0.000027141274,"about_ca_topic_score_gemma":0.000018433926,"teacher_disagreement_score":0.85981405,"about_ca_system_score_codex":0.000090039845,"about_ca_system_score_gemma":0.00032793696,"threshold_uncertainty_score":0.9996562},"labels":[],"label_agreement":null},{"id":"W3174532254","doi":"10.1002/hon.51_2879","title":"NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Nivolumab; Refractory (planetary science); Oncology; Phases of clinical research; Gastroenterology; Lymphoma; Surgery; CD30; Chemotherapy; Cancer; Immunotherapy","score_opus":0.04112583095400109,"score_gpt":0.3361191188900827,"score_spread":0.29499328793608165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174532254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845056,0.0051794946,0.0002571445,0.003137891,0.0011545478,0.0020477471,0.00019956513,0.0001731388,0.003344872],"genre_scores_gemma":[0.99185276,0.00025347096,0.0017112724,0.0031281712,0.00034717497,0.0011197998,0.00067501847,0.000047837035,0.000864486],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962912,0.0004962415,0.00088364683,0.0010016278,0.00048724125,0.00084000593],"domain_scores_gemma":[0.99558264,0.002680964,0.00036113776,0.00076034514,0.00026275052,0.00035213248],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000497763,0.00047410594,0.0016448598,0.000053746877,0.00034605624,0.000039392828,0.0002926574,0.0004511902,0.0007723502],"category_scores_gemma":[0.00073756726,0.00029477483,0.0004980491,0.00023871886,0.00019117627,0.00007500294,0.00032601185,0.00027489357,0.00020320603],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034148287,0.5118765,0.09550878,0.000669338,0.0037915476,0.05634636,0.008169873,0.0000023080622,0.0065000593,0.0040313713,0.12782279,0.15113273],"study_design_scores_gemma":[0.55076236,0.023090838,0.19079584,0.00021856363,0.0036565417,0.002728962,0.007962977,0.00045720662,0.00798427,0.0013223707,0.2100298,0.0009902662],"about_ca_topic_score_codex":0.000063874904,"about_ca_topic_score_gemma":0.00014865832,"teacher_disagreement_score":0.5166141,"about_ca_system_score_codex":0.001010582,"about_ca_system_score_gemma":0.0013691189,"threshold_uncertainty_score":0.9999504},"labels":[],"label_agreement":null},{"id":"W3174662807","doi":"10.1002/hon.7_2881","title":"T‐CELL SUBSET COMPOSITION AND FUNCTIONALITY IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Cytotoxic T cell; Chronic lymphocytic leukemia; CD19; Waldenstrom macroglobulinemia; CD8; T cell; Immunology; Macroglobulinemia; B cell; Cancer research; Lymphoma; Leukemia; Immune system; Biology; Multiple myeloma; Antibody","score_opus":0.01834866805480126,"score_gpt":0.29696716183461686,"score_spread":0.2786184937798156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174662807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926825,0.000231996,0.00005507964,0.0013470072,0.000049192422,0.0002829604,0.000009777092,0.000031325457,0.005310167],"genre_scores_gemma":[0.9967872,0.00003133461,0.0019407526,0.0008460898,0.000027683513,0.000025394085,0.00014399373,0.000008390775,0.00018917453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861604,0.00014773896,0.00027398716,0.00037339973,0.0002790858,0.0003097189],"domain_scores_gemma":[0.9991094,0.000291093,0.000055442622,0.00018691772,0.00018783001,0.00016933533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014538928,0.00012371471,0.00045859048,0.000046481935,0.000042974843,0.000009176276,0.00004320485,0.0002484143,0.0006749308],"category_scores_gemma":[0.000097549746,0.000087926106,0.000035379628,0.00021144899,0.00022902017,0.000033696047,0.00010132842,0.00030176842,0.00004313082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039919815,0.0035068963,0.975423,0.00042086007,0.00005910868,0.00681728,0.000093751674,0.000013715158,0.0011920662,0.0023775767,0.004324602,0.0017792039],"study_design_scores_gemma":[0.081922956,0.0033789917,0.89086765,0.0001675441,0.000116734795,0.006150366,0.00018808598,0.0011113618,0.006762017,0.00070037367,0.008247781,0.00038616505],"about_ca_topic_score_codex":0.000031242813,"about_ca_topic_score_gemma":0.00003598753,"teacher_disagreement_score":0.084555335,"about_ca_system_score_codex":0.0027945794,"about_ca_system_score_gemma":0.001680991,"threshold_uncertainty_score":0.7390019},"labels":[],"label_agreement":null},{"id":"W3174776325","doi":"10.1002/hon.24_2879","title":"WHOLE GENOME SEQUENCING OF MATCHED PRIMARY AND RELAPSED DLBCL REVEALS DISTINCT EVOLUTIONARY DYNAMICS ASSOCIATED WITH RELAPSE TIMING","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Simon Fraser University; Spinal Cord Injury BC","funders":"","keywords":"BCL6; Fluorescence in situ hybridization; Chromosomal translocation; Diffuse large B-cell lymphoma; Biology; Somatic evolution in cancer; Oncology; Internal medicine; Lymphoma; Cancer research; Biopsy; Liquid biopsy; Medicine; Gene; Chromosome; Genetics; Cancer; B cell","score_opus":0.030550038548892017,"score_gpt":0.2769660546229304,"score_spread":0.24641601607403837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174776325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98927367,0.0013349312,0.000116957024,0.0023802847,0.000044724922,0.00029996538,0.000048630864,0.0000671787,0.0064336495],"genre_scores_gemma":[0.9921377,0.000107571366,0.006005612,0.00054048497,0.000017797207,0.000044713383,0.0005175737,0.000017187265,0.0006113753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841493,0.00019141521,0.00047656643,0.0004013107,0.00021061738,0.0003051469],"domain_scores_gemma":[0.99835783,0.00077965326,0.00026722424,0.0002377486,0.0001926064,0.00016492991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022689482,0.00019227453,0.001000412,0.000052003143,0.00009342852,0.0000064758347,0.00005232939,0.0003264767,0.00008418755],"category_scores_gemma":[0.0005610176,0.00013490731,0.00009440816,0.00023100132,0.0002462745,0.000045163404,0.00011642447,0.0001901359,0.000011604491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072585285,0.0040384117,0.9539469,0.0004726943,0.0007431476,0.015004147,0.00039749846,0.0000129410955,0.012640523,0.010150612,0.00056388485,0.0013033733],"study_design_scores_gemma":[0.006368734,0.0016305498,0.98357487,0.00039712174,0.00048658924,0.0046178573,0.00039180988,0.00043853378,0.00036107868,0.00101767,0.00050439866,0.00021079328],"about_ca_topic_score_codex":0.000016662992,"about_ca_topic_score_gemma":0.00003845872,"teacher_disagreement_score":0.029627949,"about_ca_system_score_codex":0.001386612,"about_ca_system_score_gemma":0.00049407594,"threshold_uncertainty_score":0.550136},"labels":[],"label_agreement":null},{"id":"W3175305832","doi":"10.1002/hon.111_2881","title":"PRIORITISATION OF RELEVANT COCHRANE REVIEW TOPICS IN THE FIELD OF HAEMATOLOGY","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Meta-analysis and systematic reviews","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Hematology; Systematic review; Internal medicine; Cochrane Library; MEDLINE; Family medicine; Meta-analysis; Medical education; Political science","score_opus":0.6114149703872511,"score_gpt":0.5820760624742075,"score_spread":0.02933890791304361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175305832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50386107,0.16056374,0.013384063,0.23018791,0.0008619626,0.0025492338,0.000013373272,0.000009626972,0.088569],"genre_scores_gemma":[0.9687866,0.009258973,0.011021638,0.010078146,0.000037314105,0.000073130504,0.000008677272,0.000004680301,0.000730843],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9769613,0.013261747,0.0076074293,0.0004654433,0.0015316487,0.00017239888],"domain_scores_gemma":[0.97165596,0.022529049,0.0031541823,0.001749381,0.0008719754,0.000039457886],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.037116155,0.00013004814,0.004768278,0.00009382495,0.000025681848,0.000017261542,0.0009504147,0.00020992632,0.006929465],"category_scores_gemma":[0.1256997,0.000053863754,0.0007886574,0.0010688475,0.000119216995,0.000040419163,0.0001186546,0.00020283747,0.00014318818],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040101415,0.0012175087,0.06478065,0.005543068,0.00017318742,0.0021849717,0.001121966,0.000009668788,0.00050902506,0.64094216,0.21016465,0.07331304],"study_design_scores_gemma":[0.0010098091,0.0009823153,0.027947515,0.0021849677,0.0005705945,0.006209557,0.002036377,0.0006134847,0.002012928,0.14384487,0.8122382,0.00034936678],"about_ca_topic_score_codex":0.000006086945,"about_ca_topic_score_gemma":0.0000827753,"teacher_disagreement_score":0.60207355,"about_ca_system_score_codex":0.000013727461,"about_ca_system_score_gemma":0.00012949709,"threshold_uncertainty_score":0.9939783},"labels":[],"label_agreement":null},{"id":"W3175785263","doi":"10.1002/hon.164_2880","title":"ESCALADE: A PHASE 3 STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP FOR PATIENTS ≤65Y WITH UNTREATED NON‐GERMINAL CENTER B‐CELL–LIKE DIFFUSE LARGE B‐CELL LYMPHOMA","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Internal medicine; Population; CHOP; Vincristine; Rituximab; Ibrutinib; Oncology; Gastroenterology; Lymphoma; Cyclophosphamide; Chronic lymphocytic leukemia; Chemotherapy; Leukemia","score_opus":0.020527705995499818,"score_gpt":0.33695050610101684,"score_spread":0.31642280010551704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175785263","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955084,0.000052902105,0.00021103762,0.00020014148,0.00006286977,0.002564948,0.00003116337,0.00004126521,0.0013273197],"genre_scores_gemma":[0.9977091,0.000019465073,0.00084986765,0.0002704916,0.000020028547,0.0004070622,0.00022465097,0.0000403997,0.00045896842],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99689263,0.00029996017,0.00073044543,0.0007243477,0.0005822736,0.00077031803],"domain_scores_gemma":[0.9976286,0.00075176294,0.0002819424,0.0004598084,0.00060510734,0.00027273278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028109783,0.00032307688,0.0012148274,0.0001982281,0.00007785754,0.000013497827,0.00018450314,0.00038064696,0.00014099959],"category_scores_gemma":[0.00022284333,0.0002125272,0.000091972164,0.0006596736,0.00022224867,0.00006974383,0.00016843564,0.00028250006,0.000017852493],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041151654,0.61359596,0.32170397,0.0014905714,0.00027920798,0.012182219,0.003154182,0.0000061835694,0.0011897155,0.00020401392,0.0014100651,0.0036322556],"study_design_scores_gemma":[0.8971644,0.060309287,0.02345002,0.00025826535,0.00030680603,0.0010223369,0.0028569258,0.005105778,0.007171004,0.000032238044,0.0019353,0.00038764527],"about_ca_topic_score_codex":0.00006699055,"about_ca_topic_score_gemma":0.0002386768,"teacher_disagreement_score":0.85601276,"about_ca_system_score_codex":0.0031879554,"about_ca_system_score_gemma":0.002978554,"threshold_uncertainty_score":0.8666608},"labels":[],"label_agreement":null},{"id":"W3176017254","doi":"10.1002/hon.52_2880","title":"A CROSS‐SECTIONAL STUDY ON THE GLOBAL DIFFERENCES IN INFORMATION EXPERIENCES AND NEEDS OF PATIENTS WITH LYMPHOMA AND CLL","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Health Literacy and Information Accessibility","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Lymphoma; Medicine; Environmental health; Cross-sectional study; Oncology; Internal medicine; Dermatology; Pathology","score_opus":0.06682991492794095,"score_gpt":0.432484977272421,"score_spread":0.3656550623444801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176017254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529725,0.000018132278,0.000045240966,0.0003266264,0.00011813778,0.0005797394,0.0000141758455,0.000012323994,0.003588374],"genre_scores_gemma":[0.9979053,0.0000057216425,0.00007667344,0.0017768737,0.000007689359,0.00021035259,0.000009256701,8.75844e-7,0.0000072627945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980273,0.00063787313,0.0008815682,0.000098054195,0.00017145924,0.0001837186],"domain_scores_gemma":[0.9982777,0.0010005959,0.00033421148,0.000104079925,0.0002195668,0.00006384111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006776932,0.00008215513,0.0002670755,0.000042916494,0.00028678094,0.000017318847,0.00007307867,0.00015768241,0.00025750572],"category_scores_gemma":[0.00066992117,0.000040553055,0.000011165564,0.00026215034,0.00020817695,0.00040426434,0.00010165917,0.0001693931,0.000007197812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029236116,0.00032769208,0.9730166,0.00006209633,0.0000037821862,8.7689875e-7,0.017678605,1.726305e-7,3.128288e-8,0.0073845964,0.000013163031,0.0012200302],"study_design_scores_gemma":[0.0014817578,0.0005869292,0.9520184,0.00002329062,0.0000016602228,0.0000034100306,0.04477274,0.000060155722,0.0000011654146,0.0003499282,0.00065724744,0.000043309887],"about_ca_topic_score_codex":0.000040841707,"about_ca_topic_score_gemma":0.00006694582,"teacher_disagreement_score":0.027094133,"about_ca_system_score_codex":0.00008503182,"about_ca_system_score_gemma":0.00022448495,"threshold_uncertainty_score":0.2819507},"labels":[],"label_agreement":null},{"id":"W3176099878","doi":"10.1002/hon.49_2879","title":"IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; St. Thomas Hospital; University Health Network","funders":"Pharmacyclics; Swiss Cancer Research Foundation; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Celltrion; BeiGene; AstraZeneca; Celltrion Healthcare; Gilead Sciences; Celgene; Amgen; Pfizer; Cancer Research UK; Incyte; National Science Foundation","keywords":"Medicine; Clinical endpoint; Regimen; Rituximab; Chemoimmunotherapy; Internal medicine; Oncology; Population; Randomized controlled trial; Lymphoma; Surgery","score_opus":0.07152412977678226,"score_gpt":0.3516985184666783,"score_spread":0.2801743886898961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176099878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98673964,0.00017902852,0.000002418684,0.0031121066,0.00015579646,0.00092938606,0.0000066422626,0.000009836538,0.008865177],"genre_scores_gemma":[0.99912804,0.00006902422,0.00007285717,0.0003812185,0.000073084826,0.00021118615,0.000013975018,0.0000061248834,0.00004450374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982186,0.00045772607,0.0005393252,0.00025686694,0.0002932714,0.00023419967],"domain_scores_gemma":[0.99737644,0.0018768812,0.00027907224,0.0003172464,0.00009185362,0.00005851047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032665636,0.0001704479,0.0008680725,0.00004505087,0.000037320475,0.000003941147,0.00010820277,0.00020639019,0.0001715878],"category_scores_gemma":[0.00050044875,0.00006698639,0.00030286497,0.0002148129,0.00020481597,0.000015508664,0.000057605324,0.00016913204,0.0000084100475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025820483,0.039845977,0.9068415,0.0001193122,0.00030438462,0.0015753685,0.0013060478,0.0000032726414,0.0023229334,0.01606408,0.0013074302,0.004489173],"study_design_scores_gemma":[0.036255963,0.009825988,0.9413498,0.00004908746,0.00015136458,0.000535506,0.0004513411,0.0000047879516,0.010316393,0.00091393065,0.00007730418,0.000068512396],"about_ca_topic_score_codex":0.000037401885,"about_ca_topic_score_gemma":0.000018419842,"teacher_disagreement_score":0.03450828,"about_ca_system_score_codex":0.00060346816,"about_ca_system_score_gemma":0.00031770792,"threshold_uncertainty_score":0.27316254},"labels":[],"label_agreement":null},{"id":"W3176976111","doi":"10.1002/hon.35_2880","title":"CLINICAL UTILITY OF INTERIM CT SCANS IN PATIENTS RECEIVING CHEMOIMMUNOTHERAPY FOR FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chemoimmunotherapy; Rituximab; Follicular lymphoma; Internal medicine; Surgery; Interim analysis; Prednisone; Vincristine; Progressive disease; Cyclophosphamide; Clinical trial; Lymphoma; Chemotherapy","score_opus":0.07732641674997415,"score_gpt":0.39029687252761713,"score_spread":0.312970455777643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176976111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961674,0.0011433908,0.00007072933,0.00085387524,0.0001728197,0.0007537675,0.000028207447,0.000015583715,0.0007941836],"genre_scores_gemma":[0.99581486,0.0012995801,0.0023294324,0.00020588962,0.00002504549,0.00018946809,0.00008844756,0.00001155341,0.000035738798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980193,0.00015100391,0.0010633972,0.00038919668,0.00012703383,0.00025010685],"domain_scores_gemma":[0.99806523,0.0010076407,0.00028760053,0.00034596786,0.0002007284,0.00009282604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022592858,0.00018488926,0.0015183834,0.000051502768,0.000026223834,0.0000023769217,0.000068712514,0.00021289267,0.00019991281],"category_scores_gemma":[0.0004571175,0.00012629942,0.00042032258,0.00017395029,0.00017447147,0.000019096278,0.0000425823,0.000040764608,0.0000033572642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014444964,0.026401436,0.810914,0.000114237664,0.0002518534,0.00022101315,0.00009628333,7.0645393e-7,0.000048866823,0.0001949409,0.00010038484,0.1602118],"study_design_scores_gemma":[0.029063676,0.010596177,0.9313682,0.00018201568,0.00015779829,0.00008931156,0.000063337175,0.00014514099,0.016295072,0.00019142841,0.011744878,0.00010297439],"about_ca_topic_score_codex":0.000055677625,"about_ca_topic_score_gemma":0.00013882986,"teacher_disagreement_score":0.16010883,"about_ca_system_score_codex":0.0003092087,"about_ca_system_score_gemma":0.00028620975,"threshold_uncertainty_score":0.5150341},"labels":[],"label_agreement":null},{"id":"W3177359439","doi":"10.1002/hon.50_2880","title":"UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Bendamustine; Venetoclax; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Oncology; Gastroenterology; Minimal residual disease; clone (Java method); Refractory (planetary science); Progression-free survival; Leukemia; Lymphoma; Chemotherapy; Genetics; Biology","score_opus":0.05772649493114061,"score_gpt":0.42696265845663306,"score_spread":0.36923616352549243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177359439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897217,0.0058085457,0.000046464582,0.00078682543,0.0002720532,0.0019452703,0.000026886508,0.00018589511,0.0012063463],"genre_scores_gemma":[0.9926019,0.0010567321,0.0019876738,0.0010437435,0.0001606593,0.00043125017,0.00007827806,0.00009045972,0.0025493195],"study_design_codex":"case_report","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931243,0.001506861,0.0013347507,0.0014117811,0.000863893,0.001758438],"domain_scores_gemma":[0.9941042,0.0027822931,0.00022774907,0.0014811031,0.00033689136,0.0010677385],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014485463,0.0006340077,0.0022062284,0.00044331947,0.0001642421,0.00004458915,0.0004300771,0.0010188199,0.0030398297],"category_scores_gemma":[0.0034708087,0.000459008,0.00036541387,0.0017025665,0.00037846243,0.00006958511,0.00046032466,0.00092046976,0.0010792216],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.30440566,0.01451103,0.006239196,0.0014877866,0.0015884916,0.46048456,0.003029068,0.0067364867,0.15086336,0.00044769785,0.0164337,0.033772938],"study_design_scores_gemma":[0.57282054,0.11516758,0.010952928,0.0014300485,0.0008230191,0.053649906,0.0016003607,0.06512289,0.07796749,0.00048662856,0.09777288,0.0022057502],"about_ca_topic_score_codex":0.0005680794,"about_ca_topic_score_gemma":0.000885379,"teacher_disagreement_score":0.40683466,"about_ca_system_score_codex":0.38298455,"about_ca_system_score_gemma":0.1637713,"threshold_uncertainty_score":0.99978614},"labels":[],"label_agreement":null},{"id":"W3178904653","doi":"10.1002/hon.2898","title":"Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"Novartis Pharma; Celgene","keywords":"Ruxolitinib; International Prognostic Scoring System; Medicine; Myelofibrosis; Internal medicine; Adverse effect; Anemia; Clinical endpoint; Janus kinase inhibitor; Gastroenterology; Surgery; Clinical trial; Bone marrow; Janus kinase; Myelodysplastic syndromes","score_opus":0.02074939354465334,"score_gpt":0.3252005367022574,"score_spread":0.3044511431576041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178904653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99763507,0.00016033946,0.000046164587,0.0002344565,0.00017408926,0.0015612663,0.000020871117,0.00002553055,0.00014222127],"genre_scores_gemma":[0.99926406,0.00015159184,0.00015101586,0.00005278561,0.000021990998,0.00027420817,0.00006582587,0.0000148946765,0.0000035974488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976913,0.0003983811,0.0008050645,0.0005417803,0.00025853323,0.00030499275],"domain_scores_gemma":[0.9978818,0.0013300662,0.00030625594,0.00020262966,0.0001518396,0.0001273943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033330708,0.00025634907,0.001094641,0.00017936323,0.00006420617,0.00003564326,0.00014021907,0.00012619336,0.000025514493],"category_scores_gemma":[0.0005372397,0.00015253574,0.000045792895,0.0002523076,0.00025067735,0.00009395486,0.00034910828,0.0003664008,0.0000020020627],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032594341,0.0064201537,0.9823825,0.00020422823,0.0001914593,0.00065623043,0.0010977119,0.00001409887,0.000010688374,0.00032776655,0.0000018955785,0.0054338854],"study_design_scores_gemma":[0.028150467,0.0031835441,0.9644592,0.00092751224,0.0001562379,0.00011659233,0.0016780786,0.0010298796,0.00014011211,0.000021137197,0.000005947181,0.00013131494],"about_ca_topic_score_codex":0.000076211276,"about_ca_topic_score_gemma":0.0006983683,"teacher_disagreement_score":0.024891034,"about_ca_system_score_codex":0.00029005215,"about_ca_system_score_gemma":0.000109684224,"threshold_uncertainty_score":0.6220227},"labels":[],"label_agreement":null},{"id":"W4210422384","doi":"10.1002/hon.2879","title":"ORAL PRESENTATIONS","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Head and Neck Surgical Oncology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Pharmacyclics; Genentech; Centre Hospitalier Universitaire de Clermont-Ferrand; Centre hospitalier régional universitaire de Lille; Humanitas University; Centre Hospitalier Universitaire de Nantes; Università di Pisa; Universität zu Köln; Washington University in St. Louis; Université Paris Descartes; GlaxoSmithKline; Centre Hospitalier Universitaire Vaudois; Institute for Oil Sands Innovation, University of Alberta; Swiss Institute of Bioinformatics; AstraZeneca; Centre Hospitalier Régional Universitaire de Montpellier; Jewish General Hospital; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Seagen; Sunesis; Centre Hospitalier Universitaire de Bordeaux; BeiGene; Università Degli Studi di Modena e Reggio Emila; University of Rochester; Gilead Sciences; Institut National de la Santé et de la Recherche Médicale; Région Normandie; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Celgene; Amgen; Assistance publique-Hôpitaux de Paris; National Science Foundation","keywords":"Medicine; Geology","score_opus":0.08529804487447847,"score_gpt":0.41648617729852244,"score_spread":0.331188132424044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210422384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65377766,0.00048229974,0.00057132734,0.033905048,0.00046533643,0.0002290119,0.0000032068187,0.00018489119,0.3103812],"genre_scores_gemma":[0.9775279,0.00011602933,0.008334275,0.008453485,0.00017995233,0.000057479698,0.000047437887,0.00001155468,0.005271871],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859023,0.00023869776,0.00034894122,0.0003225511,0.00014382639,0.0003557695],"domain_scores_gemma":[0.9986354,0.0006331349,0.000051135426,0.00021360526,0.00016317419,0.00030351916],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015672375,0.00011506662,0.0006910709,0.0000419919,0.00007220555,0.0000063417488,0.000058886337,0.0003726137,0.006050244],"category_scores_gemma":[0.00076574314,0.00008359353,0.0001620742,0.0002773625,0.00018970265,0.000032293727,0.00008853127,0.0003294942,0.0007917512],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011395502,0.009590669,0.2741335,0.00022655373,0.00035625414,0.07794577,0.0003047728,0.00000611993,0.024504256,0.36531046,0.18685915,0.059622955],"study_design_scores_gemma":[0.0024754617,0.0009538574,0.054767918,0.000012580612,0.00008338864,0.011194896,0.00013922788,0.000078047575,0.0042071408,0.0028517973,0.92310816,0.0001275072],"about_ca_topic_score_codex":0.000003865492,"about_ca_topic_score_gemma":0.000016862303,"teacher_disagreement_score":0.736249,"about_ca_system_score_codex":0.000063558175,"about_ca_system_score_gemma":0.00043891423,"threshold_uncertainty_score":0.99998623},"labels":[],"label_agreement":null},{"id":"W4239670013","doi":"10.1002/hon.2881","title":"PUBLICATION","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Infectious Diseases Centre; University of British Columbia; Spinal Cord Injury BC","funders":"Key Technology Research and Development Program of Shandong; Shandong First Medical University; Università di Pisa; Università Degli Studi di Modena e Reggio Emila; Università Campus Bio-Medico di Roma; Natural Science Foundation of Shandong Province; Atara Biotherapeutics; Università degli Studi di Padova; Dipartimento di Scienze Mediche, Università degli Studi di Torino","keywords":"Business","score_opus":0.04801072544325081,"score_gpt":0.35226553010572054,"score_spread":0.30425480466246974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239670013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74753195,0.00080285885,0.0012427774,0.042131897,0.00019620484,0.00013710624,0.0000010311562,0.00015439981,0.20780174],"genre_scores_gemma":[0.98723114,0.000054790333,0.006221063,0.0041698813,0.00012790244,0.000017676672,0.000053470707,0.0000059542926,0.002118134],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99932957,0.000041318868,0.00020123167,0.0001856523,0.00009001216,0.00015221765],"domain_scores_gemma":[0.9993916,0.000121405435,0.00004487023,0.00013574134,0.00019602086,0.000110322246],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010821365,0.00006000628,0.0002949217,0.000024294763,0.000032057244,0.000007813849,0.00003090387,0.00017830185,0.0046558036],"category_scores_gemma":[0.00061696256,0.00004403673,0.00007992408,0.000171543,0.000043561668,0.00002012451,0.000039740797,0.00015259808,0.00024383355],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003823284,0.0045706,0.13840154,0.00033689442,0.00022857622,0.0054513435,0.0003141452,0.0000020905052,0.2357615,0.25341105,0.21070723,0.1504327],"study_design_scores_gemma":[0.0012492433,0.00029633558,0.0058883,0.000021327605,0.000049546303,0.005979224,0.00011219795,0.00015213307,0.096266635,0.001669605,0.8882046,0.00011089621],"about_ca_topic_score_codex":8.4220284e-7,"about_ca_topic_score_gemma":0.000001037087,"teacher_disagreement_score":0.6774973,"about_ca_system_score_codex":0.000061040155,"about_ca_system_score_gemma":0.00016196723,"threshold_uncertainty_score":0.9962541},"labels":[],"label_agreement":null},{"id":"W4281486289","doi":"10.1002/hon.3033","title":"Exome sequencing identifies <i>PD‐L2</i> as a potential predisposition gene for lymphoma","year":2022,"lang":"en","type":"letter","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"American Cancer Society","keywords":"Exome sequencing; Lymphoma; Cancer research; Germline; Biology; Follicular lymphoma; Gene; Genetics; Medicine; Immunology; Mutation","score_opus":0.036548349414169644,"score_gpt":0.3103958639145961,"score_spread":0.2738475145004265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281486289","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22237442,0.004212302,0.00039709418,0.7544308,0.0038580052,0.0053718067,0.00065936305,0.0006236114,0.008072655],"genre_scores_gemma":[0.1449502,0.00062497606,0.0031358653,0.8258564,0.0043787127,0.0074971924,0.008328556,0.00015477388,0.0050733206],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99627334,0.00028383356,0.0008592088,0.0011068329,0.0006072592,0.0008695277],"domain_scores_gemma":[0.99787337,0.00074165507,0.00047799305,0.00054603466,0.00016970916,0.00019122419],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026691883,0.000587664,0.0017938138,0.00023218547,0.0003641009,0.000054608143,0.0002763174,0.0017636676,0.0022504365],"category_scores_gemma":[0.00020946616,0.00046169446,0.00082179316,0.00018011377,0.00022674794,0.000073590585,0.00027166578,0.0006241979,0.00022583168],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010757067,0.0010872333,0.00019770209,0.00064838154,0.0007357879,0.06315497,0.000106268526,0.000005373631,0.001063433,0.0005686701,0.92871726,0.0026392015],"study_design_scores_gemma":[0.007255333,0.0060595553,0.0004952187,0.00012911094,0.0018537702,0.037813745,0.00012572874,0.000072529765,0.004105552,0.0029763095,0.93855065,0.0005625166],"about_ca_topic_score_codex":0.00008403266,"about_ca_topic_score_gemma":0.0000049515206,"teacher_disagreement_score":0.07742423,"about_ca_system_score_codex":0.002609458,"about_ca_system_score_gemma":0.00095177884,"threshold_uncertainty_score":0.99978346},"labels":[],"label_agreement":null},{"id":"W4310179086","doi":"10.1002/hon.3102","title":"The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma","year":2022,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Spine and Intervertebral Disc Pathology","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Kyphosis; Vertebral body; Bone cement; Vertebral compression fracture; Percutaneous vertebroplasty; Balloon; Surgery; Percutaneous; Radiology; Radiography; Cement","score_opus":0.052158590643568044,"score_gpt":0.3958581806660868,"score_spread":0.34369959002251876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310179086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062960046,0.9812632,0.000024440038,0.0007290343,0.00027745785,0.0026833634,0.00004621874,0.000027943763,0.008652306],"genre_scores_gemma":[0.06469221,0.9318658,0.00060783536,0.0011122458,0.00005946226,0.001355866,0.00015579848,0.000032153563,0.0001186311],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706686,0.0006870309,0.0011293138,0.00041645957,0.0003397831,0.00036055787],"domain_scores_gemma":[0.9984891,0.00044030842,0.00052412064,0.0004397497,0.000036768033,0.00006999595],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044928023,0.0003177892,0.0018282182,0.0001699144,0.00010543641,0.0000062631784,0.0006094595,0.00035431085,0.0010173735],"category_scores_gemma":[0.0002199521,0.00013986566,0.0004554276,0.0003268492,0.0002202537,0.000036361325,0.00041186064,0.00060095335,0.000027950398],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021919556,0.000700662,0.00026302398,0.00644451,0.0002543293,0.00031956215,0.00028609467,9.1552363e-7,0.000047736394,0.004277728,0.004137942,0.9830483],"study_design_scores_gemma":[0.0015051941,0.002484285,0.008227496,0.0035743755,0.0005163057,0.0007310529,0.0015758785,0.000019689824,0.00012210775,0.00072033034,0.9803241,0.00019917868],"about_ca_topic_score_codex":0.000014799756,"about_ca_topic_score_gemma":0.000045132463,"teacher_disagreement_score":0.9828491,"about_ca_system_score_codex":0.00014242553,"about_ca_system_score_gemma":0.00021138054,"threshold_uncertainty_score":0.9998958},"labels":[],"label_agreement":null},{"id":"W4319826530","doi":"10.1002/hon.3126","title":"Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia; Ministero della Salute","keywords":"Ibrutinib; Atrial fibrillation; Medicine; Internal medicine; Cardiology; Prospective cohort study; Cohort; Incidence (geometry); Chronic lymphocytic leukemia; Leukemia","score_opus":0.0553593713309901,"score_gpt":0.3744604305517121,"score_spread":0.31910105922072196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319826530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927842,0.000087003915,0.0000054281904,0.00027924145,0.00036705437,0.0016411651,0.000016714108,0.00016322313,0.0046559772],"genre_scores_gemma":[0.99891514,0.00003793116,0.000090451475,0.0000133290205,0.0001955418,0.000029012965,0.000029792152,0.000018128609,0.00067068246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974273,0.0003241482,0.00078380626,0.00038982168,0.0006488972,0.00042603354],"domain_scores_gemma":[0.99730176,0.0015476,0.00031447265,0.00032902104,0.00035596782,0.00015117235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008792476,0.0001620008,0.0012016655,0.00020080383,0.000048851813,0.0000033768858,0.00015552003,0.00039081307,0.00035492086],"category_scores_gemma":[0.004515382,0.0001198504,0.00030476265,0.0011257748,0.00036701254,0.000032294844,0.00024007617,0.00024179193,0.00009792055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006139056,0.0007471924,0.98118293,0.00021400275,0.0011967465,0.00077110523,0.0024465309,0.0000597088,0.00058129936,0.0020106807,0.0041738437,0.0004768942],"study_design_scores_gemma":[0.24374357,0.052998357,0.6747243,0.00033377716,0.0012594716,0.00074101187,0.00811883,0.005580888,0.0057250536,0.0030279201,0.0031545516,0.0005922963],"about_ca_topic_score_codex":0.0000885524,"about_ca_topic_score_gemma":0.000035419744,"teacher_disagreement_score":0.30645865,"about_ca_system_score_codex":0.0025081271,"about_ca_system_score_gemma":0.0033394971,"threshold_uncertainty_score":0.65586656},"labels":[],"label_agreement":null},{"id":"W4378347423","doi":"10.1002/hon.3183","title":"Women in Lymphoma: A 4‐year journey in promoting gender equity","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Diversity and Career in Medicine","field":"Social Sciences","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Snowdome Foundation","keywords":"Equity (law); Gender equity; Lymphoma; Political science; Gender studies; Medicine; Internal medicine; Sociology; Law","score_opus":0.1743821584335879,"score_gpt":0.4082756117455758,"score_spread":0.2338934533119879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378347423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87157303,0.00003319066,0.0000037649186,0.00408477,0.00022000838,0.00015955408,8.2911504e-7,0.00009261714,0.12383224],"genre_scores_gemma":[0.99862933,0.00010016821,0.000075334676,0.0007214262,0.00007068353,0.000031983447,0.0000019675308,0.000003257111,0.00036585098],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9977319,0.00050539116,0.00023868491,0.00022894671,0.00039738693,0.0008976623],"domain_scores_gemma":[0.9992315,0.0004098436,0.000058886097,0.00007841773,0.000031787393,0.00018954212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0056242547,0.00007439547,0.0003532528,0.00016571609,0.00015319607,0.000021417585,0.000394769,0.00029217527,0.0006549885],"category_scores_gemma":[0.0016341922,0.0000644333,0.000035729696,0.0009025097,0.00033226528,0.0000783179,0.00038137185,0.0002035241,0.00030805467],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015272941,0.0010323018,0.59111893,0.00010226039,0.000021527012,0.006093775,0.20645432,0.000014274881,0.00006583664,0.15137228,0.008968749,0.03460301],"study_design_scores_gemma":[0.0052418998,0.00059276866,0.31969112,0.00009362607,0.000012068967,0.00005501199,0.43277538,0.00016548847,0.00002543999,0.13131662,0.109610066,0.00042050035],"about_ca_topic_score_codex":0.00023737464,"about_ca_topic_score_gemma":0.0010242837,"teacher_disagreement_score":0.2714278,"about_ca_system_score_codex":0.0007557764,"about_ca_system_score_gemma":0.00032005817,"threshold_uncertainty_score":0.7171665},"labels":[],"label_agreement":null},{"id":"W4379927848","doi":"10.1002/hon.3190","title":"Primary testicular lymphoma demonstrates overexpression of the Wilms tumor 1 gene and different mRNA and miRNA expression profiles compared to nodal diffuse large B‐cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Cancer Foundation; University of Alberta; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"microRNA; Diffuse large B-cell lymphoma; Cancer research; Biology; Lymphoma; Epigenetics; Downregulation and upregulation; Somatic cell; Pathogenesis; Cancer; NODAL; Gene; Immunology; Genetics","score_opus":0.00988987320435452,"score_gpt":0.2422449806771493,"score_spread":0.23235510747279478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379927848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976456,0.0012094264,0.00003648831,0.00026547897,0.00010827692,0.00038270833,0.00003817628,0.000028433627,0.0002853724],"genre_scores_gemma":[0.9984679,0.00042574437,0.0004470092,0.00037972716,0.00004119125,0.00006752367,0.000047897356,0.000015471773,0.00010750087],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985647,0.00016649185,0.0003227092,0.00044430554,0.00015556447,0.0003462235],"domain_scores_gemma":[0.9992704,0.00010287289,0.0001647195,0.00024309005,0.000043906035,0.00017502783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010041499,0.00022580233,0.00042871514,0.00004097356,0.00015205219,0.000012759984,0.00019816906,0.0003047305,0.0000065904337],"category_scores_gemma":[0.00008813647,0.00012282337,0.00008759413,0.00012750344,0.00025942316,0.00000421111,0.0005886929,0.00007808269,0.0000041322414],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030517243,0.000678711,0.02046359,0.00011294873,0.000024346797,0.000043736964,0.00005188885,0.000010814833,0.9760418,0.000033078464,0.0015495109,0.0006844036],"study_design_scores_gemma":[0.003836177,0.00047427783,0.112144746,0.00015505137,0.00003246271,0.00026752622,0.00012308612,0.00021105244,0.8805,0.00013384612,0.0019113309,0.00021044936],"about_ca_topic_score_codex":0.0000061520323,"about_ca_topic_score_gemma":0.0000021993155,"teacher_disagreement_score":0.095541805,"about_ca_system_score_codex":0.000028845341,"about_ca_system_score_gemma":0.00007598881,"threshold_uncertainty_score":0.5008592},"labels":[],"label_agreement":null},{"id":"W4379979648","doi":"10.1002/hon.3164_263","title":"An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; CancerCare Manitoba; Jewish General Hospital","funders":"Gilead Sciences","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Cohort; Internal medicine; Lymphoma; Oncology; Gastroenterology; Cancer; Surgery; Immunotherapy","score_opus":0.05988519933506927,"score_gpt":0.378718182469252,"score_spread":0.31883298313418273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993894,0.000099635996,0.0000050948515,0.00033216688,0.000076211334,0.004202335,0.00002672192,0.00015588012,0.0012079824],"genre_scores_gemma":[0.9976928,0.00009719541,0.0005305519,0.00017335227,0.000026816298,0.0011356239,0.00018739146,0.0000526965,0.00010353038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964947,0.00047400274,0.00083392585,0.0009912546,0.00052523334,0.00068087777],"domain_scores_gemma":[0.99787176,0.0004105787,0.00038230952,0.00078186864,0.00017113928,0.00038232858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021093602,0.00051976857,0.002228568,0.0002776353,0.0001135377,0.000030385812,0.00032384813,0.00036164653,0.0000768706],"category_scores_gemma":[0.00007643673,0.0002856331,0.00006925504,0.0006617161,0.00027541502,0.00016380867,0.00018115033,0.00016408357,0.000067187895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02354375,0.18125673,0.7489075,0.000054503074,0.00046411846,0.0056393207,0.0010169233,0.0000158838,0.00004941428,0.00022133792,0.00017907211,0.038651425],"study_design_scores_gemma":[0.2131124,0.17762275,0.6064234,0.00011596856,0.00043748686,0.00021849717,0.000609425,0.00022927455,0.00017386685,0.00001757199,0.00078014756,0.00025924848],"about_ca_topic_score_codex":0.00020387892,"about_ca_topic_score_gemma":0.00034087725,"teacher_disagreement_score":0.18956864,"about_ca_system_score_codex":0.0013321674,"about_ca_system_score_gemma":0.000703732,"threshold_uncertainty_score":0.9999596},"labels":[],"label_agreement":null},{"id":"W4379979709","doi":"10.1002/hon.3164_421","title":"A phase II, open‐label, multicenter study of capivasertib, a potent, oral pan‐AKT inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma (CAPITAL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"","keywords":"Medicine; Mantle cell lymphoma; Internal medicine; Follicular lymphoma; Gastroenterology; Lymphoma; Phases of clinical research; Marginal zone B-cell lymphoma; Oncology; Clinical trial; Immunology; B cell; Marginal zone","score_opus":0.06263963328599681,"score_gpt":0.38228564150884176,"score_spread":0.31964600822284495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942682,0.00004913232,0.0000045519573,0.0002639465,0.00017273572,0.0043742927,0.000019170895,0.00010918218,0.00073880743],"genre_scores_gemma":[0.99750173,0.000030451936,0.0005966023,0.00036667095,0.00003429229,0.00045618822,0.0000938793,0.00006193215,0.00085825747],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954572,0.0005226826,0.0011891356,0.0009740043,0.00083689747,0.0010201184],"domain_scores_gemma":[0.9972999,0.0007751361,0.0003832319,0.00083229144,0.00031592292,0.00039352337],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007526882,0.0004293838,0.0017253418,0.00044418423,0.00013319566,0.000022798948,0.00060636614,0.0005180453,0.00032649405],"category_scores_gemma":[0.0007939916,0.00026862847,0.00008088095,0.0012271827,0.00036561931,0.00018489474,0.0011898794,0.00049967546,0.00018687302],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19745837,0.5212998,0.16178615,0.0013302078,0.0007980735,0.04393779,0.014657396,0.000021374317,0.006174878,0.00007248274,0.015610277,0.036853194],"study_design_scores_gemma":[0.7287088,0.2215531,0.035703428,0.00040803352,0.00024551837,0.000196538,0.005637924,0.0025687583,0.002695527,0.00003784777,0.0016673822,0.00057715806],"about_ca_topic_score_codex":0.0010226219,"about_ca_topic_score_gemma":0.00077569496,"teacher_disagreement_score":0.5312504,"about_ca_system_score_codex":0.0052177715,"about_ca_system_score_gemma":0.0041579213,"threshold_uncertainty_score":0.9999766},"labels":[],"label_agreement":null},{"id":"W4379979778","doi":"10.1002/hon.3166_ot15","title":"PHASE 1 STUDY OF PRT1419 (MCL1 INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID OR B‐CELL MALIGNANCIES","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Universitat Autònoma de Barcelona","keywords":"Venetoclax; Medicine; Azacitidine; Tolerability; Internal medicine; Myeloid leukemia; Oncology; Myeloid; Ven; Rituximab; Lymphoma; Cancer research; Leukemia; Chronic lymphocytic leukemia; Adverse effect; Biology","score_opus":0.03958954685764432,"score_gpt":0.3475295426058064,"score_spread":0.30793999574816205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955631,0.000034259956,0.000011936609,0.00045375637,0.000056947243,0.0033308547,0.000009421539,0.000106256055,0.00043349536],"genre_scores_gemma":[0.9971293,0.00010633673,0.0004941656,0.00028980256,0.00002597172,0.00056159066,0.00007134011,0.000051686417,0.0012697758],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9967888,0.00045639474,0.00083062623,0.0006182049,0.0006643719,0.0006415777],"domain_scores_gemma":[0.99778783,0.0010555735,0.00031331435,0.0003964318,0.00026377934,0.00018306388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058058416,0.00033045234,0.0012814491,0.000649246,0.00005756556,0.000009910818,0.00022918424,0.0004033662,0.0004476748],"category_scores_gemma":[0.00053731137,0.00016991608,0.00004118725,0.0019126581,0.00030543396,0.00013147568,0.000120152305,0.00069917267,0.00006094797],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29587543,0.05682054,0.6080506,0.0007186936,0.00021164145,0.01971126,0.0056595565,0.00010484305,0.0033424124,0.00019677581,0.0022680415,0.0070402515],"study_design_scores_gemma":[0.29056254,0.4090038,0.2765482,0.00073330116,0.00011965752,0.00039546468,0.009546862,0.0006033352,0.007441129,0.00011739695,0.0042226575,0.0007056662],"about_ca_topic_score_codex":0.00014230132,"about_ca_topic_score_gemma":0.0007363322,"teacher_disagreement_score":0.35218325,"about_ca_system_score_codex":0.0011651012,"about_ca_system_score_gemma":0.0016941875,"threshold_uncertainty_score":0.6928976},"labels":[],"label_agreement":null},{"id":"W4379979795","doi":"10.1002/hon.3164_325","title":"Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Post-hoc analysis; Clinical endpoint; Oncology; Autologous stem-cell transplantation; Cohort; Refractory (planetary science); Transplantation; Clinical trial; Multiple myeloma","score_opus":0.04577710757521213,"score_gpt":0.38758623869763525,"score_spread":0.3418091311224231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568635,0.000363592,0.0000505667,0.0005780627,0.00013734482,0.0013895793,0.00033559944,0.000025383713,0.0014335408],"genre_scores_gemma":[0.99789417,0.00013910727,0.00073170825,0.00013664717,0.000042083266,0.00013423187,0.0004206527,0.000033556284,0.00046784003],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9971201,0.00023110794,0.00085598405,0.0005593726,0.00064103986,0.00059244275],"domain_scores_gemma":[0.99639195,0.0017499893,0.00036018938,0.00042562428,0.0008690525,0.00020320444],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005521928,0.00028302884,0.0020827802,0.00085564295,0.00004307112,0.0000090768835,0.00028442938,0.00039717383,0.005068451],"category_scores_gemma":[0.00054681336,0.00019492148,0.00046115534,0.0013738892,0.00039470845,0.000046159457,0.00011740892,0.00039711833,0.000020939076],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6813391,0.003049888,0.23159418,0.00062372343,0.0060421275,0.001192408,0.0059368773,0.0001718491,0.0060992953,0.0004552439,0.000603032,0.062892325],"study_design_scores_gemma":[0.30062312,0.3374096,0.24306437,0.00065626006,0.0031955934,0.00018953823,0.017120078,0.0020458754,0.04893396,0.00035947983,0.045097128,0.0013050174],"about_ca_topic_score_codex":0.000068854984,"about_ca_topic_score_gemma":0.0013634573,"teacher_disagreement_score":0.38071594,"about_ca_system_score_codex":0.00052685314,"about_ca_system_score_gemma":0.0006150251,"threshold_uncertainty_score":0.995841},"labels":[],"label_agreement":null},{"id":"W4379979901","doi":"10.1002/hon.3165_463","title":"POLATUZUMAB AND THE PROGRESSION‐FREE SURVIVAL (PFS) PREDICAMENT: A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT AGENCY (HTA) REVIEWS","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Cost-effectiveness analysis; Progression-free survival; Regimen; Cost–benefit analysis; Agency (philosophy); Health technology; Oncology; Family medicine; Internal medicine; Health care; Overall survival; Cost effectiveness; Political science; Economic growth; Economics","score_opus":0.5361641187209318,"score_gpt":0.5553214294596311,"score_spread":0.019157310738699307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979901","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38503766,0.06351757,0.008369199,0.51650894,0.0009977785,0.006212018,0.00041088575,0.00037575525,0.018570198],"genre_scores_gemma":[0.98506486,0.0050866236,0.0049290815,0.0038280957,0.000050425457,0.00084140326,0.00007192457,0.000011973755,0.000115593866],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99066687,0.002480133,0.0055311616,0.0006652714,0.00014991987,0.00050663983],"domain_scores_gemma":[0.9909443,0.0036215517,0.00447234,0.000745645,0.00006673822,0.0001493743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.028666709,0.00022137882,0.0043047806,0.0008375154,0.00029940406,0.000020820684,0.0005418544,0.00032233947,0.00029859802],"category_scores_gemma":[0.0046404153,0.00016510214,0.0002677527,0.0018961456,0.0007873786,0.00009461812,0.0003598246,0.00035800843,0.00022883479],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043030817,0.00023915527,0.051223908,0.0002695338,0.0005589009,0.0000037120926,0.0022102187,0.000029523471,0.0000010104968,0.9317733,0.012126502,0.001521202],"study_design_scores_gemma":[0.008619718,0.0021133346,0.34725818,0.00033091765,0.0004143199,0.00004932586,0.013850574,0.051192056,0.0000037147765,0.23492076,0.34040058,0.00084652175],"about_ca_topic_score_codex":0.00012398812,"about_ca_topic_score_gemma":0.00016514433,"teacher_disagreement_score":0.69685256,"about_ca_system_score_codex":0.00032140134,"about_ca_system_score_gemma":0.00026454742,"threshold_uncertainty_score":0.99353665},"labels":[],"label_agreement":null},{"id":"W4379979997","doi":"10.1002/hon.3163_19","title":"A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; Cancer Research UK; Swiss Cancer Research Foundation; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Medicine; Clinical endpoint; Hazard ratio; Regimen; Randomized controlled trial; Randomization; Internal medicine; Rituximab; Oncology; Lymphoma; Nuclear medicine; Radiology; Confidence interval","score_opus":0.03295171682899981,"score_gpt":0.30465833751503085,"score_spread":0.271706620686031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504656,0.00083209266,0.00005199345,0.0011876705,0.00022162276,0.0023103629,0.00002745552,0.00006566523,0.0002565658],"genre_scores_gemma":[0.9947117,0.0005130705,0.0031274664,0.00048681436,0.000040489173,0.0009630804,0.00010011443,0.00002317798,0.00003410979],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973116,0.0008433456,0.0007323389,0.00034754968,0.00042361816,0.0003415742],"domain_scores_gemma":[0.99603546,0.00315764,0.0002983563,0.00026891814,0.00013704917,0.0001025848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009712194,0.00024625755,0.0019419339,0.00023159485,0.000031282918,0.000006999551,0.0000933388,0.00022728514,0.00013698335],"category_scores_gemma":[0.0003555893,0.00014962994,0.00023048284,0.00049648306,0.0003079219,0.000046768037,0.000032651875,0.00008679211,0.000016110596],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9518155,0.0031708942,0.039522678,0.000041296033,0.00024173973,0.0003464676,0.00028763228,0.0000022239374,0.00022464512,0.0002114749,0.00008527253,0.004050194],"study_design_scores_gemma":[0.68654317,0.006805874,0.3041308,0.000043299704,0.000119062766,0.000013064229,0.000027347847,0.000027768441,0.00032716303,0.00005398412,0.0018068746,0.00010163378],"about_ca_topic_score_codex":0.00002530619,"about_ca_topic_score_gemma":0.0000072786456,"teacher_disagreement_score":0.26527232,"about_ca_system_score_codex":0.00051179633,"about_ca_system_score_gemma":0.0004622309,"threshold_uncertainty_score":0.61017317},"labels":[],"label_agreement":null},{"id":"W4379981083","doi":"10.1002/hon.3163_t04","title":"MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Pharmacyclics; Seagen; BeiGene; Celgene; Gilead Sciences","keywords":"Obinutuzumab; Medicine; Lenalidomide; Rituximab; Ibrutinib; Internal medicine; Idelalisib; Oncology; Bruton's tyrosine kinase; Follicular lymphoma; Salvage therapy; Chronic lymphocytic leukemia; Lymphoma; Chemotherapy; Leukemia; Multiple myeloma; Tyrosine kinase","score_opus":0.060030952773189254,"score_gpt":0.3721584572127411,"score_spread":0.31212750443955184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99469626,0.00013464042,0.000072695184,0.00059088075,0.000502311,0.002283371,0.000029570103,0.00017150486,0.0015187537],"genre_scores_gemma":[0.9978745,0.00012857036,0.00071948115,0.00016572412,0.0001329568,0.00023732969,0.00017045063,0.000055841723,0.00051517674],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953195,0.00047013166,0.0011397178,0.0008333605,0.001101025,0.0011362802],"domain_scores_gemma":[0.9961687,0.0020718768,0.00039728437,0.0006986604,0.0002503235,0.00041319773],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089700945,0.0004231625,0.002269369,0.00050589285,0.000089144356,0.000014255745,0.00037615965,0.00074432587,0.0006279781],"category_scores_gemma":[0.0019638834,0.00027622466,0.000243235,0.0013494703,0.0007205462,0.000108560096,0.0003217065,0.0005197274,0.00033427155],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.95803696,0.011298862,0.0009635369,0.00045405686,0.00035143163,0.018955072,0.00028404678,0.000036920395,0.00014587009,0.0006883056,0.0025281094,0.006256833],"study_design_scores_gemma":[0.95287657,0.030966528,0.0018509361,0.00022723794,0.0002034145,0.0004780636,0.0003059432,0.0029569785,0.00047308346,0.000039215458,0.009292231,0.00032981174],"about_ca_topic_score_codex":0.0002511591,"about_ca_topic_score_gemma":0.000083006475,"teacher_disagreement_score":0.019667665,"about_ca_system_score_codex":0.010297499,"about_ca_system_score_gemma":0.0112047,"threshold_uncertainty_score":0.999969},"labels":[],"label_agreement":null},{"id":"W4379981126","doi":"10.1002/hon.3164_453","title":"Analyses of a patient with 3 sequential Post Transplant Lymphoprolierative Disease (PTLD) biopsies reveal persistence of Histone 1 gene mutation, suspected to mediate PTLD","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Histopathology; Lymphoma; Biology; Pathology; Tonsil; Rituximab; Lymphomatoid granulomatosis; Cancer research; Medicine","score_opus":0.05473514137890682,"score_gpt":0.36372947059617367,"score_spread":0.3089943292172668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99540895,0.00038293345,0.000039422266,0.0029402324,0.00006288335,0.00067286345,0.00019910949,0.000064408785,0.00022917388],"genre_scores_gemma":[0.99741507,0.00010404502,0.0015632646,0.00036056747,0.000019238632,0.00020386904,0.0002828303,0.0000114483255,0.000039668543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983063,0.00013811239,0.0005493498,0.00037878047,0.00033994854,0.00028754087],"domain_scores_gemma":[0.99854386,0.00031601428,0.00024024898,0.00021119312,0.00037939666,0.0003093019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090500434,0.00020518964,0.0008817479,0.00021960885,0.000060999108,0.0000035218784,0.000080080514,0.00011510462,0.00013700276],"category_scores_gemma":[0.00020903711,0.00012619636,0.0001660515,0.00058797275,0.00033213585,0.00003122589,0.00003913043,0.000056643585,0.000026230273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044358984,0.018046778,0.47227323,0.002171979,0.0046862112,0.08336407,0.02666733,0.001556597,0.3336073,0.0049549965,0.0027952439,0.005517285],"study_design_scores_gemma":[0.010059758,0.017462824,0.5600557,0.0005088751,0.0024026334,0.0025606614,0.0030189443,0.00030537107,0.40271944,0.0002188257,0.00022057022,0.00046640093],"about_ca_topic_score_codex":0.0001524773,"about_ca_topic_score_gemma":0.00006807595,"teacher_disagreement_score":0.08778247,"about_ca_system_score_codex":0.00027961924,"about_ca_system_score_gemma":0.000488199,"threshold_uncertainty_score":0.51461387},"labels":[],"label_agreement":null},{"id":"W4379981156","doi":"10.1002/hon.3164_270","title":"Analysis of Real‐World Treatment Patterns and Outcomes Among Patients With Relapsed/Refractory Follicular Lymphoma Including POD24 Patients","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Follicular lymphoma; Medicine; Internal medicine; Refractory (planetary science); Follicular phase; Demographics; Chemoimmunotherapy; Lymphoma; Oncology; Rituximab; Biology","score_opus":0.030421045072058867,"score_gpt":0.31378527222432356,"score_spread":0.2833642271522647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978578,0.000032202373,0.000003100808,0.00020336486,0.00007259136,0.00065242336,0.00006498985,0.00010185598,0.0010116894],"genre_scores_gemma":[0.9985416,0.0002776863,0.00013280411,0.00017810932,0.000009711785,0.00019364744,0.00049457035,0.000020216417,0.00015166888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803936,0.0001274561,0.0005652844,0.0005229923,0.00035038762,0.000394507],"domain_scores_gemma":[0.9983029,0.00064410345,0.0003291765,0.0003484783,0.00013293148,0.00024242022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104457795,0.0003158298,0.0015666123,0.00056712865,0.00010335832,0.000009387068,0.00007355991,0.00021137718,0.00009971637],"category_scores_gemma":[0.00008600525,0.00017831396,0.00028741988,0.00089053554,0.00016298571,0.000061108,0.000121339355,0.0000565849,0.000017752229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029039837,0.0048166406,0.98178333,0.000039522893,0.002868087,0.00042243645,0.0002068837,0.000005881797,0.0000014830877,0.00018547082,0.00007952695,0.009300355],"study_design_scores_gemma":[0.010567848,0.0038581258,0.98145795,0.00005480582,0.0030128858,0.000003540378,0.000079964564,0.00008057754,0.000074240445,0.000018734387,0.00062428415,0.00016702565],"about_ca_topic_score_codex":0.0009112738,"about_ca_topic_score_gemma":0.0011155243,"teacher_disagreement_score":0.010277449,"about_ca_system_score_codex":0.00060114113,"about_ca_system_score_gemma":0.00006814577,"threshold_uncertainty_score":0.7271432},"labels":[],"label_agreement":null},{"id":"W4379981345","doi":"10.1002/hon.3166_ot29","title":"LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH <i>R</i>/<i>R</i> DLBCL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Oncology; Clinical endpoint; Diffuse large B-cell lymphoma; Phases of clinical research; Refractory (planetary science); Neutropenia; Randomized controlled trial; Lymphoma; Clinical trial; Chemotherapy","score_opus":0.03914161227868253,"score_gpt":0.3791918403689819,"score_spread":0.3400502280902994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940351,0.00009857607,0.000050041188,0.00030460107,0.000091305265,0.0038800482,0.0000066855814,0.00019583505,0.0013377571],"genre_scores_gemma":[0.99817616,0.000046772926,0.00095614954,0.00017879964,0.0000392743,0.0003676186,0.0000910994,0.000066651344,0.00007746627],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957374,0.00064937834,0.0010107325,0.00078733574,0.00092755805,0.0008876062],"domain_scores_gemma":[0.9963421,0.0019194073,0.00034853868,0.00076921866,0.00033886175,0.0002818438],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012083653,0.0004233327,0.0027932292,0.00042708265,0.00008667716,0.000016881371,0.00033702876,0.00029455643,0.00017351174],"category_scores_gemma":[0.0005469237,0.0002568479,0.00012814265,0.0013820338,0.0007498452,0.00013991253,0.00017250459,0.0005736089,0.000065988934],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8841598,0.06042957,0.043179102,0.0002676148,0.00075487985,0.00422776,0.0018689366,0.000053088574,0.00020126312,0.00022658051,0.00020688352,0.004424513],"study_design_scores_gemma":[0.9447171,0.04568636,0.0045504584,0.00013771933,0.00021068199,0.00021606521,0.0011973451,0.0022392604,0.0005116639,0.000031532978,0.0002141479,0.00028765886],"about_ca_topic_score_codex":0.00033209843,"about_ca_topic_score_gemma":0.00021835243,"teacher_disagreement_score":0.0605573,"about_ca_system_score_codex":0.0025629953,"about_ca_system_score_gemma":0.0020506433,"threshold_uncertainty_score":0.9999884},"labels":[],"label_agreement":null},{"id":"W4379981358","doi":"10.1002/hon.3166_ot33","title":"ONKOFRAIL: PERSONALIZATION OF A PHYSICAL EXERCISE PROGRAM IN OLDER PATIENTS WITH LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Psychological intervention; Population; Randomized controlled trial; Cancer; Intervention (counseling); Physical therapy; Physical exercise; Internal medicine; Nursing","score_opus":0.018667229695986807,"score_gpt":0.31730461017011424,"score_spread":0.2986373804741274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680114,0.0000477888,0.000018876883,0.0003465015,0.000059189348,0.00068975537,0.0000040589657,0.00012706645,0.0019056002],"genre_scores_gemma":[0.99926084,0.000015375319,0.0001240291,0.00014570788,0.000023535655,0.00024379116,0.00007857196,0.000012093177,0.00009603409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990649,0.000050831986,0.00019396193,0.00023280004,0.00022272133,0.00023476749],"domain_scores_gemma":[0.9995023,0.00010967273,0.00007354561,0.00012556936,0.000108554515,0.00008035928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000069933594,0.00010977309,0.000525355,0.00010663601,0.000017256238,0.0000027335614,0.000055675686,0.00015274915,0.000083775754],"category_scores_gemma":[0.00005271074,0.00007258985,0.00007240818,0.0006428421,0.00013546301,0.000027720822,0.000037658687,0.00008329437,0.000032707598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015449795,0.005451269,0.8678086,0.0005162463,0.000030524312,0.00033561655,0.003553801,0.000004724243,0.000052338877,0.0018661511,0.0007977689,0.11803799],"study_design_scores_gemma":[0.0057298513,0.0033838742,0.98395264,0.00029267315,0.000069567235,0.000020997524,0.0008804876,0.00064525777,0.00027649867,0.00022784786,0.0043735486,0.00014678141],"about_ca_topic_score_codex":0.000046379228,"about_ca_topic_score_gemma":0.00012378745,"teacher_disagreement_score":0.11789121,"about_ca_system_score_codex":0.0000821925,"about_ca_system_score_gemma":0.00009877035,"threshold_uncertainty_score":0.29601282},"labels":[],"label_agreement":null},{"id":"W4379981406","doi":"10.1002/hon.3163_22","title":"PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"Helsingin Yliopisto","keywords":"Medicine; Refractory (planetary science); Internal medicine; Lymphoma; Gastroenterology; Biology","score_opus":0.04697189223102332,"score_gpt":0.3827252295165396,"score_spread":0.33575333728551626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98924726,0.00067472877,0.000009710322,0.00015083839,0.00022417064,0.001644435,0.000086411565,0.000033674136,0.00792874],"genre_scores_gemma":[0.9990204,0.00032306535,0.00005346542,0.00004703325,0.000019426167,0.00009043645,0.00006294818,0.000020408768,0.0003628383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99506545,0.0018818062,0.0012547229,0.00043239645,0.0009166211,0.00044902257],"domain_scores_gemma":[0.99450916,0.003782702,0.00052277907,0.00072003587,0.00034620828,0.000119092074],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022459247,0.00022798305,0.0036081262,0.0006164175,0.000043925,0.0000028271995,0.00035536865,0.00035220076,0.0010667153],"category_scores_gemma":[0.001015381,0.00014378785,0.0007525999,0.0019666264,0.00045555233,0.000021955108,0.00033856893,0.0003423228,0.0000050939198],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90400237,0.019283121,0.028619286,0.0006466529,0.003129218,0.00070819753,0.0056740274,0.00011266196,0.032311928,0.0005018009,0.00023816995,0.004772542],"study_design_scores_gemma":[0.92407095,0.02093595,0.03146497,0.00006492552,0.0025560302,0.000008995054,0.0077990396,0.00052568637,0.01037044,0.000068509114,0.0019165284,0.00021796796],"about_ca_topic_score_codex":0.00010580153,"about_ca_topic_score_gemma":0.0005764018,"teacher_disagreement_score":0.021941487,"about_ca_system_score_codex":0.00043943647,"about_ca_system_score_gemma":0.0005644103,"threshold_uncertainty_score":0.99984646},"labels":[],"label_agreement":null},{"id":"W4379981428","doi":"10.1002/hon.3163_t05","title":"SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"Astellas Pharma; Pfizer","keywords":"Medicine; Rituximab; Brentuximab vedotin; Internal medicine; Oncology; Refractory (planetary science); Lymphoma; Chimeric antigen receptor; Phases of clinical research; Clinical trial; Immunotherapy; Cancer; CD30","score_opus":0.0644506952634808,"score_gpt":0.3914333370511365,"score_spread":0.3269826417876557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98909247,0.00096953486,0.000019822392,0.0011047367,0.00075544626,0.0020552138,0.000026407422,0.00016512055,0.005811258],"genre_scores_gemma":[0.99671966,0.00072318414,0.000384489,0.00015075404,0.00025049763,0.0002664922,0.00012214936,0.000059698345,0.0013230566],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99552345,0.00055798725,0.0013122263,0.00087258196,0.0007127235,0.0010210302],"domain_scores_gemma":[0.99507874,0.0031028767,0.00059368316,0.0006221767,0.00018248709,0.00042004825],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010181163,0.00044977892,0.0024704686,0.0006755399,0.00011410227,0.000017961238,0.0003199725,0.0009974132,0.001594596],"category_scores_gemma":[0.0022085211,0.00037375937,0.0002632833,0.0011817486,0.0008398453,0.00008218784,0.0004101849,0.00084159325,0.00014683638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86310446,0.0066736774,0.0005405866,0.00043724125,0.00042548534,0.014229342,0.002534003,0.000049667455,0.03143402,0.0016513347,0.003501939,0.07541822],"study_design_scores_gemma":[0.94173265,0.028433997,0.0019771731,0.00025698225,0.00017540905,0.0009317852,0.0014759409,0.008136476,0.0034591642,0.00053233514,0.01236687,0.00052120874],"about_ca_topic_score_codex":0.00027841105,"about_ca_topic_score_gemma":0.00018876695,"teacher_disagreement_score":0.078628175,"about_ca_system_score_codex":0.0012950341,"about_ca_system_score_gemma":0.0013588212,"threshold_uncertainty_score":0.99987143},"labels":[],"label_agreement":null},{"id":"W4379981441","doi":"10.1002/hon.3164_163","title":"Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head‐to‐Head Trial of Acalabrutinib Versus Ibrutinib","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Ibrutinib; Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Medicine; Oncology; Progression-free survival; Fludarabine; Cancer research; Internal medicine; Immunology; Leukemia; Tyrosine kinase; Chemotherapy; Receptor","score_opus":0.07190435046110251,"score_gpt":0.3793572972091509,"score_spread":0.3074529467480484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956609,0.00012691198,0.0001620867,0.00032186395,0.00025517528,0.0021509915,0.00006239347,0.00010717323,0.0011524891],"genre_scores_gemma":[0.9979243,0.00026973907,0.0008744081,0.00006243572,0.00008508173,0.00022013858,0.00023308124,0.000035924342,0.00029484395],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958551,0.00045883266,0.001635102,0.00065243134,0.0006632566,0.00073527626],"domain_scores_gemma":[0.9962825,0.0019170382,0.0006500326,0.0006678349,0.0002353978,0.000247173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089331844,0.00029262557,0.0021163132,0.00046320874,0.000030290517,0.0000043603195,0.0003632855,0.00059262547,0.0002461031],"category_scores_gemma":[0.0020735927,0.00024396369,0.00022633065,0.0018670652,0.0004720844,0.000053230826,0.00024875085,0.00030645906,0.00009708157],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.40540126,0.0011123344,0.000511066,0.001911802,0.00037760285,0.0013273876,0.0012672541,0.00012457267,0.57386273,0.008587789,0.000322228,0.0051939697],"study_design_scores_gemma":[0.5993744,0.02828207,0.008945332,0.0019690953,0.00034656722,0.00008899782,0.00032038524,0.009544925,0.34700018,0.001891481,0.001709234,0.00052733143],"about_ca_topic_score_codex":0.0014649212,"about_ca_topic_score_gemma":0.0014612613,"teacher_disagreement_score":0.22686256,"about_ca_system_score_codex":0.025728319,"about_ca_system_score_gemma":0.016444018,"threshold_uncertainty_score":0.99485505},"labels":[],"label_agreement":null},{"id":"W4379981642","doi":"10.1002/hon.3164_313","title":"Final analysis of Australasian Leukaemia &amp; Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"Cilag","keywords":"Medicine; Ibrutinib; Rituximab; Vincristine; Internal medicine; Diffuse large B-cell lymphoma; International Prognostic Index; Prednisone; CHOP; Lymphoma; Cyclophosphamide; Gastroenterology; Surgery; Oncology; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.05034906859150347,"score_gpt":0.3679076374841846,"score_spread":0.31755856889268114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817157,0.00006680484,0.000013677225,0.00019421363,0.00003645939,0.0011115022,0.00002836897,0.00005743736,0.00031999766],"genre_scores_gemma":[0.9990732,0.00003984289,0.00046402946,0.00006140327,0.00001635996,0.000114291586,0.00012484545,0.000021353215,0.000084639876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966992,0.0003228267,0.0009999415,0.0006727994,0.00065453036,0.00065067376],"domain_scores_gemma":[0.9974375,0.0013217877,0.000329662,0.00046207782,0.00017251911,0.0002764871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053130183,0.00029080623,0.0020242208,0.00093030883,0.00007680364,0.000008454299,0.00023624266,0.000395153,0.0002264716],"category_scores_gemma":[0.0007431373,0.00021152486,0.0001615979,0.0026334706,0.00054096774,0.00007385787,0.00029429462,0.00027885457,0.000016550432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019560939,0.08811328,0.83789426,0.00069679774,0.0027388462,0.0075617563,0.0059603313,0.00008991172,0.00046732574,0.00032493373,0.0014102324,0.035181392],"study_design_scores_gemma":[0.3012385,0.044964842,0.64677775,0.00015788373,0.0014878658,0.00019942559,0.0023780088,0.0018299067,0.00008313477,0.00006172665,0.00052499125,0.0002959655],"about_ca_topic_score_codex":0.0008535521,"about_ca_topic_score_gemma":0.0016964861,"teacher_disagreement_score":0.28167757,"about_ca_system_score_codex":0.0018017917,"about_ca_system_score_gemma":0.0013535655,"threshold_uncertainty_score":0.8625734},"labels":[],"label_agreement":null},{"id":"W4379981685","doi":"10.1002/hon.3164_210","title":"Biological and clinical relevance of CD79 protein and gene expression in diffuse large B‐cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Medicine; Internal medicine; Rituximab; Immunohistochemistry; Oncology; Germinal center; Hematology; Pathology; Antibody; B cell; Immunology","score_opus":0.05289518463836473,"score_gpt":0.35816274357793804,"score_spread":0.3052675589395733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635077,0.0013521771,0.000012791372,0.0010484222,0.00004889233,0.0005945648,0.000009137616,0.00005055943,0.0005327127],"genre_scores_gemma":[0.99357176,0.0032850737,0.0026479878,0.00024000467,0.00002834483,0.0001261973,0.000017598433,0.000008101389,0.00007491445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824226,0.00024923103,0.00059293583,0.00046678595,0.000113536415,0.0003352301],"domain_scores_gemma":[0.99841416,0.0010344675,0.00014603669,0.00018905422,0.000031165724,0.00018509873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045617882,0.00016298413,0.00087912986,0.00008383171,0.00004026912,0.0000039085676,0.000057756286,0.0004732773,0.000038309292],"category_scores_gemma":[0.00066023105,0.000098325225,0.00008195216,0.00018727826,0.00029376044,0.000024613932,0.00022311894,0.00011469093,0.000035671892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009403012,0.015092996,0.95251656,0.000121466925,0.000028102688,0.00285101,0.000095753596,7.115608e-8,0.012979418,0.0011687976,0.00041379084,0.013791716],"study_design_scores_gemma":[0.030701064,0.0037451065,0.9336785,0.00016582706,0.000040307834,0.00039903758,0.00013997963,0.00013367794,0.024023,0.0011468414,0.0056652557,0.00016137316],"about_ca_topic_score_codex":0.0000053828203,"about_ca_topic_score_gemma":0.000008081422,"teacher_disagreement_score":0.029760763,"about_ca_system_score_codex":0.00005634469,"about_ca_system_score_gemma":0.000061272964,"threshold_uncertainty_score":0.40095863},"labels":[],"label_agreement":null},{"id":"W4379981707","doi":"10.1002/hon.3164_398","title":"Neurotoxicity in patients with CNS lymphomas treated with CAR‐T cell therapy. A LOC network study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neurotoxicity; Lymphoma; Encephalopathy; Internal medicine; Toxicity; Gastroenterology; Pediatrics; Oncology","score_opus":0.04181337863293949,"score_gpt":0.3220643908578386,"score_spread":0.2802510122248991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956335,0.000052350646,0.0000054679826,0.0003293769,0.00004094035,0.003453785,0.0000029925543,0.00024349996,0.0063082315],"genre_scores_gemma":[0.99761486,0.000049655817,0.00009070879,0.00053453527,0.00005560192,0.0004606533,0.000034902063,0.00004991413,0.0011091472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969605,0.0005811558,0.0004003694,0.0006563624,0.00053495367,0.00086664717],"domain_scores_gemma":[0.9984854,0.00054353126,0.00011254489,0.00045619273,0.00014984643,0.0002525222],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004303469,0.0003108994,0.0010353029,0.00020395957,0.000095033625,0.000015245906,0.00020029258,0.0002706779,0.0011474206],"category_scores_gemma":[0.000054831955,0.00017877933,0.000073209354,0.0016421925,0.00025893722,0.000037812024,0.00011291201,0.0005097612,0.00012477803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011912773,0.0053052623,0.97471046,0.000025554618,0.00009612602,0.0038256603,0.00028826212,0.00008086663,0.00029485178,0.00003710375,0.0006195922,0.0028034577],"study_design_scores_gemma":[0.0248569,0.031918406,0.93803394,0.00003445136,0.00004095558,0.00010910332,0.00031391092,0.00014400402,0.0004642086,0.000039859333,0.0038034155,0.000240845],"about_ca_topic_score_codex":0.00011353979,"about_ca_topic_score_gemma":0.00021751612,"teacher_disagreement_score":0.03667655,"about_ca_system_score_codex":0.00025043252,"about_ca_system_score_gemma":0.0002329437,"threshold_uncertainty_score":0.9997657},"labels":[],"label_agreement":null},{"id":"W4379981722","doi":"10.1002/hon.3163_43","title":"GOLIDOCITINIB IN TREATING REFRACTORY OR RELAPSED PERIPHERAL T‐CELL LYMPHOMA: PRIMARY ANALYSIS OF THE MULTINATIONAL PIVOTAL STUDY RESULTS (JACKPOT8)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Refractory (planetary science); Clinical endpoint; Gastroenterology; Oncology; Surgery; Clinical trial","score_opus":0.04208158833851896,"score_gpt":0.342433251329565,"score_spread":0.30035166299104604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98706967,0.000078054625,0.0000011396464,0.0010592176,0.00010923011,0.0007840895,0.000042854743,0.00007413834,0.010781583],"genre_scores_gemma":[0.9977142,0.000042673695,0.0004233604,0.00031730844,0.000035056455,0.00023666675,0.00013367509,0.000012741828,0.0010842953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973844,0.00044325506,0.00091381354,0.0004985609,0.00040359428,0.00035634273],"domain_scores_gemma":[0.99712044,0.0019413631,0.0003637553,0.00037063455,0.00010500241,0.00009879463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005313468,0.0002169416,0.0011255285,0.0003126808,0.00010254888,0.000007652574,0.0001629419,0.00025209354,0.00016812599],"category_scores_gemma":[0.00087381346,0.00011676017,0.00032973054,0.0018896519,0.0001726681,0.000039548573,0.00017559214,0.000148378,0.000026618885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032179756,0.0210813,0.95913863,0.00006714219,0.0008546892,0.0030013197,0.002410245,0.00014381531,0.00042585077,0.00021083404,0.0009715866,0.008476606],"study_design_scores_gemma":[0.019741533,0.0022244349,0.9728632,0.0000358446,0.0007865958,0.0000843215,0.0018612529,0.000926559,0.00025017752,0.000018597424,0.0010883769,0.00011911497],"about_ca_topic_score_codex":0.00014235498,"about_ca_topic_score_gemma":0.00034616547,"teacher_disagreement_score":0.018856866,"about_ca_system_score_codex":0.0007638904,"about_ca_system_score_gemma":0.0003854748,"threshold_uncertainty_score":0.47613418},"labels":[],"label_agreement":null},{"id":"W4379981730","doi":"10.1002/hon.3165_637","title":"COMPARATIVE EFFECTIVENESS OF SALVAGE CHEMOTHERAPY AND CHIMERIC ANTIGEN T‐CELL RECEPTOR THERAPIES IN R/R DLBCL: A SYSTEMATIC REVIEW AND NETWORK META‐ANALYSIS","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Takeda Pharmaceuticals International","keywords":"Internal medicine; Oncology; Medicine; Etoposide; Gemcitabine; Carboplatin; Regimen; Ifosfamide; Cytarabine; Rituximab; Chemotherapy; Cisplatin; Lymphoma","score_opus":0.1821421503594694,"score_gpt":0.4575280083319074,"score_spread":0.275385857972438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981730","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029343582,0.9908216,0.000019969495,0.00011748944,0.000032677082,0.008243389,0.000020396492,0.000058862326,0.0003922052],"genre_scores_gemma":[0.00025614552,0.9969305,0.00031959088,0.00019427028,0.000026320768,0.00185527,0.00007397597,0.00005874368,0.00028520107],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9907655,0.0058581084,0.0016504244,0.00085454935,0.0003311876,0.000540207],"domain_scores_gemma":[0.9900327,0.00814438,0.00092154834,0.00058814,0.000121585705,0.00019168068],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.003809328,0.0006803551,0.026117181,0.0005040702,0.000053526186,0.000015408807,0.00026515243,0.0006841349,0.00077673426],"category_scores_gemma":[0.00021319407,0.00039661443,0.0016066597,0.002685047,0.0005282473,0.000030000007,0.00017451654,0.00079130975,0.000035456284],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012314711,0.00041714223,0.00010423728,0.91087645,0.086425245,0.000112989626,0.00014271098,3.8847622e-7,0.000018172515,0.000108481974,0.00007477569,0.0015962346],"study_design_scores_gemma":[0.0032481293,0.0030094583,0.00032039892,0.2680268,0.6567097,0.0008490842,0.00018758183,0.000027916625,0.000030415296,0.00024366044,0.06615417,0.0011927204],"about_ca_topic_score_codex":0.00002516208,"about_ca_topic_score_gemma":0.000018707551,"teacher_disagreement_score":0.6428497,"about_ca_system_score_codex":0.00014711752,"about_ca_system_score_gemma":0.00023077051,"threshold_uncertainty_score":0.99984854},"labels":[],"label_agreement":null},{"id":"W4379981753","doi":"10.1002/hon.3163_111","title":"CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia","funders":"Genentech; F. Hoffmann-La Roche; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Medicine; Internal medicine; Hazard ratio; Diffuse large B-cell lymphoma; Oncology; Gastroenterology; Lymphoma; Nuclear medicine; Confidence interval","score_opus":0.018820468289993533,"score_gpt":0.3107343171608774,"score_spread":0.2919138488708839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984453,0.00012872014,0.000005939344,0.0001558948,0.000082996914,0.0008856677,0.000025700425,0.000019206078,0.00025062254],"genre_scores_gemma":[0.99873894,0.00015638047,0.00006925874,0.0007863458,0.000028989425,0.00008874205,0.000092822265,0.00001914098,0.000019380053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774724,0.00043232145,0.00054849166,0.00054314476,0.00014439029,0.00058439677],"domain_scores_gemma":[0.9987984,0.0005476781,0.00016747403,0.00032709853,0.000045515175,0.000113838614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006103054,0.00021889125,0.00054730487,0.000074771655,0.000076722004,0.000028144217,0.00020885476,0.0002322484,0.000005123682],"category_scores_gemma":[0.00065348874,0.00013859998,0.00007013993,0.0002574429,0.0001231307,0.0000040991467,0.00027787624,0.00018202905,0.000010525177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026719683,0.008266729,0.9896865,0.000013593054,0.00003406728,0.0004338781,0.0003025038,0.0000048679776,0.000045256078,0.00008740399,0.00010124396,0.0007567781],"study_design_scores_gemma":[0.019181099,0.0036495263,0.9743502,0.000009414013,0.000036577614,0.000024977204,0.00097481086,0.00006720702,0.0000318119,0.000066094464,0.0014112933,0.00019694878],"about_ca_topic_score_codex":0.00015239298,"about_ca_topic_score_gemma":0.0025274202,"teacher_disagreement_score":0.0189139,"about_ca_system_score_codex":0.00006398107,"about_ca_system_score_gemma":0.00014511071,"threshold_uncertainty_score":0.5651943},"labels":[],"label_agreement":null},{"id":"W4379981760","doi":"10.1002/hon.3165_523","title":"THE LOW‐RISK EARLY‐STAGE HODGKIN LYMPHOMA PATIENTS WITH INADEQUATE RESPONSE TO CHEMOTHERAPY. THE PRELIMINARY EXPERIENCE FROM THE RAFTING TRIAL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"ABVD; Medicine; Stage (stratigraphy); Radiation therapy; Internal medicine; Dacarbazine; Chemotherapy; Oncology; Surgery; Vincristine; Cyclophosphamide","score_opus":0.023930521339907054,"score_gpt":0.3082493475796885,"score_spread":0.2843188262397815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.972957,0.00013947861,0.000017518916,0.024159607,0.00026492568,0.0021550697,0.000021669182,0.00012445461,0.00016026292],"genre_scores_gemma":[0.994832,0.00014478712,0.00015505416,0.0030604377,0.00012374042,0.0013619198,0.000015470494,0.00002456827,0.0002820649],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9971172,0.0009613713,0.00044904827,0.00048092194,0.00043412216,0.0005573153],"domain_scores_gemma":[0.99063116,0.008184016,0.00024034231,0.0006963718,0.0000831072,0.00016501588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088519056,0.00026373597,0.0005101681,0.000034561617,0.0007304034,0.000058188303,0.00040696227,0.0001957209,0.00007172683],"category_scores_gemma":[0.0015841876,0.000093596616,0.00014345603,0.00045752604,0.00036764675,0.00003903957,0.00023176044,0.00018621501,0.00026469328],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45438707,0.002673867,0.36135945,0.000010003837,0.0004090996,0.0013092438,0.013279456,0.000017907052,0.000071951494,0.00044668897,0.007074204,0.15896107],"study_design_scores_gemma":[0.038559545,0.008298671,0.91808665,0.000052046227,0.00008931912,0.000029272933,0.0019380945,0.000069350965,0.00063384796,0.00010012123,0.03199731,0.0001457823],"about_ca_topic_score_codex":0.00028512362,"about_ca_topic_score_gemma":0.000048866514,"teacher_disagreement_score":0.5567272,"about_ca_system_score_codex":0.0002380746,"about_ca_system_score_gemma":0.00019468376,"threshold_uncertainty_score":0.5617747},"labels":[],"label_agreement":null},{"id":"W4379981780","doi":"10.1002/hon.3164_282","title":"Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada); Precision Nanosystems (Canada)","funders":"BeiGene","keywords":"Medicine; Internal medicine; Progression-free survival; Logistic regression; Percentile; Hazard ratio; Oncology; Urology; Gastroenterology; Overall survival; Confidence interval; Statistics; Mathematics","score_opus":0.10490629633047638,"score_gpt":0.3881888356474517,"score_spread":0.28328253931697533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97779214,0.000643915,0.000037474,0.0010517967,0.00071508565,0.00092811795,0.000017304761,0.00039284248,0.018421339],"genre_scores_gemma":[0.99698097,0.0002885218,0.0012173756,0.00022451917,0.00013797104,0.00013212582,0.00013834023,0.000060158833,0.000820026],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945177,0.00067512674,0.0015553657,0.00090538245,0.0009560223,0.0013904388],"domain_scores_gemma":[0.99394196,0.004166191,0.00048131467,0.0007725154,0.00017773849,0.00046030685],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014796344,0.00045929046,0.00237513,0.000779623,0.000109772336,0.000015481235,0.0005267454,0.0011165299,0.00092182367],"category_scores_gemma":[0.001437147,0.00038191237,0.00030526513,0.0018870966,0.0008020591,0.00007652585,0.00055443356,0.0008981963,0.0010659948],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2005523,0.037691906,0.22638164,0.008315536,0.003308677,0.10611455,0.021354426,0.0011313647,0.037156668,0.05693305,0.11037422,0.19068566],"study_design_scores_gemma":[0.4636408,0.032703735,0.2849321,0.0020213919,0.0007309947,0.009470283,0.014484909,0.024401842,0.02678456,0.0037829736,0.1342718,0.002774583],"about_ca_topic_score_codex":0.0006577408,"about_ca_topic_score_gemma":0.00031018164,"teacher_disagreement_score":0.26308852,"about_ca_system_score_codex":0.0070715714,"about_ca_system_score_gemma":0.005298819,"threshold_uncertainty_score":0.9999915},"labels":[],"label_agreement":null},{"id":"W4379981833","doi":"10.1002/hon.3163_37","title":"LUNG STAGING IN PEDIATRIC HODGKIN LYMPHOMA: STAGING EVALUATION &amp; RESPONSE CRITERIA HARMONIZATION FOR CHILDHOOD, ADOLESCENT &amp; YOUNG ADULT HL (SEARCH FOR CAYAHL) CONSENSUS","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; London Health Sciences Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Population; Cohort; Lung; Pediatrics; Pathology","score_opus":0.08851257481726457,"score_gpt":0.41003496185568383,"score_spread":0.3215223870384193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98423564,0.00056428433,0.0016982878,0.007907701,0.0004545123,0.0047069024,0.00009940751,0.00021096223,0.00012227133],"genre_scores_gemma":[0.98953027,0.00034794564,0.0060410104,0.0006620984,0.0002063417,0.0022332745,0.0008131835,0.000048143476,0.00011772726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99640673,0.0007136538,0.0008265783,0.00076951145,0.0004585487,0.0008249445],"domain_scores_gemma":[0.9960318,0.0025197687,0.00021832407,0.00034313172,0.00066386507,0.00022309653],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025564611,0.0003177601,0.0008332005,0.00055550406,0.00023285706,0.00004277586,0.00012236628,0.00036648678,0.00007631542],"category_scores_gemma":[0.0034662073,0.00026753548,0.00020241599,0.0007377295,0.000090473026,0.000055348246,0.00010134772,0.00013812643,0.000073226656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0087390775,0.003676978,0.94895643,0.0008706266,0.00013212186,0.0003154292,0.002219227,0.00019474282,0.001184164,0.0012160847,0.018218046,0.014277062],"study_design_scores_gemma":[0.025892058,0.00093965227,0.95584655,0.00020900629,0.00053410535,0.0002715456,0.00058574014,0.0110938875,0.0011139426,0.000406941,0.0027216915,0.00038490197],"about_ca_topic_score_codex":0.00007106609,"about_ca_topic_score_gemma":0.00014886339,"teacher_disagreement_score":0.017152982,"about_ca_system_score_codex":0.0015992728,"about_ca_system_score_gemma":0.00091015664,"threshold_uncertainty_score":0.9999777},"labels":[],"label_agreement":null},{"id":"W4379981851","doi":"10.1002/hon.3163_146","title":"IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"International Prognostic Index; Rituximab; Vincristine; Medicine; Diffuse large B-cell lymphoma; Cyclophosphamide; Internal medicine; Prednisone; CHOP; Tumor microenvironment; Immune system; Lymphoma; Oncology; Hazard ratio; CD20; Gastroenterology; Cancer research; Immunology; Chemotherapy","score_opus":0.019905273090356675,"score_gpt":0.30525955882170136,"score_spread":0.2853542857313447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98591316,0.006205544,0.000024377123,0.0052654813,0.0008755797,0.00076991325,0.00007697834,0.00020161015,0.00066737446],"genre_scores_gemma":[0.9928121,0.0003745494,0.00026223407,0.00077746256,0.000022892507,0.00034934582,0.000204786,0.000030140816,0.0051665176],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99536425,0.001551117,0.0009475345,0.0009275823,0.000085942826,0.0011235807],"domain_scores_gemma":[0.9975933,0.0013483502,0.0002473061,0.0006783618,0.00004028605,0.00009243239],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009702436,0.00045891484,0.0015272589,0.0008365074,0.00020171616,0.000016596961,0.0005579717,0.00076187414,0.0025439472],"category_scores_gemma":[0.0004184723,0.00036033784,0.00039869797,0.0014829382,0.0003912082,0.000057423644,0.00037422898,0.0005710649,0.0050298823],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061910786,0.0014029286,0.033114955,0.000015470885,0.0013388015,0.0021563573,0.0016415191,0.0001779679,0.945315,0.00041826683,0.0027934727,0.0054341657],"study_design_scores_gemma":[0.0063556656,0.0048162728,0.40368718,0.00005867146,0.0006751122,0.0010393508,0.0019898985,0.000014072452,0.29519135,0.00031331257,0.28488418,0.0009749426],"about_ca_topic_score_codex":0.0003885785,"about_ca_topic_score_gemma":0.00054788485,"teacher_disagreement_score":0.65012366,"about_ca_system_score_codex":0.0010527727,"about_ca_system_score_gemma":0.00021621882,"threshold_uncertainty_score":0.99988484},"labels":[],"label_agreement":null},{"id":"W4379981852","doi":"10.1002/hon.3166_ot28","title":"PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"National Institutes of Health; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Rituximab; Diffuse large B-cell lymphoma; Vincristine; Cytokine release syndrome; Oncology; Prednisone; CHOP; International Prognostic Index; Cyclophosphamide; Phases of clinical research; CD20; Lymphoma; Discontinuation; Gastroenterology; Clinical trial; Chemotherapy; Cancer; Immunotherapy","score_opus":0.04596949735079359,"score_gpt":0.36019912368922496,"score_spread":0.3142296263384314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949367,0.00010939865,0.000016783699,0.00053521566,0.0007027545,0.0025766555,0.00006167234,0.0002182886,0.006285553],"genre_scores_gemma":[0.9971738,0.00031798,0.00027288575,0.00025956339,0.0001837864,0.00032269745,0.00018820848,0.0000764133,0.0012046878],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99525964,0.00052771566,0.0010687826,0.0008815328,0.00093833584,0.0013239966],"domain_scores_gemma":[0.9952233,0.0028781777,0.00033967613,0.0007742813,0.00027351134,0.0005110459],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000682961,0.00046915133,0.0018439078,0.00053311925,0.00009910667,0.00001881077,0.00042483,0.00078271795,0.0013747581],"category_scores_gemma":[0.0012108466,0.00034827145,0.00030886402,0.0014221836,0.00043473672,0.00007857749,0.00026783242,0.00063548714,0.00038314686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7539799,0.15487291,0.017186893,0.0003221808,0.00025120514,0.027466055,0.0008637865,0.00000424392,0.002359759,0.00069013116,0.0037200686,0.038282827],"study_design_scores_gemma":[0.9072056,0.06839499,0.0039153593,0.000087658635,0.00013700273,0.0002846544,0.00057844026,0.00031540173,0.0009759687,0.00011094862,0.017592983,0.00040103344],"about_ca_topic_score_codex":0.00007857669,"about_ca_topic_score_gemma":0.00014388206,"teacher_disagreement_score":0.15322563,"about_ca_system_score_codex":0.0006317787,"about_ca_system_score_gemma":0.00056500814,"threshold_uncertainty_score":0.99989694},"labels":[],"label_agreement":null},{"id":"W4379981853","doi":"10.1002/hon.3164_189","title":"Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Medical Research Council; National Health and Medical Research Council; Mater Foundation","keywords":"Stage (stratigraphy); Medicine; CD8; Follicular lymphoma; Internal medicine; Lymphoma; Cohort; Oncology; Human leukocyte antigen; Immunology; Biology; Antigen","score_opus":0.04746191264766503,"score_gpt":0.33938508126465805,"score_spread":0.291923168616993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933848,0.00085418037,0.000009067142,0.00063368864,0.00015233888,0.0008840534,0.000026706679,0.00014879038,0.003906403],"genre_scores_gemma":[0.9978373,0.0009786325,0.00042730558,0.00015902682,0.00004010328,0.0001894954,0.00007777191,0.000022755248,0.00026763143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978183,0.00016257419,0.00065791595,0.00048130698,0.00025765577,0.0006222738],"domain_scores_gemma":[0.9982427,0.000869641,0.00018667767,0.00037898653,0.00008031892,0.00024171463],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002676234,0.00027957532,0.0011715507,0.00030821122,0.00004365306,0.000009335453,0.00013967992,0.0004076773,0.0006084347],"category_scores_gemma":[0.00020590151,0.00018262582,0.00042993255,0.00090671005,0.00018216982,0.00003765291,0.000112189824,0.0001157708,0.0008348275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005884474,0.0056643873,0.94284225,0.00016782699,0.0002779575,0.018705297,0.00027467078,0.000085478954,0.009519501,0.003195835,0.008133063,0.01054527],"study_design_scores_gemma":[0.0066002035,0.0039508957,0.96301013,0.00013749338,0.000100324825,0.0006110476,0.00016901888,0.00037709955,0.0095142,0.0002860931,0.0150225535,0.00022093524],"about_ca_topic_score_codex":0.00008174516,"about_ca_topic_score_gemma":0.000014693899,"teacher_disagreement_score":0.02016787,"about_ca_system_score_codex":0.0004909494,"about_ca_system_score_gemma":0.00030494548,"threshold_uncertainty_score":0.99994314},"labels":[],"label_agreement":null},{"id":"W4379981884","doi":"10.1002/hon.3163_83","title":"MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Refractory (planetary science); Follicular phase; Gastroenterology; Phases of clinical research; Clinical endpoint; Dosing; Lymphoma; Urology; Oncology; Surgery; Clinical trial; Materials science","score_opus":0.030225123102663037,"score_gpt":0.34757183728010405,"score_spread":0.317346714177441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775696,0.00021400931,0.0000047525305,0.0003129926,0.00002232678,0.0012876666,0.00001977933,0.000091351416,0.0002901879],"genre_scores_gemma":[0.99885243,0.00009335039,0.00015557022,0.00007901112,0.000006915105,0.00012200133,0.00009005162,0.000021888012,0.00057880394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973214,0.0005965936,0.00061872357,0.0005358786,0.00045671492,0.00047067576],"domain_scores_gemma":[0.99820656,0.0008628772,0.00018704913,0.00038782615,0.00018371474,0.00017198437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007303663,0.00023727177,0.0013684266,0.00086833816,0.00011452347,0.000011159788,0.00013921148,0.0002729887,0.0009281465],"category_scores_gemma":[0.0003246997,0.00015634121,0.00012605436,0.0026035307,0.00039914108,0.00006687053,0.00013552429,0.00025068803,0.0000091056445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029770948,0.015388319,0.9244285,0.00004370991,0.0025651942,0.0017728467,0.0019301848,0.0000124668495,0.0062696747,0.00006319706,0.0001253139,0.017629623],"study_design_scores_gemma":[0.03449585,0.03855675,0.9206368,0.000035532557,0.0007717255,0.000055192497,0.0027058455,0.0007457588,0.0006635947,0.000040998428,0.0010830313,0.00020893279],"about_ca_topic_score_codex":0.000094227296,"about_ca_topic_score_gemma":0.00020101294,"teacher_disagreement_score":0.023168432,"about_ca_system_score_codex":0.00018197746,"about_ca_system_score_gemma":0.000271616,"threshold_uncertainty_score":0.99998516},"labels":[],"label_agreement":null},{"id":"W4379981896","doi":"10.1002/hon.3164_365","title":"Role of upfront autologous stem cell transplantation (ASCT) in adults with T‐NHL in first complete remission (CR1): A systematic literature review and meta‐analysis","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Autologous stem-cell transplantation; Oncology; Randomized controlled trial; Hazard ratio; Meta-analysis; Observational study; Transplantation; Confidence interval","score_opus":0.02524563465409945,"score_gpt":0.28523598792378485,"score_spread":0.2599903532696854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7726947,0.22071993,0.000011387589,0.0029604845,0.000012668876,0.0027426914,0.000050010432,0.0000734727,0.00073462666],"genre_scores_gemma":[0.9619522,0.036707193,0.00038996205,0.00027297187,0.000002261788,0.00052843837,0.000101838225,0.0000075601047,0.000037548518],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.9981999,0.00032562355,0.0007009675,0.00037474858,0.00016660277,0.00023217843],"domain_scores_gemma":[0.9987929,0.0005956747,0.00024349055,0.00021214261,0.000056316665,0.00009950808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032576398,0.00020461231,0.0026721826,0.00028161157,0.000028874998,0.0000051824527,0.00006458574,0.000219091,0.00004787145],"category_scores_gemma":[0.00002680703,0.000109911605,0.00021154853,0.0010418198,0.000057205674,0.00003422977,0.000023713217,0.00013388184,0.000009833042],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002939982,0.004887386,0.20985669,0.7251196,0.021659456,0.022714894,0.009633394,0.00021009785,0.00024237474,0.0016778223,0.00035331032,0.00070500374],"study_design_scores_gemma":[0.018734954,0.0070165605,0.53284186,0.06961289,0.3574106,0.005854331,0.0022658724,0.003817617,0.00096466445,0.000255977,0.00037832747,0.0008463114],"about_ca_topic_score_codex":0.00005113622,"about_ca_topic_score_gemma":0.00056268944,"teacher_disagreement_score":0.6555067,"about_ca_system_score_codex":0.00010376079,"about_ca_system_score_gemma":0.00004337608,"threshold_uncertainty_score":0.4482065},"labels":[],"label_agreement":null},{"id":"W4379981910","doi":"10.1002/hon.3164_340","title":"Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Pharmacyclics","keywords":"Medicine; Ibrutinib; Adverse effect; Internal medicine; Ven; Chronic lymphocytic leukemia; Oncology; Venetoclax; Gastroenterology; Leukemia","score_opus":0.14501260973266877,"score_gpt":0.46213556874558415,"score_spread":0.3171229590129154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99583584,0.00010031193,0.0002342391,0.00008665482,0.00014959207,0.003087101,0.000055302877,0.000056980134,0.0003939823],"genre_scores_gemma":[0.9977347,0.00022967542,0.0009909765,0.00003482552,0.000040563762,0.0004506334,0.00032401178,0.000023232664,0.000171382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99450916,0.0010124642,0.002546451,0.00066296314,0.0006852883,0.0005836906],"domain_scores_gemma":[0.9942374,0.0036103118,0.000959128,0.00066799385,0.0003135838,0.0002115874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053353207,0.00023801616,0.0033722497,0.00068541325,0.000034261444,0.0000017516162,0.00027158498,0.00054636924,0.00008042207],"category_scores_gemma":[0.0016250287,0.00016570206,0.000807375,0.002243077,0.0003125176,0.000054683314,0.00018164917,0.0002359677,0.00003807992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.062339935,0.0032433255,0.8505797,0.0045914324,0.02505736,0.00050673157,0.00047959446,0.013575083,0.00028490086,0.0067856084,0.00089670834,0.031659644],"study_design_scores_gemma":[0.07983777,0.0054795053,0.8612122,0.00027007484,0.0058319797,0.0000039861875,0.00015618402,0.046341978,0.00024662196,0.0001879599,0.00022588186,0.0002058403],"about_ca_topic_score_codex":0.00020892882,"about_ca_topic_score_gemma":0.00002598246,"teacher_disagreement_score":0.032766894,"about_ca_system_score_codex":0.016806573,"about_ca_system_score_gemma":0.008562119,"threshold_uncertainty_score":0.9970584},"labels":[],"label_agreement":null},{"id":"W4379981917","doi":"10.1002/hon.3163_68","title":"BTG2 SUPER‐ENHANCER MUTATIONS DISRUPT TFAP4 BINDING AND DYSREGULATE BTG2 EXPRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Genome British Columbia","funders":"","keywords":"Biology; Diffuse large B-cell lymphoma; Somatic hypermutation; Enhancer; Cancer research; Gene; Genetics; Lymphoma; Transcription factor; B cell; Immunology","score_opus":0.013859577037701265,"score_gpt":0.2959074096299436,"score_spread":0.28204783259224236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680483,0.0007980137,0.00042197472,0.00054154015,0.00030792883,0.0003262976,0.000026486834,0.00007454439,0.00069840427],"genre_scores_gemma":[0.9973104,0.0005244295,0.00042951189,0.000100615194,0.000103682505,0.00013396062,0.00035696462,0.000028831073,0.0010116155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981409,0.00018758753,0.0004063346,0.00060392043,0.0001360781,0.0005252162],"domain_scores_gemma":[0.9993139,0.000111626134,0.00012458354,0.00027355936,0.00004434775,0.00013196694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025843232,0.00022310404,0.00036515016,0.000159975,0.00014770462,0.00002027414,0.0001444607,0.00063041097,0.0000634548],"category_scores_gemma":[0.00012841626,0.00019577036,0.00008562664,0.00037807864,0.00015746463,0.000011361447,0.0002819659,0.00012889679,0.00008341276],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022316255,0.0010934165,0.008598512,0.00006426046,0.000025505971,0.00012942172,0.00030663967,0.00016517949,0.98173577,0.00028592034,0.0029865727,0.0043856716],"study_design_scores_gemma":[0.020550916,0.0011778901,0.060461327,0.00014096349,0.000075257056,0.0004515018,0.0010411912,0.004559886,0.8282645,0.0016136614,0.08059651,0.0010664364],"about_ca_topic_score_codex":0.000007228451,"about_ca_topic_score_gemma":0.00010796329,"teacher_disagreement_score":0.15347128,"about_ca_system_score_codex":0.00009422186,"about_ca_system_score_gemma":0.00009138621,"threshold_uncertainty_score":0.7983284},"labels":[],"label_agreement":null},{"id":"W4379981918","doi":"10.1002/hon.3163_140","title":"RITUXIMAB‐CONTAINING COMBINED MODALITY THERAPY IN LIMITED STAGE FOLLICULAR LYMPHOMA: MATURE FOLLOW UP AND DERIVATION OF A NOVEL PROGNOSTIC SCORE FROM THE TROG99.03 TRIAL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Follicular lymphoma; Internal medicine; Regimen; Oncology; Radiation therapy; Stage (stratigraphy); Lymphoma; Progression-free survival; Gastroenterology; Surgery; Overall survival","score_opus":0.0890290924963258,"score_gpt":0.32970095318427256,"score_spread":0.24067186068794677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99107486,0.0006382134,0.000029783683,0.0058713187,0.00017671462,0.001981111,0.000034873286,0.00009110622,0.00010202188],"genre_scores_gemma":[0.99760723,0.00026117172,0.00051072217,0.00079503236,0.000049020033,0.00054081227,0.00019852676,0.000014902548,0.00002260982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99824303,0.00023412691,0.000558275,0.0004093908,0.00023448905,0.0003206716],"domain_scores_gemma":[0.997287,0.0020352064,0.00022852622,0.00027850692,0.00007641602,0.00009439738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040758806,0.00022346796,0.0010314297,0.00008305664,0.00008081064,0.000016460406,0.00010926067,0.00038901594,0.000038331986],"category_scores_gemma":[0.0008370873,0.00012730532,0.00015901397,0.00043700964,0.00017106383,0.00004424551,0.00008548857,0.00013770991,0.000008081886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06433644,0.0109703485,0.89501023,0.00009171505,0.0005494621,0.0012293564,0.0016543603,0.000009015186,0.0017799325,0.012095432,0.00036161096,0.011912068],"study_design_scores_gemma":[0.24498518,0.00533642,0.7446284,0.00013893297,0.0001430915,0.000061046136,0.00052479026,0.0013059526,0.00079544703,0.0012559679,0.0006780627,0.0001466837],"about_ca_topic_score_codex":0.00028929667,"about_ca_topic_score_gemma":0.00011724127,"teacher_disagreement_score":0.18064874,"about_ca_system_score_codex":0.0001534976,"about_ca_system_score_gemma":0.00018449803,"threshold_uncertainty_score":0.519136},"labels":[],"label_agreement":null},{"id":"W4379981977","doi":"10.1002/hon.3164_288","title":"Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Canadian Red Cross Society; Health Canada; Baker Hughes (Canada); Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Hospital; Sunnybrook Health Science Centre; Agricultural Research Institute of Ontario; Health Sciences North; Juravinski Cancer Centre; McGill University Health Centre","funders":"","keywords":"Bendamustine; Medicine; Rituximab; Adverse effect; Internal medicine; Waldenstrom macroglobulinemia; Lymphoplasmacytic Lymphoma; Clinical trial; Ibrutinib; Oncology; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.0431760209306247,"score_gpt":0.37044516589517396,"score_spread":0.3272691449645493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854445,0.0005391562,0.00001845324,0.0060395077,0.00017346554,0.00065820507,0.000009682878,0.00028860103,0.0068284366],"genre_scores_gemma":[0.9962827,0.0005226288,0.0012311368,0.0009458559,0.00013334132,0.00013188286,0.000055268974,0.000029796825,0.00066739693],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99696124,0.0001882982,0.0006787502,0.0007143697,0.00043632888,0.0010210393],"domain_scores_gemma":[0.99805546,0.00096947193,0.000101006495,0.0003745177,0.000086301734,0.00041326202],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067589997,0.00027846312,0.001097292,0.00032116714,0.0000807329,0.000018445686,0.00020464777,0.00066387444,0.0004257025],"category_scores_gemma":[0.0012475285,0.00021310341,0.000107306754,0.00091395114,0.0005818492,0.000049153932,0.00052802655,0.00048419385,0.0008618136],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011968436,0.013278739,0.15188324,0.00431562,0.0005964723,0.22859183,0.0032398703,0.000087076856,0.0126436185,0.048231915,0.11486952,0.41029367],"study_design_scores_gemma":[0.37406024,0.009288019,0.2683598,0.0010763776,0.0003391983,0.081666045,0.0030426485,0.06714571,0.007978176,0.007697293,0.17736062,0.001985848],"about_ca_topic_score_codex":0.00013597179,"about_ca_topic_score_gemma":0.0000702966,"teacher_disagreement_score":0.40830782,"about_ca_system_score_codex":0.004131575,"about_ca_system_score_gemma":0.0025276851,"threshold_uncertainty_score":0.99991614},"labels":[],"label_agreement":null},{"id":"W4379981988","doi":"10.1002/hon.3164_394","title":"Developing CAR‐T‐sparing Radiotherapy ‐ early dosimetric results","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Nuclear medicine; Radiation therapy; Surgery","score_opus":0.12701227083581387,"score_gpt":0.412145902536441,"score_spread":0.2851336317006271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95115143,0.00054147316,0.0005348213,0.0097703645,0.00034233608,0.0007268652,0.000004109469,0.00067047944,0.036258116],"genre_scores_gemma":[0.98340505,0.0012815453,0.0044953884,0.0015507635,0.0003280861,0.00012365112,0.00003812589,0.00005314643,0.008724223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99732614,0.00024398117,0.0005721515,0.0005763995,0.00044534996,0.0008360117],"domain_scores_gemma":[0.9976182,0.0014517884,0.000109898305,0.0004166145,0.00012703451,0.00027646753],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010433801,0.00021932664,0.00086065126,0.0005988575,0.000136116,0.00002600478,0.00024557908,0.00047333862,0.0010253727],"category_scores_gemma":[0.0010008905,0.0001677464,0.00017402717,0.0022524272,0.00021376497,0.000047717196,0.00016209154,0.0006000218,0.0007744147],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018127054,0.0016677142,0.20086809,0.00078664516,0.0015747402,0.028017672,0.0032611676,0.00006246969,0.2462941,0.07057036,0.057317838,0.37145215],"study_design_scores_gemma":[0.0130574,0.0045818603,0.2001571,0.00014857147,0.000057875455,0.0028090503,0.0003681147,0.0012295393,0.020770205,0.0020988353,0.7540406,0.0006808315],"about_ca_topic_score_codex":0.00007982005,"about_ca_topic_score_gemma":0.00001329604,"teacher_disagreement_score":0.6967228,"about_ca_system_score_codex":0.0008198717,"about_ca_system_score_gemma":0.00033574746,"threshold_uncertainty_score":0.9998878},"labels":[],"label_agreement":null},{"id":"W4379982010","doi":"10.1002/hon.3163_34","title":"PATTERNS OF PRESENTATION AND OUTCOMES IN STAGE IV HODGKIN LYMPHOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG) AHOD1331 TRIAL","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health; Children’s Oncology Group","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Vincristine; Etoposide; Oncology; B symptoms; Cyclophosphamide; Lymphoma; Vinblastine; Hazard ratio; ABVD; Chemotherapy; Surgery; Confidence interval","score_opus":0.05011501305050776,"score_gpt":0.36634257648300383,"score_spread":0.3162275634324961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379982010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99089515,0.00021768766,0.000018555198,0.0063832705,0.0002770666,0.0015930366,0.000060476978,0.0000724648,0.00048226165],"genre_scores_gemma":[0.99769807,0.00031207904,0.00029868644,0.0006385596,0.000090276546,0.00056149944,0.00025592337,0.000013214336,0.00013167803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99774635,0.0004074417,0.00080773205,0.00047175764,0.000239377,0.00032736387],"domain_scores_gemma":[0.99635434,0.0028045138,0.00035471105,0.00033759244,0.000037851798,0.00011097243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005006915,0.0002049579,0.0011223255,0.00010513649,0.000055320015,0.000009154053,0.00011512854,0.00037211954,0.00016973501],"category_scores_gemma":[0.0007086786,0.00011539851,0.00015488271,0.00019858115,0.00015481336,0.000041709296,0.00017572778,0.00012828984,0.000027813549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004254466,0.0025499533,0.9748144,0.000019009049,0.00022090646,0.0044494686,0.00035723025,0.0000010597114,0.00005589105,0.0010351666,0.0007547684,0.011487644],"study_design_scores_gemma":[0.053205572,0.0024696253,0.94001865,0.000029421077,0.00017410846,0.00058571884,0.00042038946,0.000036480593,0.00017446326,0.0004711563,0.002315575,0.000098856784],"about_ca_topic_score_codex":0.0019188933,"about_ca_topic_score_gemma":0.0009989722,"teacher_disagreement_score":0.048951104,"about_ca_system_score_codex":0.00022580933,"about_ca_system_score_gemma":0.00016714534,"threshold_uncertainty_score":0.47058144},"labels":[],"label_agreement":null},{"id":"W4380077901","doi":"10.1002/hon.3166_ot11","title":"A PHASE 1 STUDY EVALUATING PRT2527, A POTENT AND HIGHLY SELECTIVE CDK9 INHIBITOR, IN PATIENTS WITH SELECT RELAPSED/REFRACTORY B‐CELL MALIGNANCIES","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Gilead Sciences","keywords":"Lymphoma; Mantle cell lymphoma; Cancer research; Medicine; Aggressive lymphoma; Follicular lymphoma; B cell; Chronic lymphocytic leukemia; B-cell lymphoma; Internal medicine; Oncology; Rituximab; Immunology; Leukemia; Antibody","score_opus":0.042266537325065905,"score_gpt":0.36924586721374025,"score_spread":0.32697932988867434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380077901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957129,0.00015935097,0.000009645383,0.00029288503,0.00007161519,0.0025811526,0.0000047422236,0.00017278339,0.0009949631],"genre_scores_gemma":[0.9984281,0.000027442953,0.0005670477,0.00019607638,0.000045342753,0.00040945254,0.000030874442,0.00003578295,0.00025985794],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964683,0.00058470696,0.0005862308,0.0007734244,0.00076281367,0.0008245432],"domain_scores_gemma":[0.9978083,0.0010663181,0.00017713645,0.0002961073,0.00038883946,0.0002632924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001040219,0.00029816042,0.0009605106,0.00035008782,0.0001255155,0.00001843486,0.00012895775,0.0003191685,0.000042633135],"category_scores_gemma":[0.0012604366,0.00020139769,0.000051208386,0.0013521351,0.00026377532,0.00008591671,0.00024570854,0.0006719599,0.0000908241],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039003007,0.070655055,0.8145734,0.001267271,0.0006286891,0.019568335,0.0133746965,0.00011437826,0.0089581115,0.0003058232,0.0069571594,0.024594046],"study_design_scores_gemma":[0.43219036,0.283436,0.26213235,0.00049751456,0.0004265112,0.0009748749,0.004720191,0.009573971,0.0038799709,0.00037346722,0.00083026174,0.00096452323],"about_ca_topic_score_codex":0.000114532064,"about_ca_topic_score_gemma":0.00007759539,"teacher_disagreement_score":0.55244106,"about_ca_system_score_codex":0.005514096,"about_ca_system_score_gemma":0.0043606977,"threshold_uncertainty_score":0.99830353},"labels":[],"label_agreement":null},{"id":"W4380078158","doi":"10.1002/hon.3163_156","title":"MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (<i>R</i>/<i>R</i> CLL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Calgary","funders":"F. Hoffmann-La Roche; AstraZeneca","keywords":"Medicine; Bendamustine; Internal medicine; Hazard ratio; Rituximab; Regimen; Confidence interval; Gastroenterology; Chronic lymphocytic leukemia; Refractory (planetary science); Progression-free survival; Surgery; Leukemia; Overall survival; Lymphoma","score_opus":0.02797735490506649,"score_gpt":0.3028320781248924,"score_spread":0.2748547232198259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565154,0.00064369716,0.000014559644,0.00017444028,0.00010773859,0.0011554806,0.000022346247,0.00026237252,0.00196782],"genre_scores_gemma":[0.99694395,0.00059206143,0.000290219,0.00021959831,0.000057094418,0.00026408688,0.00034014945,0.000053116866,0.0012396956],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99598116,0.00032147425,0.0007534437,0.001060484,0.0007302299,0.0011532162],"domain_scores_gemma":[0.9976374,0.00084368757,0.00021276523,0.00069120724,0.00016750299,0.0004474323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045262376,0.00046674735,0.0017516734,0.0007521007,0.0001349923,0.000027913698,0.00023350885,0.00068304135,0.000383272],"category_scores_gemma":[0.0003486405,0.00033250437,0.00025160148,0.0026871,0.0005240365,0.000102544676,0.0002542187,0.0005848267,0.0004933639],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02877677,0.0024901915,0.8966483,0.001517633,0.005464876,0.034377623,0.0016074348,0.003615802,0.00065926794,0.001296152,0.008556133,0.014989832],"study_design_scores_gemma":[0.43691173,0.026243323,0.42413822,0.00078230863,0.004118952,0.0016180305,0.0005617465,0.08526765,0.0011006484,0.0004828328,0.01708753,0.0016870182],"about_ca_topic_score_codex":0.00092419126,"about_ca_topic_score_gemma":0.0007140556,"teacher_disagreement_score":0.47251007,"about_ca_system_score_codex":0.10039052,"about_ca_system_score_gemma":0.014617342,"threshold_uncertainty_score":0.9999127},"labels":[],"label_agreement":null},{"id":"W4380078597","doi":"10.1002/hon.3196_lba4","title":"TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Follicular lymphoma; Gastroenterology; Clinical endpoint; Oncology; Rituximab; Phases of clinical research; Neutropenia; Lymphoma; Surgery; Clinical trial; Chemotherapy","score_opus":0.026445015820580627,"score_gpt":0.32725908484804633,"score_spread":0.3008140690274657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966496,0.00014554925,0.000057371537,0.00027935053,0.000085995925,0.0011566648,0.000055828146,0.000042528318,0.0015271037],"genre_scores_gemma":[0.9984331,0.00012345154,0.00021297886,0.00010855544,0.000037000682,0.00017738492,0.00037404444,0.000029119312,0.00050438143],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970989,0.00050205993,0.0007201008,0.0007081418,0.0004153589,0.00055540464],"domain_scores_gemma":[0.9987861,0.00011007675,0.00021128428,0.00051972433,0.00019494332,0.00017785316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063633657,0.0002677882,0.0006075163,0.00022720777,0.00008170076,0.000011898113,0.00034997426,0.00047766484,0.00007322975],"category_scores_gemma":[0.00039761647,0.00020442849,0.00012798735,0.0006217282,0.00021933584,0.000009501106,0.0001551377,0.00021407162,0.00006313284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08198649,0.088839665,0.47718656,0.00054127653,0.00102159,0.0049094944,0.002732047,0.0006704924,0.22135322,0.0006394734,0.018891606,0.10122807],"study_design_scores_gemma":[0.18402478,0.092649065,0.44723365,0.00012781147,0.0001362658,0.00011654174,0.0022309322,0.0006037558,0.09380366,0.00019710655,0.17732583,0.001550612],"about_ca_topic_score_codex":0.000058080474,"about_ca_topic_score_gemma":0.00023583898,"teacher_disagreement_score":0.15843423,"about_ca_system_score_codex":0.00007022555,"about_ca_system_score_gemma":0.00018974622,"threshold_uncertainty_score":0.8336352},"labels":[],"label_agreement":null},{"id":"W4380078621","doi":"10.1002/hon.3165_666","title":"ASSOCIATION OF COVID‐19 PANDEMIC WITH INDOLENT LYMPHOMA CARE DELIVERY AND OUTCOMES IN ONTARIO, CANADA: A POPULATION‐BASED ANALYSIS","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pandemic; Hazard ratio; Regimen; Cohort; Population; Rituximab; Confidence interval; Retrospective cohort study; Internal medicine; Emergency medicine; Pediatrics; Coronavirus disease 2019 (COVID-19); Disease; Lymphoma; Infectious disease (medical specialty); Environmental health","score_opus":0.06870494288643084,"score_gpt":0.3726465455330916,"score_spread":0.3039416026466608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262273,0.00008073701,0.000020203885,0.006804732,0.000032316737,0.00030344236,0.00001588539,0.000043578464,0.000076354394],"genre_scores_gemma":[0.99585176,0.000021353566,0.00012432729,0.003708985,0.0000054384377,0.000027782458,0.00015015143,0.000005053759,0.00010514223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986524,0.00015479693,0.00039285698,0.00023574322,0.0002867899,0.0002774083],"domain_scores_gemma":[0.9980988,0.0011950593,0.00021683262,0.00012839853,0.000107936125,0.0002529864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029444898,0.000115985305,0.00089261704,0.00034183083,0.00004808211,0.000003043558,0.000042197484,0.00025251752,0.000105472216],"category_scores_gemma":[0.00085558667,0.00008201904,0.00006561813,0.0005539625,0.000028705266,0.000019607387,0.000030154388,0.00015550687,0.0000012236056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00031147702,0.00007981487,0.9972201,0.00015582981,0.00016285866,0.00032958243,0.0006325866,0.00020294677,0.0000047978265,0.00003523577,0.00015398052,0.00071080966],"study_design_scores_gemma":[0.0027666576,0.0004283943,0.994318,0.000022703283,0.00031552548,0.000025545543,0.00054029917,0.00018508614,0.000004476519,0.000029773828,0.0012836806,0.000079872225],"about_ca_topic_score_codex":0.94698244,"about_ca_topic_score_gemma":0.9989236,"teacher_disagreement_score":0.051941186,"about_ca_system_score_codex":0.006182097,"about_ca_system_score_gemma":0.005681499,"threshold_uncertainty_score":0.99995536},"labels":[],"label_agreement":null},{"id":"W4380078644","doi":"10.1002/hon.3163_5","title":"NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Princess Margaret Cancer Centre; Hospital for Sick Children; McGill University Health Centre","funders":"National Cancer Institute; Agenzia Italiana del Farmaco, Ministero della Salute; National Institutes of Health; Seagen; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Brentuximab vedotin; Neutropenia; Clinical endpoint; Oncology; Progression-free survival; Phases of clinical research; Randomized controlled trial; Chemotherapy; Lymphoma; Hodgkin lymphoma","score_opus":0.041521264897604895,"score_gpt":0.36706873840055537,"score_spread":0.3255474735029505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818264,0.00037895585,0.000010498467,0.006767494,0.000565527,0.0018099712,0.00012385454,0.00032354135,0.008193735],"genre_scores_gemma":[0.99510235,0.00018805603,0.0022352233,0.0005950976,0.00007596634,0.0006482776,0.00020493823,0.00004325894,0.00090684125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954899,0.00038494475,0.0014009165,0.0010428646,0.0006729266,0.0010084548],"domain_scores_gemma":[0.9964503,0.0014562006,0.00047131447,0.0009292169,0.00019907113,0.0004939109],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006656519,0.00048243586,0.0020430018,0.00040132838,0.00010869489,0.000019758852,0.0004535768,0.0005197356,0.00014867776],"category_scores_gemma":[0.0017803424,0.00035191898,0.0002796036,0.0011506194,0.00033296723,0.0000871521,0.0005809276,0.00023043166,0.0004464971],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0489295,0.041196365,0.3990979,0.0015344812,0.00092496816,0.0275306,0.003086466,0.00014611153,0.032321393,0.01893683,0.046745863,0.37954953],"study_design_scores_gemma":[0.08250049,0.014421772,0.8225558,0.00090424524,0.00020977079,0.0005242618,0.0020711324,0.00096981943,0.019541496,0.0014748155,0.053983912,0.00084247976],"about_ca_topic_score_codex":0.00026957647,"about_ca_topic_score_gemma":0.00058379915,"teacher_disagreement_score":0.42345792,"about_ca_system_score_codex":0.00068709056,"about_ca_system_score_gemma":0.000557246,"threshold_uncertainty_score":0.9998933},"labels":[],"label_agreement":null},{"id":"W4380078645","doi":"10.1002/hon.3164_355","title":"Rituximab combined with chemotherapy and acalabrutinib prior to autologous stem cell transplantation in mantle cell lymphoma: The Rectangle Trial","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; University Health Network; University of Toronto; Dalhousie University; Sunnybrook Health Science Centre; Hôpital de l'Enfant-Jésus; BC Cancer Agency; Centre hospitalier universitaire de Québec; McMaster University; Spinal Cord Injury BC","funders":"AstraZeneca","keywords":"Mantle cell lymphoma; Ibrutinib; Medicine; Rituximab; Internal medicine; Autologous stem-cell transplantation; Oncology; Transplantation; Diffuse large B-cell lymphoma; Surgery; Chemotherapy; Lymphoma; Leukemia; Chronic lymphocytic leukemia","score_opus":0.02952925078592086,"score_gpt":0.31925459144591384,"score_spread":0.289725340659993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98742956,0.00013833365,0.000068814705,0.0062549757,0.000107298925,0.0022315287,0.000005284443,0.00016144091,0.0036027639],"genre_scores_gemma":[0.99664193,0.0003185571,0.00064875494,0.0010240272,0.000051103696,0.00033805025,0.000018667566,0.000028754235,0.0009301586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978178,0.0002944479,0.0004366514,0.00050509954,0.00033284392,0.00061313924],"domain_scores_gemma":[0.9980018,0.0013550295,0.0000918183,0.00030085078,0.000052630843,0.00019783023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006670417,0.00021650307,0.00080241676,0.00016156919,0.00010606263,0.000018448698,0.00019363425,0.00037293177,0.00008387922],"category_scores_gemma":[0.0000564369,0.00012409374,0.00006198847,0.0007160342,0.0002571563,0.00003241085,0.00007203943,0.00027374932,0.000219953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7653899,0.013977794,0.0043497076,0.0026874612,0.00021943184,0.033815138,0.014390511,0.00006428974,0.009261759,0.002951464,0.014218411,0.13867414],"study_design_scores_gemma":[0.91742516,0.025412265,0.010400384,0.00016315505,0.0001541688,0.0045562913,0.0018993248,0.003588898,0.021688767,0.00035979683,0.013838701,0.00051308225],"about_ca_topic_score_codex":0.00007369843,"about_ca_topic_score_gemma":0.00010353176,"teacher_disagreement_score":0.15203527,"about_ca_system_score_codex":0.0017438686,"about_ca_system_score_gemma":0.0016379697,"threshold_uncertainty_score":0.50603956},"labels":[],"label_agreement":null},{"id":"W4380078977","doi":"10.1002/hon.3164_442","title":"First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada; BeiGene; Regeneron Pharmaceuticals","keywords":"Medicine; Lenalidomide; Internal medicine; Refractory (planetary science); Interim analysis; Diffuse large B-cell lymphoma; Oncology; Lymphoma; Gastroenterology; Clinical trial; Multiple myeloma","score_opus":0.038378589875354925,"score_gpt":0.35861039738261186,"score_spread":0.32023180750725694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99751866,0.00008380106,0.00003026107,0.00009602762,0.00007188619,0.0012560014,0.000040771625,0.00007617032,0.00082644494],"genre_scores_gemma":[0.9992849,0.000060020007,0.00011038025,0.00009832278,0.000015296588,0.00013555013,0.00011605989,0.000031339885,0.00014808764],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960942,0.00042511645,0.00127775,0.00067833834,0.00077525,0.000749335],"domain_scores_gemma":[0.9965767,0.0015914615,0.00051756453,0.0007770901,0.0002778347,0.0002593256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008096568,0.0003120841,0.0022309937,0.0011690882,0.000055898607,0.0000058280066,0.0003536483,0.00038532677,0.00034338766],"category_scores_gemma":[0.00086101517,0.00021504317,0.00026058275,0.0029242889,0.0003473901,0.0000696188,0.00040363308,0.00032118638,0.000054046774],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03080152,0.31751782,0.63322204,0.0008362054,0.0026641493,0.0048780716,0.0066508525,0.00007357283,0.0003367969,0.00024887754,0.0010772547,0.0016928613],"study_design_scores_gemma":[0.66048783,0.038014065,0.2828973,0.00024879377,0.0017631712,0.000059159614,0.004646663,0.009063674,0.0008062734,0.000040145347,0.0015491165,0.00042382194],"about_ca_topic_score_codex":0.0003468751,"about_ca_topic_score_gemma":0.0006450253,"teacher_disagreement_score":0.6296863,"about_ca_system_score_codex":0.0030262813,"about_ca_system_score_gemma":0.0014989062,"threshold_uncertainty_score":0.8769206},"labels":[],"label_agreement":null},{"id":"W4380078993","doi":"10.1002/hon.3163_80","title":"SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Calvary Mater Newcastle; National Institutes of Health; Masarykova Univerzita; Barts Health NHS Trust; BeiGene; Institut Bergonié; Tianjin Medical University; Peking University; Università degli Studi dell'Insubria; Jewish General Hospital; Harbin Medical University","keywords":"Medicine; Rituximab; Follicular lymphoma; Ibrutinib; Internal medicine; Hazard ratio; Ofatumumab; Randomized controlled trial; Clinical endpoint; Lymphoma; Placebo; Randomization; International Prognostic Index; Surgery; Oncology; Gastroenterology; Confidence interval; Leukemia; Chronic lymphocytic leukemia; Pathology","score_opus":0.0345031175598008,"score_gpt":0.35621661827911133,"score_spread":0.32171350071931054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380078993","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908166,0.00010728766,0.00016893377,0.00031921058,0.00006674043,0.007893152,0.00001553571,0.000086585635,0.00052594487],"genre_scores_gemma":[0.99522173,0.00017648395,0.0028967694,0.00012017528,0.000025543266,0.0012417401,0.00010335763,0.000040578525,0.00017364165],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99699295,0.00037038632,0.0009896007,0.0004844012,0.00055820757,0.00060447236],"domain_scores_gemma":[0.99528664,0.0033025532,0.0004508183,0.00041037778,0.00039572918,0.00015385979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087636226,0.00029322229,0.0031969887,0.00029858196,0.000037318285,0.0000044706244,0.00019479872,0.00039076104,0.000102830105],"category_scores_gemma":[0.0015719476,0.0001440535,0.00021706178,0.001008708,0.0007598033,0.000048260106,0.00006516047,0.0001439243,0.0000085152815],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98617876,0.003479441,0.0037878132,0.00025656977,0.0003538509,0.00030106746,0.00022759492,0.00002678841,0.00022365162,0.0003112816,0.000102973136,0.0047501847],"study_design_scores_gemma":[0.96982974,0.02197678,0.0006050596,0.00025104402,0.00013879818,0.00010355797,0.00016828359,0.0024461306,0.0036658968,0.00016418676,0.00047962554,0.00017090555],"about_ca_topic_score_codex":0.000113582275,"about_ca_topic_score_gemma":0.00006738181,"teacher_disagreement_score":0.018497339,"about_ca_system_score_codex":0.0013254683,"about_ca_system_score_gemma":0.003860492,"threshold_uncertainty_score":0.6848347},"labels":[],"label_agreement":null},{"id":"W4380079804","doi":"10.1002/hon.3164_441","title":"CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Queen's University; Spinal Cord Injury BC; University of British Columbia; McGill University; Jewish General Hospital","funders":"Loxo Oncology; AbbVie Canada; National Institutes of Health; Pharmacyclics; National Comprehensive Cancer Network; Breast Cancer Research Foundation; TG Therapeutics; Regeneron Pharmaceuticals; Genentech; Celgene; Gilead Sciences","keywords":"Medicine; Salvage therapy; Internal medicine; Gemcitabine; Rituximab; Oncology; Follicular lymphoma; Lymphoma; Refractory (planetary science); Gastroenterology; Cancer; Chemotherapy","score_opus":0.09117545114869888,"score_gpt":0.3840070893897315,"score_spread":0.29283163824103264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380079804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92626846,0.000011584171,0.00004502198,0.0011540822,0.000093550465,0.071965724,0.000024829238,0.000084279876,0.00035245062],"genre_scores_gemma":[0.8650145,0.000013311121,0.0005032845,0.0004937515,0.000030750543,0.13359943,0.0000952295,0.00002249814,0.00022722379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984535,0.00010725626,0.000487762,0.00034801793,0.00028696453,0.00031648116],"domain_scores_gemma":[0.997917,0.0010812299,0.00032160783,0.00033403802,0.0002518255,0.000094316805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025575666,0.00021757341,0.0006614926,0.00008531513,0.00011505682,0.000008738235,0.00013272774,0.00022685906,0.00011348049],"category_scores_gemma":[0.00018669464,0.00009403728,0.00012416122,0.00031198305,0.00019686575,0.000046263634,0.000046941157,0.00006928749,0.000023927816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11751214,0.16852736,0.55521065,0.0007056231,0.0014469026,0.00063826505,0.0017029364,0.000010933809,0.0011659103,0.009660741,0.01763749,0.12578103],"study_design_scores_gemma":[0.26074916,0.08724437,0.5593471,0.00015900802,0.00022230878,0.00012064463,0.00030525358,0.0004693683,0.0034491827,0.00029048132,0.08735108,0.00029204498],"about_ca_topic_score_codex":0.000009563202,"about_ca_topic_score_gemma":0.0000086877835,"teacher_disagreement_score":0.14323704,"about_ca_system_score_codex":0.0003134023,"about_ca_system_score_gemma":0.0003359419,"threshold_uncertainty_score":0.3834729},"labels":[],"label_agreement":null},{"id":"W4380079942","doi":"10.1002/hon.3164_200","title":"A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Oncology; Follicular lymphoma; Logistic regression; Cohort; Proportional hazards model; Lymphoma","score_opus":0.023737172665012036,"score_gpt":0.30324733167869805,"score_spread":0.27951015901368603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380079942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98994875,0.0014066808,0.00004734729,0.0055448404,0.00019280551,0.0024073855,0.000062241874,0.00024040327,0.00014955422],"genre_scores_gemma":[0.9943122,0.0010391012,0.0006569355,0.0019475793,0.00028548908,0.0012615067,0.000347494,0.000030348943,0.00011933436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637264,0.0005979705,0.00084940554,0.0010503888,0.00041086433,0.0007187416],"domain_scores_gemma":[0.99660856,0.0018388598,0.0002369099,0.00075168686,0.00009187395,0.00047212615],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005277057,0.00042582667,0.0017101825,0.00028230093,0.00016805866,0.000060124716,0.0002777274,0.000392209,0.00017135001],"category_scores_gemma":[0.0008920221,0.00025586123,0.00027708273,0.0015247412,0.0002066295,0.00009527382,0.0002153792,0.0001384822,0.00022050271],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14187936,0.015168119,0.57977,0.00029449174,0.008922584,0.07494272,0.0081829475,0.0028305438,0.0012333086,0.0075496924,0.010134013,0.14909218],"study_design_scores_gemma":[0.21311541,0.012785973,0.72989535,0.00037107372,0.005119764,0.0009682502,0.0011494176,0.014452139,0.0033345364,0.0016274496,0.016295686,0.00088495086],"about_ca_topic_score_codex":0.0025451458,"about_ca_topic_score_gemma":0.0014720666,"teacher_disagreement_score":0.15012532,"about_ca_system_score_codex":0.000895435,"about_ca_system_score_gemma":0.0004399209,"threshold_uncertainty_score":0.9999894},"labels":[],"label_agreement":null},{"id":"W4380080193","doi":"10.1002/hon.3163_108","title":"AVELUMAB MONOTHERAPY FOLLOWED BY A PET ADAPTED CHEMOTHERAPY APPROACH IN THE FIRST LINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA: INITIAL RESULTS FROM THE AVENUE WINDOW STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Avelumab; Internal medicine; Oncology; Clinical endpoint; Chemotherapy; Classical Hodgkin lymphoma; Lymphoma; Cancer; Hodgkin lymphoma; Nivolumab; Immunotherapy; Clinical trial","score_opus":0.06510614357631912,"score_gpt":0.34308420220909897,"score_spread":0.27797805863277986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380080193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97281134,0.0004195993,0.000013351157,0.023126926,0.00009274013,0.0022899255,0.00016402567,0.000077720426,0.001004382],"genre_scores_gemma":[0.9959887,0.00052960584,0.00019502215,0.0016152522,0.00015227117,0.0011030402,0.0003320965,0.000025023826,0.000058961155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726635,0.0005525432,0.0007691773,0.00059910724,0.0003846304,0.00042816924],"domain_scores_gemma":[0.9961402,0.0028513467,0.0002491044,0.0006244718,0.000044017084,0.00009086616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043829135,0.00034527454,0.0011804657,0.00007370938,0.00013697037,0.00001795298,0.0002857126,0.00025318225,0.000046469202],"category_scores_gemma":[0.00015061772,0.00016005259,0.00027109796,0.0005479365,0.00025205634,0.000023857656,0.000047453617,0.00013639903,0.00004410537],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047735665,0.21965577,0.49339572,0.000053096413,0.0032916996,0.016985016,0.046403706,0.000061311934,0.00050665607,0.0012242805,0.057670735,0.113016345],"study_design_scores_gemma":[0.13124463,0.023561822,0.78530586,0.00006415836,0.00042743856,0.0005454559,0.004533684,0.0011561181,0.0010284608,0.00036154894,0.051421404,0.00034943462],"about_ca_topic_score_codex":0.0005083522,"about_ca_topic_score_gemma":0.00042786504,"teacher_disagreement_score":0.2919101,"about_ca_system_score_codex":0.00037311163,"about_ca_system_score_gemma":0.00018280478,"threshold_uncertainty_score":0.6526755},"labels":[],"label_agreement":null},{"id":"W4380080865","doi":"10.1002/hon.3164_305","title":"Patient‐ versus clinician‐reported symptoms in the POLARIX study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Complementary and Alternative Medicine Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); University of Alberta","funders":"","keywords":"Medicine; Constipation; Nausea; Adverse effect; Vomiting; Placebo; Incidence (geometry); Common Terminology Criteria for Adverse Events; Diarrhea; MedDRA; Quality of life (healthcare); Internal medicine; Clinical trial; Physical therapy; Alternative medicine; Pharmacovigilance","score_opus":0.19067640523722945,"score_gpt":0.4670811599714729,"score_spread":0.2764047547342435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380080865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837379,0.00011521109,0.000003624797,0.0048041325,0.0007183868,0.0009525631,0.000002687739,0.000100667174,0.009564844],"genre_scores_gemma":[0.99829507,0.00003214444,0.000032203847,0.0012449363,0.00014584605,0.00014613908,0.000026333242,0.0000065732293,0.00007075257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809605,0.00036020053,0.00057793607,0.00031591533,0.00029982845,0.00035005654],"domain_scores_gemma":[0.99759656,0.0019096731,0.0001239762,0.00025758956,0.000049430488,0.00006275786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064081035,0.00014842715,0.00059569324,0.00012953793,0.00010772405,0.0000044348767,0.00013270536,0.000040289284,0.00030799836],"category_scores_gemma":[0.0010553589,0.00007954718,0.000088245564,0.0005987185,0.00017603982,0.000022205408,0.00017090328,0.0003896335,0.00016417794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009991942,0.0021867887,0.96009403,0.000014546819,0.0002522929,0.010150093,0.0035669738,9.4225777e-7,0.000021717604,0.0011825211,0.003213698,0.018317169],"study_design_scores_gemma":[0.008700592,0.019770497,0.8921122,0.000029247962,0.00017912079,0.00030625134,0.036374625,0.000047486345,0.0000136507,0.00043270012,0.041907728,0.00012589905],"about_ca_topic_score_codex":0.000057853904,"about_ca_topic_score_gemma":0.00020434616,"teacher_disagreement_score":0.06798186,"about_ca_system_score_codex":0.00006224492,"about_ca_system_score_gemma":0.00004964683,"threshold_uncertainty_score":0.3372366},"labels":[],"label_agreement":null},{"id":"W4380080925","doi":"10.1002/hon.3163_81","title":"ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Seoul National University; Seoul National University Hospital; Institut National de la Santé et de la Recherche Médicale; Regeneron Pharmaceuticals; Cleveland Clinic","keywords":"Medicine; Obinutuzumab; Internal medicine; Follicular lymphoma; Rituximab; Refractory (planetary science); Oncology; International Prognostic Index; Clinical endpoint; Progression-free survival; Neutropenia; Salvage therapy; Gastroenterology; Surgery; Chemotherapy; Lymphoma; Randomized controlled trial","score_opus":0.032784762104367975,"score_gpt":0.3275913327918503,"score_spread":0.29480657068748234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380080925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957247,0.00006775901,0.000004468891,0.000152598,0.00026646702,0.0018489971,0.000019466239,0.00014058196,0.001774958],"genre_scores_gemma":[0.9991407,0.000016895565,0.00006760727,0.00011810605,0.000022812319,0.00016773904,0.00016748205,0.00003517935,0.00026351106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99562573,0.00065045,0.0009490278,0.0007934068,0.0011349259,0.00084648345],"domain_scores_gemma":[0.99687696,0.001093564,0.00036094422,0.0011495197,0.00029499552,0.00022401316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007180771,0.0003508084,0.0018067997,0.0006719651,0.00012134982,0.000012601007,0.00055346504,0.0005073561,0.00031180392],"category_scores_gemma":[0.00093441195,0.00020212783,0.00035249448,0.0057235844,0.00049701624,0.00006829642,0.0005409962,0.00048133364,0.00010848563],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.08490586,0.014241026,0.8427515,0.00042578246,0.016171053,0.011327554,0.0058270018,0.010753824,0.00021364428,0.0023437093,0.007266481,0.0037725389],"study_design_scores_gemma":[0.21794192,0.013289036,0.74151504,0.00007953581,0.0029965942,0.00007114954,0.002251848,0.019059027,0.0001943959,0.000049663,0.0021203961,0.00043137113],"about_ca_topic_score_codex":0.0006570112,"about_ca_topic_score_gemma":0.00064581895,"teacher_disagreement_score":0.13303605,"about_ca_system_score_codex":0.038950004,"about_ca_system_score_gemma":0.011975501,"threshold_uncertainty_score":0.9936257},"labels":[],"label_agreement":null},{"id":"W4380082565","doi":"10.1002/hon.3164_306","title":"Subgroup analysis of elderly patients (pts) with diffuse large B‐cell lymphoma (DLBCL) in the Phase 3 POLARIX study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia","funders":"Genentech; F. Hoffmann-La Roche; American Society of Clinical Oncology","keywords":"Medicine; Vincristine; Internal medicine; Rituximab; Prednisone; Hazard ratio; CHOP; Diffuse large B-cell lymphoma; International Prognostic Index; Gastroenterology; Cyclophosphamide; Confidence interval; Lymphoma; Surgery; Oncology; Chemotherapy","score_opus":0.026968334041344685,"score_gpt":0.3401676760293203,"score_spread":0.3131993419879756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380082565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970633,0.00009616486,0.000008779576,0.0005616883,0.000039164202,0.0010363807,0.00003550637,0.00005391428,0.0011051494],"genre_scores_gemma":[0.9988978,0.00003779463,0.00006242956,0.00050463417,0.000011568381,0.0002648646,0.0001654811,0.000011151901,0.00004426305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978736,0.00035203827,0.0005266449,0.00041464114,0.0003959678,0.00043708322],"domain_scores_gemma":[0.9983632,0.0007917997,0.00019774286,0.00044538142,0.00008654153,0.000115365765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004181903,0.0002174065,0.00111857,0.0003857453,0.00007441183,0.000010251908,0.00018485473,0.00018118085,0.000096839234],"category_scores_gemma":[0.000115725496,0.00010756823,0.00020381734,0.0019740805,0.00010169798,0.000034500543,0.00008129722,0.00010500551,0.000061086284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006704429,0.15783663,0.8332287,0.000024737206,0.00062195136,0.0024090188,0.0014569127,0.000001117415,0.000012699522,0.0004202474,0.00033923195,0.0029783219],"study_design_scores_gemma":[0.07192912,0.014707785,0.9069766,0.000014169801,0.0019904182,0.000033320073,0.002524414,0.00018069144,0.00007994521,0.000029726378,0.0014164743,0.00011736982],"about_ca_topic_score_codex":0.00017572292,"about_ca_topic_score_gemma":0.00061241916,"teacher_disagreement_score":0.14312884,"about_ca_system_score_codex":0.00017448245,"about_ca_system_score_gemma":0.00009060473,"threshold_uncertainty_score":0.4386505},"labels":[],"label_agreement":null},{"id":"W4380082876","doi":"10.1002/hon.3164_308","title":"Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Internal medicine; Hazard ratio; Rituximab; Progression-free survival; Lymphoma; Proportional hazards model; Log-rank test; Oncology; Gastroenterology; Overall survival; Confidence interval","score_opus":0.015922070545087295,"score_gpt":0.2785733071257824,"score_spread":0.26265123658069506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380082876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914332,0.00011806627,0.0000046201317,0.00077180803,0.00042428175,0.00063438684,0.000045856123,0.00021148444,0.00635628],"genre_scores_gemma":[0.99832505,0.00024709903,0.00039953852,0.0003352755,0.00005272025,0.00023006056,0.00020364964,0.000027034372,0.00017957803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978525,0.00016613162,0.00041076922,0.00054007786,0.00030612445,0.00072441756],"domain_scores_gemma":[0.99848366,0.0006661861,0.00016396958,0.00035153033,0.00007342138,0.00026124733],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017088855,0.0002847962,0.0008339458,0.00018835833,0.000104385705,0.000012743114,0.00012320429,0.0003633546,0.0001902096],"category_scores_gemma":[0.00021706503,0.00017910491,0.000115293624,0.0005392219,0.00011212367,0.000054374115,0.00013757485,0.00016113855,0.00087625656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020692893,0.016240515,0.9727021,0.00003624553,0.0000897925,0.0024068942,0.00016047308,0.0000012018291,0.000006822565,0.001819845,0.0018259236,0.0026409226],"study_design_scores_gemma":[0.087191366,0.0039843423,0.9027502,0.000038703398,0.0001548922,0.00005838151,0.00016186925,0.000047039877,0.00021784831,0.00013179237,0.005081812,0.00018175246],"about_ca_topic_score_codex":0.0002767067,"about_ca_topic_score_gemma":0.000515676,"teacher_disagreement_score":0.08512207,"about_ca_system_score_codex":0.0005666579,"about_ca_system_score_gemma":0.0001475567,"threshold_uncertainty_score":0.99990165},"labels":[],"label_agreement":null},{"id":"W4380083458","doi":"10.1002/hon.3164_446","title":"Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Tolerability; Obinutuzumab; Internal medicine; Rituximab; CHOP; Refractory (planetary science); Gastroenterology; Lymphoma; CD20; Oncology; Dosing; Phases of clinical research; Immunology; Adverse effect; Chemotherapy; Biology","score_opus":0.036268815423270026,"score_gpt":0.3635415401709561,"score_spread":0.32727272474768604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380083458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856672,0.0003692139,0.000069752256,0.0015195744,0.00009187419,0.0024920607,0.000010318221,0.00021002036,0.009569975],"genre_scores_gemma":[0.9955402,0.0007317093,0.00083642616,0.00031568363,0.00004052937,0.00022440613,0.00005439509,0.00006452201,0.002192141],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99609613,0.0005173232,0.0010315983,0.0007885232,0.0005850125,0.0009813989],"domain_scores_gemma":[0.9973021,0.0012034555,0.00028181152,0.0007945923,0.00016584783,0.00025216152],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014045867,0.00040958132,0.0018237423,0.00052282296,0.00012022984,0.00001910124,0.00041657663,0.00046362483,0.0026224658],"category_scores_gemma":[0.00023034052,0.00029569195,0.00018624203,0.0018004784,0.0005471582,0.00008167589,0.00017903934,0.000603116,0.00027566738],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20094791,0.07920053,0.11537315,0.0012158838,0.003092713,0.0526033,0.0065620025,0.0005945668,0.27744085,0.0021874066,0.0055738837,0.2552078],"study_design_scores_gemma":[0.44749,0.09664349,0.31309813,0.00096877804,0.0006353893,0.005440102,0.018612763,0.009201545,0.050215185,0.0011564605,0.054431297,0.0021068645],"about_ca_topic_score_codex":0.00021970744,"about_ca_topic_score_gemma":0.00014462713,"teacher_disagreement_score":0.25310096,"about_ca_system_score_codex":0.00060249766,"about_ca_system_score_gemma":0.0006969441,"threshold_uncertainty_score":0.9999495},"labels":[],"label_agreement":null},{"id":"W4380083530","doi":"10.1002/hon.3164_386","title":"Matching‐adjusted indirect comparison of axicabtagene ciloleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma patients after 2 prior systemic treatments","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Raincoast Conservation Foundation","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Oncology; Hazard ratio; Proportional hazards model; Fludarabine; Clinical trial; Alemtuzumab; Progression-free survival; Refractory (planetary science); Lymphoma; Overall survival; Confidence interval; Chemotherapy; Transplantation; Cyclophosphamide","score_opus":0.06551910042501254,"score_gpt":0.36349055388389534,"score_spread":0.2979714534588828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380083530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994479,0.0007909577,0.000004409184,0.00012804716,0.00040950024,0.0013330373,0.000017572265,0.00016742553,0.0026700683],"genre_scores_gemma":[0.99803555,0.00018750012,0.00017401247,0.00007679179,0.000040016857,0.00038209735,0.00012468906,0.000045451066,0.0009338662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99646544,0.00054363586,0.0010153084,0.0006087089,0.0006471232,0.00071979436],"domain_scores_gemma":[0.9979138,0.00090351823,0.00029704344,0.0005082406,0.00012747363,0.00024995703],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043189898,0.0003304534,0.0017322835,0.00047220502,0.000058951508,0.000008393596,0.00023315736,0.0006955277,0.0008197071],"category_scores_gemma":[0.00024927728,0.00025635434,0.00026235593,0.0008962548,0.00020190125,0.000041962445,0.00020520967,0.0003810516,0.00034194256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03599409,0.01139015,0.8190998,0.0009845968,0.0010398362,0.0053734477,0.0039759506,0.00008483797,0.023695061,0.0001485331,0.0010149035,0.09719879],"study_design_scores_gemma":[0.05762387,0.013693535,0.9080445,0.0005781177,0.00038963888,0.0002253705,0.0017457806,0.0008763457,0.010837922,0.0001747905,0.005235307,0.0005747849],"about_ca_topic_score_codex":0.00010117383,"about_ca_topic_score_gemma":0.00008176491,"teacher_disagreement_score":0.09662401,"about_ca_system_score_codex":0.0012377676,"about_ca_system_score_gemma":0.0002913353,"threshold_uncertainty_score":0.99998885},"labels":[],"label_agreement":null},{"id":"W4380083674","doi":"10.1002/hon.3164_204","title":"Impact of the Dark Zone Signature on Central Nervous System Relapse in a Real‐World Diffuse Large B‐cell Lymphoma Population","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Genome British Columbia; Genome Canada; Leukemia and Lymphoma Society","keywords":"Diffuse large B-cell lymphoma; Population; Lymphoma; Medicine; Internal medicine; Cumulative incidence; Oncology; Incidence (geometry); Rituximab; Pathology; Cohort","score_opus":0.021357897191109206,"score_gpt":0.31652756029610046,"score_spread":0.29516966310499126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380083674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99430054,0.0001386229,0.0000017587881,0.00075233827,0.00023913353,0.0007671882,0.000036640846,0.00013228392,0.00363151],"genre_scores_gemma":[0.9991886,0.00008022358,0.000044715453,0.00016439089,0.000048166683,0.00009752233,0.00009053724,0.000020654266,0.00026521366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980484,0.0002734035,0.0005226214,0.00035905847,0.0002605074,0.0005359874],"domain_scores_gemma":[0.9986471,0.0005145017,0.00023382498,0.0004115886,0.000037994843,0.00015500202],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020591384,0.00022822327,0.00084246154,0.00019654087,0.000072209514,0.0000061976534,0.00012791366,0.00035865998,0.000042522366],"category_scores_gemma":[0.0001242635,0.000121209516,0.0003518901,0.00081810565,0.00005926534,0.000023504468,0.0000990211,0.00018962433,0.00005749219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009877824,0.010935169,0.968701,0.0001797111,0.000087526794,0.0025921937,0.00023355627,0.00008146352,0.0003243873,0.008059212,0.004093712,0.0037242584],"study_design_scores_gemma":[0.009700335,0.0012034128,0.9871682,0.00023216811,0.000090093636,0.00021029533,0.00012062161,0.0004996423,0.00024076001,0.00009770941,0.0003312986,0.00010549339],"about_ca_topic_score_codex":0.00074972725,"about_ca_topic_score_gemma":0.0006159391,"teacher_disagreement_score":0.018467143,"about_ca_system_score_codex":0.0013833115,"about_ca_system_score_gemma":0.0001501101,"threshold_uncertainty_score":0.49427804},"labels":[],"label_agreement":null},{"id":"W4380084290","doi":"10.1002/hon.3163_60","title":"DISTINCT HODGKIN LYMPHOMA SUBTYPES IDENTIFIED BY NONINVASIVE GENOMIC PROFILING","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Genotyping; Copy number analysis; Genotype; Lymphoma; Oncology; Medicine; Biology; Genetics; Cancer research; Internal medicine; Copy-number variation; Gene; Genome","score_opus":0.019602277630382033,"score_gpt":0.2876460069356689,"score_spread":0.26804372930528686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939911,0.0009155137,0.0004590182,0.0005134096,0.0004672126,0.00028138194,0.00009254131,0.00007557261,0.0032042775],"genre_scores_gemma":[0.9963079,0.00065449096,0.0005946726,0.000632993,0.00022731803,0.00011962317,0.0006879687,0.00003057573,0.0007444608],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99841124,0.00009300507,0.00034552737,0.00056295213,0.00010414807,0.00048312248],"domain_scores_gemma":[0.9991224,0.00020541273,0.00014034487,0.0003154047,0.00006978495,0.00014669263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002444461,0.00020776727,0.0003632959,0.000051395684,0.00013242417,0.00003108232,0.00029255348,0.00038999936,0.000066594315],"category_scores_gemma":[0.00047870318,0.00018644414,0.00013243448,0.00017151707,0.00018623694,0.0000025215854,0.00034755428,0.000090480156,0.00039225077],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004136546,0.00041249732,0.03198887,0.000071927956,0.00015885537,0.0005740175,0.00007283794,0.000055540622,0.823711,0.00443774,0.13020936,0.007893721],"study_design_scores_gemma":[0.003192832,0.0019008308,0.024833258,0.000021088392,0.00009629989,0.0006230665,0.00034791237,0.0003354891,0.46075615,0.0032679376,0.5036509,0.0009742043],"about_ca_topic_score_codex":0.000020162128,"about_ca_topic_score_gemma":0.00006536177,"teacher_disagreement_score":0.37344155,"about_ca_system_score_codex":0.00007232632,"about_ca_system_score_gemma":0.00020706072,"threshold_uncertainty_score":0.7602971},"labels":[],"label_agreement":null},{"id":"W4380084535","doi":"10.1002/hon.3163_109","title":"FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Refractory (planetary science); Medicine; Internal medicine; Oncology; Clinical trial; Gastroenterology; Immunotherapy; Cancer","score_opus":0.04668407612535397,"score_gpt":0.349987444580797,"score_spread":0.30330336845544303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98474383,0.0007526767,0.00034571678,0.006298843,0.00044155237,0.0008263071,0.000010670107,0.00019900173,0.0063814213],"genre_scores_gemma":[0.99681866,0.00021536475,0.0016284973,0.0008040383,0.00011984327,0.000098657096,0.00003459325,0.00003258492,0.00024778605],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996842,0.0004736309,0.0010474657,0.0005488593,0.00041373554,0.00067425845],"domain_scores_gemma":[0.9959811,0.0029213745,0.00040314946,0.00046903078,0.000099800505,0.00012554866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008677872,0.00031857475,0.0012753012,0.00026096872,0.00014448285,0.000012856769,0.00031192217,0.0005996311,0.0002535199],"category_scores_gemma":[0.00124288,0.00019747461,0.00037384746,0.0010838133,0.0009153944,0.00008665017,0.00020514271,0.0005713583,0.0001520015],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10450408,0.01547001,0.07448643,0.0018753161,0.0026948736,0.015111705,0.01736836,0.00095519447,0.07371121,0.044096842,0.027684525,0.62204146],"study_design_scores_gemma":[0.055824913,0.0064758104,0.8685041,0.0007610132,0.00031977825,0.0031561453,0.0016708839,0.024364475,0.0028856292,0.0028626497,0.032393664,0.0007809465],"about_ca_topic_score_codex":0.000070505695,"about_ca_topic_score_gemma":0.000029933452,"teacher_disagreement_score":0.7940177,"about_ca_system_score_codex":0.00059366674,"about_ca_system_score_gemma":0.00058666634,"threshold_uncertainty_score":0.8052781},"labels":[],"label_agreement":null},{"id":"W4380084899","doi":"10.1002/hon.3164_420","title":"Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Gilead Sciences; Eisai; Sanofi; Servier; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Adverse effect; Rituximab; Follicular lymphoma; Clinical endpoint; Phases of clinical research; Lymphoma; Refractory (planetary science); Gastroenterology; Surgery; Oncology; Chemotherapy; Clinical trial","score_opus":0.039572228225482425,"score_gpt":0.31659483745637307,"score_spread":0.2770226092308906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974395,0.00010395713,0.0000024030217,0.00076637615,0.00006022693,0.0005819802,0.000031941272,0.00003417601,0.000979414],"genre_scores_gemma":[0.99873066,0.00036288737,0.00051777705,0.00011933591,0.000010398968,0.000030784377,0.00007516728,0.000011598183,0.0001413648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855065,0.00011265198,0.00059300516,0.00030456853,0.00020666755,0.00023244078],"domain_scores_gemma":[0.99844813,0.0009111238,0.00024344733,0.0002225908,0.00008098648,0.00009370605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002277639,0.0001514468,0.0008885954,0.0001307852,0.00002397733,0.0000019106467,0.00006603517,0.00023252383,0.00007656794],"category_scores_gemma":[0.0003581723,0.00008584401,0.00006048588,0.00032860367,0.00021864595,0.000028502533,0.00005083752,0.000118158816,0.0000140432885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09973941,0.0049666506,0.8743674,0.00012763898,0.00017870273,0.00053580425,0.00059806637,0.000007357823,0.00008375962,0.00070098933,0.0020797402,0.016614439],"study_design_scores_gemma":[0.07337371,0.014335924,0.90665305,0.00016876408,0.000054597855,0.000022337037,0.00008869358,0.000013872473,0.0005529391,0.000029917883,0.004619287,0.00008687597],"about_ca_topic_score_codex":0.00004635374,"about_ca_topic_score_gemma":0.00005641372,"teacher_disagreement_score":0.032285634,"about_ca_system_score_codex":0.00014035292,"about_ca_system_score_gemma":0.00019209231,"threshold_uncertainty_score":0.3500617},"labels":[],"label_agreement":null},{"id":"W4380084938","doi":"10.1002/hon.3163_95","title":"GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (<i>R</i>/<i>R</i>) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Kite Pharma; F. Hoffmann-La Roche; Genentech; Celgene; Gilead Sciences; Pharmacyclics; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Refractory (planetary science); Medicine; Lymphoma; Oncology; Internal medicine; Physics","score_opus":0.046888727290113154,"score_gpt":0.37710057351762066,"score_spread":0.3302118462275075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541235,0.00047064314,0.000024569534,0.00035554174,0.00015371227,0.0017722467,0.00005874844,0.00021222893,0.0015399548],"genre_scores_gemma":[0.9967512,0.00019842913,0.00026946692,0.00056966813,0.00006749115,0.00024590315,0.00018480557,0.00005964803,0.0016533848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99626607,0.0005772116,0.00067179,0.00094849337,0.0006576342,0.00087878434],"domain_scores_gemma":[0.9978475,0.00087795674,0.00019165828,0.0005730202,0.00014006387,0.00036981708],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058888586,0.00042317226,0.0014693358,0.00042042122,0.00019175929,0.000027090528,0.00022984178,0.00042373917,0.0013054968],"category_scores_gemma":[0.0001905736,0.0002909395,0.00015516148,0.0009615636,0.00022947963,0.00010871362,0.00026529477,0.0004959323,0.000087593835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055717014,0.06990155,0.81133133,0.00007525838,0.0007295393,0.0058290535,0.003766075,0.0000015442115,0.011061094,0.000049870676,0.0027313347,0.038806316],"study_design_scores_gemma":[0.3111354,0.061396927,0.60506254,0.00008202655,0.0002806676,0.000080377074,0.0028831249,0.00035628222,0.0011977023,0.00032276666,0.016552433,0.0006497646],"about_ca_topic_score_codex":0.00017365608,"about_ca_topic_score_gemma":0.0003299672,"teacher_disagreement_score":0.2554184,"about_ca_system_score_codex":0.00027802447,"about_ca_system_score_gemma":0.00023242233,"threshold_uncertainty_score":0.9999543},"labels":[],"label_agreement":null},{"id":"W4380084965","doi":"10.1002/hon.3163_62","title":"THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOW","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; B symptoms; Hodgkin lymphoma; Lymphoma; Stage (stratigraphy); Proportional hazards model; Quartile; Classical Hodgkin lymphoma; Oncology; Gastroenterology; Pathology; Confidence interval","score_opus":0.07101162091048586,"score_gpt":0.44677877395406196,"score_spread":0.3757671530435761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969453,0.0002600253,0.000021774134,0.0006420961,0.00033211816,0.0015675147,0.000115401715,0.000068714864,0.000047047382],"genre_scores_gemma":[0.99882877,0.00034142242,0.00012364317,0.00006282321,0.00006615844,0.00036986455,0.00016363397,0.000016988637,0.000026680536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99783975,0.00030398267,0.00078429625,0.0004484389,0.00023298088,0.0003905547],"domain_scores_gemma":[0.9956905,0.0034195248,0.0002630377,0.00031011438,0.000114871626,0.0002019413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006803934,0.0002429198,0.0009096083,0.000065506734,0.0001457413,0.000025135103,0.0002166787,0.00021017577,0.000043776126],"category_scores_gemma":[0.0011085469,0.00011327918,0.0003467313,0.00011623383,0.0002851371,0.000043260567,0.00015959439,0.00008178649,0.000009171701],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014689574,0.0037592815,0.94451493,0.00001829284,0.0005863526,0.00022494426,0.0002641162,0.0000015235343,0.00008101941,0.0001046056,0.00042130903,0.04855469],"study_design_scores_gemma":[0.011317444,0.013276009,0.9720345,0.000024643256,0.00020363182,0.00028264476,0.0007170273,0.00071571494,0.00022902516,0.0001025525,0.000982033,0.0001147713],"about_ca_topic_score_codex":0.00022417714,"about_ca_topic_score_gemma":0.000047204314,"teacher_disagreement_score":0.048439916,"about_ca_system_score_codex":0.00024178122,"about_ca_system_score_gemma":0.0002463044,"threshold_uncertainty_score":0.4619391},"labels":[],"label_agreement":null},{"id":"W4380085040","doi":"10.1002/hon.3163_91","title":"COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Tolerability; Lymphoma; Follicular lymphoma; Gastroenterology; Dosing; Oncology; Adverse effect","score_opus":0.03924295893968783,"score_gpt":0.3232265847332438,"score_spread":0.28398362579355596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380085040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923167,0.0001430375,0.000006778797,0.0016364926,0.0001216047,0.00060660904,0.00003804546,0.00010311556,0.0050276117],"genre_scores_gemma":[0.9954564,0.00020761312,0.0011327661,0.0010074977,0.000064619366,0.000058100628,0.00010694268,0.000034696888,0.0019313807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973073,0.00020760628,0.00056830124,0.0006756646,0.00048050124,0.0007606227],"domain_scores_gemma":[0.9974527,0.0016512785,0.00014131842,0.00029214338,0.00009696538,0.0003656333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029459855,0.00032155227,0.001076712,0.00022780267,0.00013741192,0.000024893658,0.00020069291,0.0004559632,0.0006576444],"category_scores_gemma":[0.00025598312,0.00020284312,0.00009072989,0.0004986053,0.00033612893,0.000077834455,0.00031967886,0.000539047,0.00036594123],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012768807,0.0022742322,0.9581694,0.00019518015,0.000107683234,0.004860005,0.0014149318,0.0000019893675,0.0020948264,0.00014239752,0.0023044846,0.015666053],"study_design_scores_gemma":[0.013412726,0.0077072554,0.96752584,0.00021499273,0.00004474695,0.00011352517,0.00024107184,0.00033306985,0.0011972801,0.00009894173,0.008819847,0.00029071173],"about_ca_topic_score_codex":0.00032668817,"about_ca_topic_score_gemma":0.00008217554,"teacher_disagreement_score":0.015375342,"about_ca_system_score_codex":0.00016127776,"about_ca_system_score_gemma":0.00019806092,"threshold_uncertainty_score":0.82717025},"labels":[],"label_agreement":null},{"id":"W4380186961","doi":"10.1002/hon.3164_352","title":"Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Venetoclax; Ibrutinib; Obinutuzumab; Medicine; Internal medicine; Mantle cell lymphoma; Bendamustine; Adverse effect; Regimen; Oncology; Gastroenterology; Lymphoma; Rituximab; Leukemia; Chronic lymphocytic leukemia","score_opus":0.03096810663968442,"score_gpt":0.3221062621097234,"score_spread":0.29113815547003896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380186961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581957,0.00014543436,0.00002997354,0.0009846842,0.000106217114,0.0006981987,0.0000038908615,0.00008715628,0.0021248797],"genre_scores_gemma":[0.9989762,0.00006420102,0.00007479568,0.00017145966,0.000023091585,0.000049536688,0.00006783462,0.00001726523,0.0005556244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984722,0.0001582946,0.00030272914,0.00030419472,0.00036271248,0.0003998481],"domain_scores_gemma":[0.9983717,0.0009243759,0.00013838978,0.00027144133,0.00017024369,0.00012379966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003160467,0.00015045457,0.0005228367,0.00010659004,0.00011584258,0.000010940627,0.00012674069,0.00024869162,0.0001267561],"category_scores_gemma":[0.0003337488,0.00008157663,0.000058183163,0.00046088075,0.0005503827,0.000042185777,0.00016716958,0.0002537094,0.00006615222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0103311315,0.0013074455,0.886766,0.0017312419,0.0009020452,0.0032578465,0.003321864,0.00008916662,0.0017689193,0.016377317,0.018843176,0.055303853],"study_design_scores_gemma":[0.11865092,0.012834001,0.8455574,0.0007134331,0.00047993893,0.0017530776,0.00066879933,0.009550742,0.003776375,0.0011309406,0.00438412,0.0005002351],"about_ca_topic_score_codex":0.00006232517,"about_ca_topic_score_gemma":0.000035880144,"teacher_disagreement_score":0.10831979,"about_ca_system_score_codex":0.004045064,"about_ca_system_score_gemma":0.0020719648,"threshold_uncertainty_score":0.9997782},"labels":[],"label_agreement":null},{"id":"W4380423065","doi":"10.1002/hon.3191","title":"Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T‐cell lymphoma","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Lymphoma; Medicine; Peripheral T-cell lymphoma; Disease; Oncology; Epidemiology; Internal medicine; Omics; Bioinformatics; Pathology; Biology; Immunology; T cell; Immune system","score_opus":0.06318122779493782,"score_gpt":0.376297969735976,"score_spread":0.3131167419410382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380423065","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04131665,0.91829354,9.679515e-7,0.002555284,0.0024858613,0.003137845,0.000065322594,0.00030982867,0.031834718],"genre_scores_gemma":[0.0029814872,0.9889127,0.0006653114,0.0009348102,0.0027532796,0.0018624199,0.00025262396,0.00016352968,0.0014738516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9888161,0.0018647525,0.003917441,0.0017818878,0.0007080586,0.0029117765],"domain_scores_gemma":[0.99337965,0.0031633899,0.0013634864,0.0007218395,0.00015433122,0.001217318],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0017845989,0.0015841973,0.011941142,0.0011673674,0.00020807909,0.00010499459,0.0008757255,0.004322655,0.0051146094],"category_scores_gemma":[0.0010450964,0.0010654582,0.0013764075,0.0016174637,0.00071738724,0.00013815465,0.0006979869,0.001330077,0.0034083584],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096762105,0.01988289,0.0074987276,0.006286723,0.0005300286,0.17898422,0.0007082804,0.0000018601075,6.964718e-7,0.0009886833,0.023837492,0.7603128],"study_design_scores_gemma":[0.014769572,0.0042465692,0.0023548126,0.0035991445,0.0005490399,0.043972522,0.00058936875,0.000014152969,0.0000039463102,0.0006912686,0.9283174,0.00089218613],"about_ca_topic_score_codex":0.00007473127,"about_ca_topic_score_gemma":0.00023337881,"teacher_disagreement_score":0.9044799,"about_ca_system_score_codex":0.013956159,"about_ca_system_score_gemma":0.004629009,"threshold_uncertainty_score":0.9996906},"labels":[],"label_agreement":null},{"id":"W4382501478","doi":"10.1002/hon.3197","title":"Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Medicine; Primary central nervous system lymphoma; Lymphoma; Central nervous system; Intensive care medicine; Population; Oncology; Immunology; Internal medicine; Environmental health","score_opus":0.09116949360590577,"score_gpt":0.3914465801124898,"score_spread":0.300277086506584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382501478","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014427886,0.97832537,0.000027173224,0.00012164225,0.0005887368,0.004276582,0.00014937554,0.0003455843,0.0017376303],"genre_scores_gemma":[0.047852825,0.9493379,0.0007467631,0.000015385069,0.00016957703,0.001213514,0.00033598262,0.00008317811,0.00024485786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99539524,0.000685737,0.0016977757,0.0010424716,0.0003041407,0.00087463064],"domain_scores_gemma":[0.9969752,0.0008382355,0.0009744505,0.00054060796,0.00007384042,0.000597681],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002893463,0.0008298285,0.0059130336,0.00024877905,0.00014013654,0.00003142574,0.00012781804,0.0011209635,0.000029639019],"category_scores_gemma":[0.00004766528,0.00051930296,0.00081349496,0.00030192558,0.00025143236,0.000039128507,0.00020642586,0.00023228985,0.000027221724],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013235527,0.0016339881,0.0021698002,0.049976166,0.0017674591,0.0058967755,0.0000905238,8.362096e-7,7.3089643e-7,0.020606214,0.00027402956,0.91745114],"study_design_scores_gemma":[0.017687313,0.022143554,0.059474573,0.09586953,0.035512857,0.08555869,0.0023163522,0.00036940092,0.000016323676,0.00014885384,0.6790331,0.001869437],"about_ca_topic_score_codex":0.00014615786,"about_ca_topic_score_gemma":0.000037916172,"teacher_disagreement_score":0.9155817,"about_ca_system_score_codex":0.004530273,"about_ca_system_score_gemma":0.0010746577,"threshold_uncertainty_score":0.9997259},"labels":[],"label_agreement":null},{"id":"W4383998685","doi":"10.1002/hon.3202","title":"Diffuse large B‐cell lymphoma","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; Vincristine; Lymphoma; CHOP; Prednisone; Oncology; Clinical trial; Internal medicine; Intensive care medicine; Cyclophosphamide; Chemotherapy","score_opus":0.1736930225114751,"score_gpt":0.45716910312321773,"score_spread":0.2834760806117427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383998685","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000784785,0.95279425,0.00001462678,0.00027146717,0.00043114458,0.0020066604,0.000045676545,0.00049962744,0.04385804],"genre_scores_gemma":[0.000009796842,0.95193124,0.00021086985,0.00045868923,0.00041144248,0.00064445735,0.00025499964,0.00015776137,0.045920726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953087,0.0007435638,0.001168261,0.0009862733,0.00054579007,0.0012474171],"domain_scores_gemma":[0.9956437,0.002390917,0.00036226405,0.0009348054,0.00010743682,0.0005609021],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00085072726,0.0006533656,0.0057969415,0.00042366027,0.00011142888,0.000024008901,0.00052792486,0.0022863047,0.0075386898],"category_scores_gemma":[0.00061449734,0.00042372648,0.0013659635,0.00088971533,0.0002849295,0.000022821529,0.00059817976,0.0011143356,0.011692661],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013170153,0.006609725,0.000011590626,0.028278472,0.0003464491,0.011469239,0.0000339808,4.117998e-9,0.0000061769665,0.0016874268,0.019999783,0.93142545],"study_design_scores_gemma":[0.005182715,0.0010109093,0.00000430967,0.0025195617,0.0007302252,0.0040593543,0.000028263345,0.0000049075206,0.0000048947004,0.00016755046,0.98592454,0.00036276216],"about_ca_topic_score_codex":0.000007356631,"about_ca_topic_score_gemma":0.000010187078,"teacher_disagreement_score":0.96592474,"about_ca_system_score_codex":0.00079923635,"about_ca_system_score_gemma":0.0012654415,"threshold_uncertainty_score":0.9998215},"labels":[],"label_agreement":null},{"id":"W4385144282","doi":"10.1002/hon.3205","title":"Personalised therapy in follicular lymphoma – is the dial turning?","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Genentech; Terry Fox Foundation; ViewRay; Cancer Research UK; Incyte; Eisai; BeiGene; National Cancer Research Institute; AstraZeneca; Celgene; Blood Cancer UK; Gilead Sciences","keywords":"Follicular lymphoma; Medicine; Dial; Oncology; Lymphoma; Internal medicine; Engineering","score_opus":0.13647644419123028,"score_gpt":0.40956122111084264,"score_spread":0.27308477691961236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385144282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033237182,0.989339,4.7530085e-7,0.0027311603,0.00029994137,0.0021240227,0.000026571613,0.00012273328,0.0020324106],"genre_scores_gemma":[0.0006259709,0.9943112,0.00006543013,0.0021694968,0.00023424848,0.0019759485,0.00010407898,0.000056830384,0.00045678302],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969336,0.0005721845,0.0008626753,0.00071164174,0.00033395446,0.00058593496],"domain_scores_gemma":[0.996648,0.002268492,0.000347917,0.00051315356,0.000046239216,0.00017618579],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043470878,0.0005641525,0.003752075,0.00017377941,0.000102631246,0.000024086128,0.00030874604,0.00112176,0.000526352],"category_scores_gemma":[0.0002819244,0.0002551893,0.0012671725,0.0005777761,0.00023175665,0.000018552237,0.00013805156,0.00035294087,0.0009988692],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010817175,0.0015574876,0.00078522245,0.0019219614,0.00073627324,0.010193919,0.00024222166,4.1072187e-8,1.707068e-7,0.001501353,0.006903268,0.9760499],"study_design_scores_gemma":[0.003629094,0.0009811749,0.00079385354,0.002618395,0.0006740574,0.0029094447,0.00005413764,0.0000045165953,0.0000026539385,0.00017710193,0.9879058,0.0002497923],"about_ca_topic_score_codex":0.00006419675,"about_ca_topic_score_gemma":0.000017133378,"teacher_disagreement_score":0.9810025,"about_ca_system_score_codex":0.00076678133,"about_ca_system_score_gemma":0.000794568,"threshold_uncertainty_score":0.99999005},"labels":[],"label_agreement":null},{"id":"W4387356945","doi":"10.1002/hon.3225","title":"Expression of “DNA damage response” pathway genes in diffuse large B‐cell lymphoma: The potential for exploiting synthetic lethality","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; Alberta Cancer Foundation; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"Diffuse large B-cell lymphoma; Biology; Gene; Cancer research; Lymphoma; FANCA; DNA repair; Gene expression profiling; Follicular lymphoma; Cancer; Gene expression; Genetics; Immunology","score_opus":0.038836643700257974,"score_gpt":0.3187934555673111,"score_spread":0.2799568118670531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387356945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952615,0.00037904517,0.00010753441,0.002782104,0.00014016539,0.0008084807,0.00003968377,0.00008298939,0.00039852],"genre_scores_gemma":[0.9983175,0.0001167819,0.0004989235,0.00028771313,0.00004503962,0.0005723244,0.00003288478,0.000016993064,0.00011184934],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978849,0.0005440806,0.0005305869,0.00037740896,0.00019881142,0.00046420546],"domain_scores_gemma":[0.9966746,0.0026174565,0.00019214481,0.00035553088,0.00006088884,0.00009936426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010795272,0.00018219945,0.00069313304,0.00010632798,0.00012447992,0.0000073078722,0.00014916284,0.0002815226,0.000048005888],"category_scores_gemma":[0.0007360573,0.0001021419,0.00022080822,0.00023102104,0.00015661358,0.00003051069,0.00018374674,0.00008006441,0.000036350775],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021921637,0.08457811,0.0957994,0.0014880452,0.00019432964,0.012794242,0.0036624044,0.0000374225,0.73337847,0.012958447,0.004666757,0.02852073],"study_design_scores_gemma":[0.05717775,0.0033021686,0.27661726,0.00038649884,0.00022230271,0.000589463,0.004789671,0.0014757351,0.6363983,0.0023774884,0.016266841,0.00039651064],"about_ca_topic_score_codex":0.000013926235,"about_ca_topic_score_gemma":0.000009856197,"teacher_disagreement_score":0.18081786,"about_ca_system_score_codex":0.00015536572,"about_ca_system_score_gemma":0.0001585893,"threshold_uncertainty_score":0.4165226},"labels":[],"label_agreement":null},{"id":"W4388768670","doi":"10.1002/hon.3229","title":"Early intervention of extracorporeal photopheresis for advancing/progressing cutaneous T‐cell lymphoma","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Extracorporeal Photopheresis; Photopheresis; Medicine; Cutaneous T-cell lymphoma; Tolerability; Lymphoma; Disease; Extracorporeal; Dermatology; Surgery; Mycosis fungoides; Immunology; Internal medicine; Adverse effect; Graft-versus-host disease","score_opus":0.1169548985801202,"score_gpt":0.4524361838372104,"score_spread":0.3354812852570902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388768670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039833616,0.987554,0.00034915068,0.000066624154,0.00027207605,0.0049038185,0.00012911824,0.00023044868,0.0025113712],"genre_scores_gemma":[0.00091299386,0.9899459,0.0046298653,0.000043954602,0.00015297643,0.0015257626,0.0003545928,0.00017853707,0.0022554167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99529546,0.00043751972,0.0019113155,0.0009438285,0.0004786695,0.00093321246],"domain_scores_gemma":[0.9946835,0.0028639822,0.001170305,0.00053227285,0.00042010783,0.00032981386],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00058766926,0.00062970846,0.005032528,0.00046650984,0.00012137797,0.000026358457,0.0004029984,0.0014398718,0.00035200204],"category_scores_gemma":[0.0015357567,0.00046911137,0.0018644996,0.0006319548,0.00047017526,0.000039976196,0.00025458043,0.00043581548,0.00018338926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008528218,0.0023053412,0.00010412498,0.07016429,0.00041809672,0.0043897107,0.000054508335,2.7864021e-7,0.00002577406,0.00025428293,0.0013456387,0.92008513],"study_design_scores_gemma":[0.0050004735,0.008736852,0.0000134634265,0.019521376,0.002371233,0.03092889,0.0002203309,0.00015299482,0.00018174689,0.0010250987,0.93111736,0.00073016546],"about_ca_topic_score_codex":0.00006101051,"about_ca_topic_score_gemma":0.000051868854,"teacher_disagreement_score":0.9297717,"about_ca_system_score_codex":0.00077857805,"about_ca_system_score_gemma":0.0010638497,"threshold_uncertainty_score":0.9998565},"labels":[],"label_agreement":null},{"id":"W4409335490","doi":"10.1002/hon.70061","title":"Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis","year":2025,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Janssen Scientific Affairs","keywords":"Lenalidomide; Medicine; Daratumumab; Internal medicine; Hazard ratio; Multiple myeloma; Oncology; Meta-analysis; Bortezomib; Randomized controlled trial; Cochrane Library; Dexamethasone; Surgery; Confidence interval","score_opus":0.097623608691779,"score_gpt":0.40854111592677966,"score_spread":0.31091750723500067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409335490","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032332595,0.99000984,0.0000653164,0.0008809641,0.00007043367,0.0078249965,0.0003565943,0.0000924919,0.0003760125],"genre_scores_gemma":[0.0013785736,0.99003386,0.0034181152,0.00065857446,0.000035060864,0.0035103213,0.0005789283,0.000058793077,0.00032774732],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99081373,0.0031912911,0.0024498336,0.0019052214,0.0005410327,0.0010989176],"domain_scores_gemma":[0.9803923,0.01683003,0.0008059369,0.0009155258,0.0002218518,0.00083439663],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0019419006,0.0014201727,0.020209398,0.0014597457,0.00019328197,0.00012359432,0.0003320688,0.0014290089,0.00013945914],"category_scores_gemma":[0.0046103173,0.0008634537,0.0016612293,0.0027835106,0.0005294067,0.0001587136,0.00033120665,0.0016536162,0.00001545881],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017526828,0.00081836106,0.00054201856,0.87723434,0.089133315,0.012636212,0.00011819227,3.3728188e-7,8.1218036e-7,0.0002622547,0.0003152749,0.0171862],"study_design_scores_gemma":[0.021954421,0.0013606371,0.00023621485,0.13774495,0.80097276,0.00536236,0.000061229584,0.000086689055,0.0000037638736,0.00005841917,0.031034587,0.0011239713],"about_ca_topic_score_codex":0.00013468978,"about_ca_topic_score_gemma":0.00060462696,"teacher_disagreement_score":0.7394894,"about_ca_system_score_codex":0.0002851251,"about_ca_system_score_gemma":0.00049909734,"threshold_uncertainty_score":0.9998673},"labels":[],"label_agreement":null},{"id":"W4411321377","doi":"10.1002/hon.70096_549","title":"549 | PROSPECTIVE PATIENT PREFERENCE STUDY FOR CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT ATTRIBUTES IMPACTING PATIENT SHARED‐DECISION MAKING","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"BeiGene","keywords":"Chronic lymphocytic leukemia; Preference; Medicine; Leukemia; Oncology; Intensive care medicine; Internal medicine; Statistics","score_opus":0.07115118766882485,"score_gpt":0.39899846669366196,"score_spread":0.3278472790248371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411321377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858304,0.0013120823,0.0014827736,0.00021900948,0.00035505474,0.007545002,0.000035374793,0.00022100088,0.0029992957],"genre_scores_gemma":[0.99397296,0.00006926655,0.00262207,0.00027673037,0.000090006266,0.0027142551,0.000032751115,0.000032669745,0.00018931134],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99597627,0.00023016312,0.0010359052,0.0011345464,0.0005243099,0.0010987796],"domain_scores_gemma":[0.9948532,0.0034597018,0.0003075986,0.00070266053,0.00042573037,0.0002511135],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036054413,0.00048170015,0.0014374576,0.00027340036,0.00034763597,0.00005659662,0.00026441202,0.00045522346,0.00024012612],"category_scores_gemma":[0.0022397884,0.00032502832,0.00030112118,0.0005920498,0.00020873299,0.00009572899,0.00044891713,0.00033994258,0.00007816518],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04017468,0.013483929,0.07940232,0.002345889,0.0038274184,0.007931424,0.013307343,0.003808014,0.00237748,0.009527995,0.013721191,0.81009233],"study_design_scores_gemma":[0.2833838,0.32299432,0.053948566,0.0060695303,0.002980381,0.006514516,0.015531864,0.2235872,0.03184411,0.012770916,0.03756264,0.0028121609],"about_ca_topic_score_codex":0.00017788264,"about_ca_topic_score_gemma":0.00017389418,"teacher_disagreement_score":0.8072801,"about_ca_system_score_codex":0.26783454,"about_ca_system_score_gemma":0.030640692,"threshold_uncertainty_score":0.9999202},"labels":[],"label_agreement":null},{"id":"W4411325981","doi":"10.1002/hon.70094_443","title":"443 | A PHASE 1 STUDY OF PRT2527, A SELECTIVE CDK9 INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB IN RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES: UPDATED ANALYSIS","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"BeiGene; Gilead Sciences; Merck KGaA; Regeneron Pharmaceuticals; Pharmacyclics; Genentech; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Refractory (planetary science); Medicine; Oncology; Internal medicine; Cancer research; Biology","score_opus":0.020421365488204127,"score_gpt":0.36622796712773403,"score_spread":0.3458066016395299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411325981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956062,0.00042977283,0.00006517997,0.0003994443,0.000026139074,0.0016716612,0.000002489548,0.000038495094,0.001760618],"genre_scores_gemma":[0.9989256,0.000093620896,0.0001995197,0.00030749626,0.0000063885427,0.0002590979,0.000020682144,0.000012239163,0.00017534984],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973632,0.0005338129,0.00075654057,0.00060235144,0.00033534836,0.00040874426],"domain_scores_gemma":[0.9983194,0.0008309516,0.00021504618,0.00030957907,0.00021844376,0.00010660574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000662708,0.00022566247,0.0013527719,0.0010935903,0.000041469655,0.000008725538,0.00012900875,0.00036796625,0.00009136739],"category_scores_gemma":[0.00046535436,0.00016531578,0.000066146364,0.0031334318,0.0003112466,0.000054643246,0.000093124116,0.000395266,0.0000039491506],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06727837,0.07926305,0.8076046,0.0005077102,0.0030372406,0.007997402,0.011320894,0.00023774628,0.010144488,0.0033399046,0.0006776522,0.008590935],"study_design_scores_gemma":[0.7015423,0.082368605,0.14565332,0.0006936301,0.0016730872,0.0014677098,0.016351378,0.027625605,0.017996972,0.002255356,0.0015434074,0.00082859304],"about_ca_topic_score_codex":0.0011129854,"about_ca_topic_score_gemma":0.0015911837,"teacher_disagreement_score":0.6619513,"about_ca_system_score_codex":0.0054268297,"about_ca_system_score_gemma":0.0038241511,"threshold_uncertainty_score":0.99839115},"labels":[],"label_agreement":null},{"id":"W4411332234","doi":"10.1002/hon.70093_134","title":"134 | EFFICACY AND SAFETY OF FIRST‐LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre","funders":"Pharmacyclics","keywords":"Ibrutinib; Mantle cell lymphoma; Venetoclax; Lymphoma; Medicine; Cancer research; Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.02185390775549227,"score_gpt":0.33183458562934526,"score_spread":0.30998067787385297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411332234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929629,0.00025683412,0.000050922194,0.0008700552,0.000039909595,0.0028043373,0.0000074986447,0.000019655541,0.0029879145],"genre_scores_gemma":[0.99894917,0.000053084117,0.00021425517,0.00032869563,0.000009713017,0.00018934232,0.00002504617,0.000012530975,0.00021815582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775356,0.00032613595,0.000710075,0.000428226,0.0003589337,0.000423093],"domain_scores_gemma":[0.99664044,0.0026243376,0.00014107015,0.00041293408,0.000105326595,0.00007588904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048647332,0.0002072071,0.0009345671,0.00020644719,0.00008102729,0.000010485209,0.00023787227,0.00025152892,0.00013823189],"category_scores_gemma":[0.00055235677,0.00011180374,0.00004181397,0.00068801217,0.00036600698,0.000035770998,0.0001945849,0.00028344587,0.000010215984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030650383,0.027638426,0.9037311,0.0019175892,0.00030743348,0.003723722,0.010538177,0.00083221577,0.000013122421,0.0022752786,0.0010483068,0.01732426],"study_design_scores_gemma":[0.16904463,0.007920568,0.81292063,0.00053314964,0.00017258007,0.00014859375,0.0025523277,0.0046702866,0.00008567657,0.00016602382,0.0015924709,0.00019305167],"about_ca_topic_score_codex":0.00024237584,"about_ca_topic_score_gemma":0.0009616995,"teacher_disagreement_score":0.13839425,"about_ca_system_score_codex":0.003949275,"about_ca_system_score_gemma":0.0034364397,"threshold_uncertainty_score":0.9998744},"labels":[],"label_agreement":null},{"id":"W4411333669","doi":"10.1002/hon.70093_136","title":"136 | MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE‐RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE ECHO TRIAL","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AstraZeneca","keywords":"Bendamustine; Mantle cell lymphoma; Rituximab; Medicine; Minimal residual disease; Oncology; Internal medicine; Lymphoma; Cancer research; Bone marrow","score_opus":0.02236552243145124,"score_gpt":0.31067040176261346,"score_spread":0.2883048793311622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411333669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987845,0.00014737595,0.000024398892,0.0022703381,0.00007651679,0.003923882,0.00012493484,0.00013578964,0.0054517444],"genre_scores_gemma":[0.99477655,0.000031985495,0.00179172,0.0009255315,0.00011946359,0.0003663417,0.00037317502,0.00004725606,0.0015679753],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9954423,0.00057431386,0.0009054392,0.0011809178,0.00084896426,0.0010480842],"domain_scores_gemma":[0.9954226,0.0025553314,0.00031850947,0.0009724921,0.00029811042,0.00043295955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005017688,0.00052144047,0.001501919,0.00016542731,0.00017852247,0.000046672692,0.00048036338,0.0004553954,0.00018369581],"category_scores_gemma":[0.001222804,0.00022547538,0.000078891826,0.0009466369,0.0009685422,0.00008617536,0.00027788623,0.000611754,0.00005824541],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.85395926,0.0075951573,0.12917951,0.00017291208,0.00022486219,0.004236125,0.00043697437,0.0000131727675,0.0000046737146,0.00010309359,0.0027568326,0.0013174249],"study_design_scores_gemma":[0.89702445,0.01911424,0.0766891,0.0009087987,0.0007572489,0.00018192333,0.000569405,0.0007908097,0.00023685415,0.000048124926,0.003233174,0.00044586102],"about_ca_topic_score_codex":0.00076967594,"about_ca_topic_score_gemma":0.0016662574,"teacher_disagreement_score":0.052490406,"about_ca_system_score_codex":0.0039067767,"about_ca_system_score_gemma":0.0137162935,"threshold_uncertainty_score":0.99991703},"labels":[],"label_agreement":null},{"id":"W4411333827","doi":"10.1002/hon.70094_184","title":"184 | GENOMIC PROFILING OF EXTRANODAL DISEASE IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A COMBINED ANALYSIS OF POLARIX AND GOYA","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Roche (Canada)","funders":"National Cancer Institute; Gilead Sciences; Seagen; Pfizer","keywords":"Lymphoma; Diffuse large B-cell lymphoma; Medicine; Profiling (computer programming); Disease; Pathology; Computer science","score_opus":0.007201085497103421,"score_gpt":0.26195510284320767,"score_spread":0.25475401734610426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411333827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99786127,0.00084946945,0.000033587152,0.00020598508,0.000019855252,0.00053484953,0.000049825,0.000012713957,0.00043247617],"genre_scores_gemma":[0.9988967,0.000053704567,0.000713846,0.00016757364,0.000002002281,0.00005201101,0.00008530983,0.000005359937,0.000023488801],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988144,0.00009021772,0.00044591632,0.00028688388,0.00012176514,0.00024081358],"domain_scores_gemma":[0.9991722,0.00026766813,0.00015984668,0.0002055871,0.00007345362,0.00012124394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010611995,0.00014682923,0.0010370258,0.00029374077,0.00002753713,0.000002818336,0.000059275382,0.00013500958,0.000030447405],"category_scores_gemma":[0.000070979404,0.00009460715,0.00011863653,0.00050085445,0.00014293948,0.000019644533,0.00008042073,0.000050943454,0.0000013913553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028398558,0.025469014,0.96597886,0.00019807882,0.0005103481,0.00015819498,0.00006665685,0.000002948549,0.00012351165,0.0043377215,0.000010937143,0.0003038777],"study_design_scores_gemma":[0.032659393,0.0009208706,0.9632881,0.000054856057,0.0018591306,0.0000016474594,0.000045070126,0.0003601661,0.0006013636,0.00009668547,0.000039460512,0.00007320897],"about_ca_topic_score_codex":0.00005538491,"about_ca_topic_score_gemma":0.000043515018,"teacher_disagreement_score":0.029819537,"about_ca_system_score_codex":0.00015056336,"about_ca_system_score_gemma":0.00019543798,"threshold_uncertainty_score":0.38579676},"labels":[],"label_agreement":null},{"id":"W4411333831","doi":"10.1002/hon.70093_50","title":"50 | FIXED‐DURATION OUTPATIENT SUBCUTANEOUS MOSUNETUZUMAB + POLATUZUMAB VEDOTIN SHOWS ROBUST EFFICACY IN A PHASE II STUDY OF RELAPSED/REFRACTORY POST‐BTKi MANTLE CELL LYMPHOMA","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"Science and Engineering Research Board; BeiGene; F. Hoffmann-La Roche; Genentech; AstraZeneca; Celgene; Gilead Sciences; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Mantle cell lymphoma; Internal medicine; Lymphoma; Oncology; Materials science; Composite material","score_opus":0.024737485077325528,"score_gpt":0.31162199020163306,"score_spread":0.2868845051243075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411333831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909042,0.0012058493,0.000021312342,0.00072623446,0.000346496,0.0021026237,0.000019096093,0.000089565096,0.0045846393],"genre_scores_gemma":[0.99802125,0.00009314763,0.00053960516,0.0005050706,0.000028888006,0.0002537441,0.0000975675,0.000021782918,0.00043892823],"study_design_codex":"nonrandomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9967846,0.0003573214,0.0013030915,0.00071713334,0.00033605215,0.00050176284],"domain_scores_gemma":[0.99781203,0.00087722443,0.00041288242,0.00054851075,0.00017102544,0.0001783373],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021463535,0.00038833692,0.0014193557,0.00035031373,0.0001486296,0.000011993709,0.00019947745,0.00054063706,0.0002574386],"category_scores_gemma":[0.00038038575,0.00029335005,0.00020343767,0.00042995095,0.00014137042,0.000060617007,0.00022266053,0.00026563441,0.000045983943],"study_design_candidate":"nonrandomized_trial","study_design_consensus":"nonrandomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029760825,0.738319,0.103201516,0.00069821044,0.0008308748,0.018007122,0.009288543,0.00038955663,0.012753229,0.0032232518,0.0043189987,0.0792089],"study_design_scores_gemma":[0.30683535,0.35187793,0.2692854,0.00088457216,0.0022195326,0.002910197,0.01381008,0.0025208306,0.020722378,0.00030083902,0.027129326,0.0015035511],"about_ca_topic_score_codex":0.00035310458,"about_ca_topic_score_gemma":0.00040344518,"teacher_disagreement_score":0.38644105,"about_ca_system_score_codex":0.0012981166,"about_ca_system_score_gemma":0.0005699532,"threshold_uncertainty_score":0.99995184},"labels":[],"label_agreement":null},{"id":"W4411335183","doi":"10.1002/hon.70093_5","title":"5 | LARGE B‐CELL LYMPHOMA MICROENVIRONMENT ARCHETYPE PROFILES (LYMPHOMAPS) IDENTIFY SUBGROUPS WITH GREATEST BENEFIT FROM CD19 CAR T‐CELL THERAPY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"MorphoSys; Genentech; Incyte; Gilead Sciences; AstraZeneca","keywords":"CD19; Lymphoma; Medicine; B cell; Oncology; Internal medicine; Cancer research; Immunology","score_opus":0.02569170392763857,"score_gpt":0.31176753998727297,"score_spread":0.2860758360596344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411335183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724839,0.004723238,0.00021155342,0.0019230605,0.00018086917,0.0015462016,0.00006195896,0.00017174489,0.018697474],"genre_scores_gemma":[0.9777856,0.0021272602,0.0016420031,0.0023805955,0.000121218065,0.00036283061,0.00025251778,0.00006530042,0.015262682],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99634933,0.00030376812,0.00065021246,0.0010822522,0.00053642906,0.0010779774],"domain_scores_gemma":[0.9976739,0.00075896794,0.00019524108,0.00089050934,0.00012232477,0.00035900663],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040057884,0.0005188739,0.0013189706,0.00022539901,0.00020600941,0.000045313715,0.00046897322,0.0006968649,0.0051694284],"category_scores_gemma":[0.000044951372,0.00036157764,0.00027062598,0.0004496739,0.0005151897,0.00006383354,0.00030251994,0.00049123773,0.00049860805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010827897,0.0149030015,0.3049172,0.00035881708,0.00066099846,0.004688847,0.0010033909,0.00000505589,0.6376593,0.0019285278,0.005087341,0.017959636],"study_design_scores_gemma":[0.040105928,0.0053975363,0.19324519,0.00020257404,0.00029555397,0.00072221196,0.0012754574,0.00012360231,0.4675849,0.0018853112,0.28839815,0.0007635686],"about_ca_topic_score_codex":0.00022034225,"about_ca_topic_score_gemma":0.00010014397,"teacher_disagreement_score":0.2833108,"about_ca_system_score_codex":0.0007873924,"about_ca_system_score_gemma":0.00043695734,"threshold_uncertainty_score":0.9998836},"labels":[],"label_agreement":null},{"id":"W4411336441","doi":"10.1002/hon.70094_234","title":"234 | POST HOC ANALYSIS OF OUTCOMES BY POD24 STATUS FROM THE inMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Lenalidomide; Rituximab; Follicular lymphoma; Medicine; Post-hoc analysis; Oncology; Internal medicine; Refractory (planetary science); Follicular phase; Lymphoma; Biology; Multiple myeloma","score_opus":0.02154364929248844,"score_gpt":0.3335280764054523,"score_spread":0.31198442711296387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411336441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99312633,0.003296231,0.0000045028582,0.0022269366,0.00006037726,0.00081424706,0.000109366796,0.000016128932,0.00034587987],"genre_scores_gemma":[0.998187,0.0003329949,0.0002330159,0.0009713571,0.0000045472857,0.00012098099,0.00007380052,0.000007807867,0.00006850276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768007,0.00041684855,0.00089086307,0.0004551216,0.00025776564,0.00029933374],"domain_scores_gemma":[0.995847,0.0031586648,0.0003257882,0.00045730805,0.00011084672,0.00010040773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027473937,0.00024223099,0.0021693748,0.00026283896,0.00005382479,0.00000771616,0.00014662051,0.00029645674,0.00014932334],"category_scores_gemma":[0.000675779,0.00012306307,0.00021782084,0.00078446226,0.00023418305,0.000027617874,0.0001603632,0.00012223174,0.000003159569],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063043013,0.021861097,0.95698506,0.00003752224,0.00436531,0.00097127934,0.0011996138,0.000003898397,0.00025359524,0.00035957413,0.00069836277,0.0069603734],"study_design_scores_gemma":[0.055090282,0.004229462,0.9292915,0.000061973005,0.0037035288,0.000019439158,0.0056317127,0.0000851713,0.00041038886,0.00006651907,0.0012955628,0.00011446491],"about_ca_topic_score_codex":0.0025982242,"about_ca_topic_score_gemma":0.0024076703,"teacher_disagreement_score":0.04878598,"about_ca_system_score_codex":0.00041930564,"about_ca_system_score_gemma":0.00035365362,"threshold_uncertainty_score":0.50183666},"labels":[],"label_agreement":null},{"id":"W4411343965","doi":"10.1002/hon.70094_220","title":"220 | HIGH EFFICACY OF BRIEF BRAF AND MEK COINHIBITION, ALONE AND COMBINED WITH ANTI‐CD20 IMMUNOTHERAPY, IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: A PHASE‐2 TRIAL","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Celgene; Leukemia and Lymphoma Society of Canada; Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); CD20; Immunotherapy; Oncology; Leukemia; Cancer research; Internal medicine; Lymphoma; Cancer; Biology","score_opus":0.017579001975843826,"score_gpt":0.3244681010151445,"score_spread":0.3068890990393007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411343965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99230903,0.0017918671,0.00009740739,0.0014495751,0.0001079441,0.0015657917,0.000008149679,0.00006252212,0.0026076902],"genre_scores_gemma":[0.99737805,0.0006535599,0.00075208716,0.00072148547,0.00003990131,0.00008647682,0.000033825887,0.000022508077,0.00031212502],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974832,0.00034100958,0.0008040605,0.00059022463,0.00030453654,0.0004769757],"domain_scores_gemma":[0.99685967,0.002240363,0.00022503232,0.00037074983,0.00013195792,0.00017221905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057983,0.00027549514,0.0015341569,0.00027800526,0.00007611831,0.000013652457,0.00012818174,0.00059797213,0.0001337712],"category_scores_gemma":[0.00047113685,0.00019727413,0.00007645116,0.00048103058,0.0011316029,0.000052818843,0.00014822697,0.0006481288,0.0000051193642],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.853066,0.024201738,0.006942381,0.0030483203,0.00081431743,0.010761262,0.0014171115,0.000030021003,0.052637126,0.019975487,0.010682263,0.016423963],"study_design_scores_gemma":[0.9466257,0.02675178,0.005350041,0.00046931749,0.00016442421,0.0012624891,0.00021221628,0.0007486827,0.013641714,0.0008510192,0.0036282889,0.00029433664],"about_ca_topic_score_codex":0.00044936495,"about_ca_topic_score_gemma":0.00010521147,"teacher_disagreement_score":0.09355968,"about_ca_system_score_codex":0.0026172285,"about_ca_system_score_gemma":0.0049376236,"threshold_uncertainty_score":0.8759132},"labels":[],"label_agreement":null},{"id":"W4411346424","doi":"10.1002/hon.70094_296","title":"296 | LIMITED STAGE DIFFUSE LARGE B CELL LYMPHOMA IN THE MODERN ERA: REAL‐WORLD OUTCOMES IN AN INTERNATIONAL STUDY OF OVER ONE THOUSAND PATIENTS","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of British Columbia; Alberta Health Services","funders":"TG Therapeutics; AstraZeneca; Bristol-Myers Squibb","keywords":"Stage (stratigraphy); Diffuse large B-cell lymphoma; Medicine; Lymphoma; Internal medicine; Oncology; Geology","score_opus":0.03325769351432889,"score_gpt":0.3525467663493674,"score_spread":0.3192890728350385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411346424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885579,0.000040737512,0.0000033985887,0.0007177749,0.00011514071,0.0010286462,0.000023012399,0.000022057106,0.009491331],"genre_scores_gemma":[0.99800265,0.00006813624,0.000102777005,0.0012253245,0.0000096609765,0.00022856466,0.00004937451,0.0000075092885,0.0003059827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818516,0.00033096748,0.0005894348,0.00034878394,0.00027754312,0.0002680842],"domain_scores_gemma":[0.99870116,0.00069153507,0.00015106401,0.00033550902,0.00006513392,0.000055580873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024265684,0.00017630933,0.00077306764,0.00027477613,0.000033745942,0.000010973056,0.00021762583,0.00015348109,0.000073111434],"category_scores_gemma":[0.000117790325,0.00010272132,0.000075192904,0.00030191932,0.000053839616,0.000060131533,0.00013659187,0.00013461665,0.000004647791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055623776,0.14768696,0.84641546,0.000025427345,0.00007368628,0.00041163393,0.0012474306,0.0000024469264,0.000013222856,0.0020980325,0.00009443517,0.0013750301],"study_design_scores_gemma":[0.04056103,0.0018905817,0.9556623,0.00003438241,0.0000694525,0.0000023722844,0.0005915479,0.00028063598,0.00006862582,0.00027821408,0.00048281543,0.00007801129],"about_ca_topic_score_codex":0.00038232675,"about_ca_topic_score_gemma":0.0044056606,"teacher_disagreement_score":0.14579637,"about_ca_system_score_codex":0.00034847128,"about_ca_system_score_gemma":0.000088255736,"threshold_uncertainty_score":0.41888538},"labels":[],"label_agreement":null},{"id":"W4411349405","doi":"10.1002/hon.70093_56","title":"56 | GENOMIC ANALYSIS OF MATURE B‐CELL LYMPHOMAS","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Spinal Cord Injury BC; Simon Fraser University; Genome British Columbia","funders":"Celgene; Gilead Sciences","keywords":"B cell; Cancer research; Computational biology; Biology; Genetics; Medicine; Antibody","score_opus":0.0158113372617889,"score_gpt":0.3204125927343742,"score_spread":0.3046012554725853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411349405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89909434,0.0032290637,0.000063359155,0.0024238422,0.00011118027,0.0002599393,0.000011491986,0.00004940394,0.094757356],"genre_scores_gemma":[0.99517995,0.00023170744,0.0016491,0.0018022492,0.000015644579,0.00005546099,0.000043851367,0.0000046202313,0.0010174003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99889,0.00007171842,0.0004020575,0.0003046219,0.00010439698,0.00022720906],"domain_scores_gemma":[0.99901855,0.00037653642,0.00012919337,0.00031184973,0.000070062,0.00009379522],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010214295,0.00014686557,0.001121306,0.00030009294,0.000037546193,0.000004057732,0.00009715423,0.00034334284,0.00073899096],"category_scores_gemma":[0.00006808123,0.000096549644,0.000621427,0.000773383,0.00012652733,0.000011666691,0.000082823826,0.000082452716,0.000054314438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076241797,0.0065472755,0.88744044,0.000257238,0.0071220067,0.0014390664,0.0001454515,0.00003441007,0.0037609332,0.06866255,0.015657041,0.008171147],"study_design_scores_gemma":[0.00566329,0.0010375194,0.9045409,0.000048400605,0.012056708,0.00014130968,0.00017130088,0.0003138856,0.010294034,0.0011307565,0.064432524,0.00016937975],"about_ca_topic_score_codex":0.000031652206,"about_ca_topic_score_gemma":0.000018572977,"teacher_disagreement_score":0.0960856,"about_ca_system_score_codex":0.00028641967,"about_ca_system_score_gemma":0.00022767326,"threshold_uncertainty_score":0.80914325},"labels":[],"label_agreement":null},{"id":"W4411351237","doi":"10.1002/hon.70093_76","title":"76 | GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (Glofit‐GemOx) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): 2‐YEAR FOLLOW‐UP OF STARGLO","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; University College London; F. Hoffmann-La Roche; BeiGene; Sanofi","keywords":"Gemcitabine; Oxaliplatin; Diffuse large B-cell lymphoma; Refractory (planetary science); Medicine; Oncology; Lymphoma; Internal medicine; Chemotherapy; Materials science; Cancer; Colorectal cancer; Metallurgy","score_opus":0.012845842678706386,"score_gpt":0.28591853277589646,"score_spread":0.2730726900971901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411351237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892422,0.00080548285,0.000110884226,0.00049970474,0.00018856644,0.0011660066,0.000033939177,0.00007510963,0.007878126],"genre_scores_gemma":[0.9965006,0.0001535233,0.0012660006,0.0005443318,0.00002559065,0.00008326578,0.00008337524,0.000034241835,0.00130904],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965458,0.00029194893,0.0009057024,0.0007558201,0.0005966036,0.000904139],"domain_scores_gemma":[0.9974896,0.0010613792,0.00026136634,0.0006287448,0.0002613072,0.00029765893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051183824,0.0003821521,0.0015458091,0.00037482203,0.00008552554,0.000013788071,0.00027532497,0.0007014105,0.00020231081],"category_scores_gemma":[0.00080514274,0.0002736321,0.00012504101,0.0007153784,0.00053441647,0.000100727215,0.00046158888,0.00046595928,0.00003285979],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046941113,0.04054671,0.8661659,0.0030785487,0.0005773848,0.0033436911,0.0015575377,0.000010378986,0.00066088216,0.017509317,0.011138387,0.008470192],"study_design_scores_gemma":[0.72818667,0.008970447,0.23922521,0.0006559488,0.0002939725,0.00020126814,0.0009551958,0.001918611,0.0010536696,0.00086229976,0.017054731,0.0006220094],"about_ca_topic_score_codex":0.00020829639,"about_ca_topic_score_gemma":0.00022960058,"teacher_disagreement_score":0.6812455,"about_ca_system_score_codex":0.006208538,"about_ca_system_score_gemma":0.0041884957,"threshold_uncertainty_score":0.99997157},"labels":[],"label_agreement":null},{"id":"W4411353536","doi":"10.1002/hon.70094_288","title":"288 | FIVE‐YEAR ANALYSIS OF AN ASIA SUBPOPULATION WITH PREVIOUSLY UNTREATED DLBCL CONFIRMS POLA‐R‐CHP BENEFIT ON OUTCOMES: THE POLARIX STUDY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Oncology; Internal medicine; Demography; Sociology","score_opus":0.02290558256597663,"score_gpt":0.35553354163472134,"score_spread":0.3326279590687447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411353536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922671,0.0001437435,0.000012605641,0.0025875203,0.000043625896,0.0014603321,0.000029189318,0.00006268865,0.0033932452],"genre_scores_gemma":[0.99848723,0.00001832374,0.00012045465,0.0008249664,0.000010311655,0.00015036754,0.00017262106,0.000008030128,0.00020771027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982713,0.00025790566,0.00047184122,0.0004536036,0.00027453026,0.00027080823],"domain_scores_gemma":[0.99836385,0.00054817146,0.00021245032,0.0005654489,0.00016332274,0.00014674825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020594492,0.00024231164,0.0012144567,0.00026602222,0.00011448734,0.000014794904,0.00015185142,0.000185846,0.0002318613],"category_scores_gemma":[0.000115407616,0.00011504145,0.00023262191,0.0008390941,0.00013964009,0.00003788633,0.00003919432,0.00017647175,0.000014050334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011590788,0.0105579235,0.96958965,0.000024425493,0.0045545073,0.00024685013,0.00033255306,0.00006336497,0.0000067963697,0.012156565,0.000052898402,0.0012553718],"study_design_scores_gemma":[0.0049757236,0.0062242155,0.9780636,0.00004117545,0.008702106,0.000012803698,0.0013178415,0.00018237617,0.000073825606,0.00017728593,0.00012692576,0.000102131344],"about_ca_topic_score_codex":0.00087595324,"about_ca_topic_score_gemma":0.001234478,"teacher_disagreement_score":0.011979278,"about_ca_system_score_codex":0.00016830763,"about_ca_system_score_gemma":0.000119825076,"threshold_uncertainty_score":0.46912542},"labels":[],"label_agreement":null},{"id":"W4411356627","doi":"10.1002/hon.70094_422","title":"422 | MOLECULAR FEATURES ENCODED IN THE DYNAMIC ctDNA MONITORING REVEAL PROGNOSTIC VALUE, DIFFERENT CLINICAL COURSES AND CLONE EVOLUTION FOR DIFFERENT GENETIC SUBTYPES OF DLBCL","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Journal of Gastroenterology and Hepatology Foundation; Incyte; Québec Consortium for Drug Discovery; Gilead Sciences","keywords":"clone (Java method); Value (mathematics); Somatic evolution in cancer; Oncology; Computational biology; Biology; Internal medicine; Medicine; Genetics; Computer science; Gene; Cancer; Machine learning","score_opus":0.015474720923053633,"score_gpt":0.34141143494440024,"score_spread":0.3259367140213466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411356627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986141,0.007854634,0.003990055,0.0007936735,0.0003593703,0.0007298961,0.000025838472,0.0000075103594,0.00009800696],"genre_scores_gemma":[0.99692166,0.0012993776,0.0012037124,0.0002285819,0.0000721117,0.00020204618,0.000038495713,0.000010145508,0.000023886703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984323,0.00025886373,0.00051057525,0.000415609,0.000096799675,0.0002858749],"domain_scores_gemma":[0.99867,0.0007802243,0.00015921163,0.00026271748,0.00007154668,0.000056337674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002592313,0.00019329312,0.0004986672,0.000055410543,0.000062438776,0.000013866389,0.00023251091,0.00038137237,0.0000012656236],"category_scores_gemma":[0.00083038246,0.00012999217,0.00013958056,0.00007918278,0.00026150062,0.0000016202715,0.00015860163,0.00018784577,2.8391017e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000829818,0.0017137281,0.9027605,0.0002617498,0.00015687484,0.000052390176,0.000058211976,0.00013071284,0.07641452,0.011719206,0.0007339998,0.005168309],"study_design_scores_gemma":[0.0021722745,0.0019665072,0.97131157,0.000081882536,0.00017174735,0.000065036635,0.00015490837,0.00040360872,0.01571503,0.0072915247,0.00046417033,0.0002017289],"about_ca_topic_score_codex":0.00001738533,"about_ca_topic_score_gemma":0.000105609506,"teacher_disagreement_score":0.0685511,"about_ca_system_score_codex":0.00005367412,"about_ca_system_score_gemma":0.00011052614,"threshold_uncertainty_score":0.53009266},"labels":[],"label_agreement":null},{"id":"W4411388472","doi":"10.1002/hon.70094_390","title":"390 | END‐OF‐TREATMENT PET/CT COMPLETE REMISSION IS HIGHLY PROGNOSTIC IN NODAL PERIPHERAL T‐CELL LYMPHOMA: AN AUSTRALASIAN‐CANADIAN COLLABORATIVE STUDY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"T-cell and Retrovirus Studies","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"BeiGene; AstraZeneca; Bristol-Myers Squibb; CSL Behring; Amgen","keywords":"NODAL; Medicine; Peripheral; Lymphoma; Complete remission; Oncology; Internal medicine; Peripheral T-cell lymphoma; Radiology; Nuclear medicine; T cell; Chemotherapy; Immunology","score_opus":0.021018418202803334,"score_gpt":0.29086430956493253,"score_spread":0.2698458913621292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411388472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790757,0.0018611575,0.0000036800768,0.0013039397,0.00058347505,0.0011702233,0.000098840166,0.000062677005,0.015840326],"genre_scores_gemma":[0.9965889,0.00011339354,0.00017516749,0.00026091834,0.000013307482,0.0001807799,0.00006681057,0.000012034285,0.0025886833],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970639,0.00080451166,0.0006873629,0.0006691248,0.000048410875,0.00072670256],"domain_scores_gemma":[0.9988388,0.00042171963,0.00019246065,0.00031130417,0.00013306653,0.000102644895],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019720498,0.0003875325,0.001198156,0.0002743973,0.000336722,0.000011875448,0.0003051876,0.00019242188,0.0006668545],"category_scores_gemma":[0.0000976014,0.00027043573,0.00011948516,0.00049754046,0.0006634994,0.00005440249,0.00013114476,0.0002697105,0.00013883681],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023486968,0.025086936,0.8554085,0.00020202927,0.0011904959,0.008879487,0.008304192,0.000029066341,0.07152238,0.006911439,0.009657314,0.01045949],"study_design_scores_gemma":[0.043850806,0.04660609,0.32488564,0.00026653413,0.00082094385,0.0026705612,0.049154494,0.00006651639,0.047615577,0.0015074008,0.48072648,0.0018289613],"about_ca_topic_score_codex":0.009416051,"about_ca_topic_score_gemma":0.03404944,"teacher_disagreement_score":0.5305228,"about_ca_system_score_codex":0.00081238657,"about_ca_system_score_gemma":0.0010955426,"threshold_uncertainty_score":0.9999748},"labels":[],"label_agreement":null},{"id":"W4411523929","doi":"10.1002/hon.70111","title":"Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Staatssekretariat für Bildung, Forschung und Innovation; Swiss Cancer Research Foundation","keywords":"Medicine; Lymphoma; Follicular lymphoma; Retrospective cohort study; Internal medicine; Gastroenterology; Gastrointestinal tract; Presentation (obstetrics); Follicular phase; Pathology; Radiology","score_opus":0.0258332540265981,"score_gpt":0.31135873062543884,"score_spread":0.28552547659884076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411523929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974332,0.0007183792,0.00011091962,0.0019719114,0.00081656314,0.0013065363,0.000035748733,0.00006657785,0.020641373],"genre_scores_gemma":[0.9974944,0.00006551322,0.00038866972,0.0012990605,0.000042746015,0.00026341254,0.00004353838,0.000013596455,0.00038903888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973094,0.00047831767,0.0007318101,0.0006097876,0.00051620486,0.0003545222],"domain_scores_gemma":[0.9980873,0.0007401298,0.00024263364,0.0005352486,0.00028601076,0.00010866167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006660553,0.00029451572,0.001135498,0.00012396589,0.00013185182,0.00001737371,0.00042842,0.00033186242,0.000200695],"category_scores_gemma":[0.00054426934,0.00017431306,0.00034679397,0.00052699074,0.00032890783,0.000049945156,0.00031873825,0.00011545964,0.000019588553],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012330544,0.016050037,0.96338695,0.00003956649,0.000794767,0.00070494326,0.00014672686,0.000001032227,0.00038317003,0.007019694,0.0016713941,0.0085686715],"study_design_scores_gemma":[0.013865154,0.0015855231,0.9792711,0.00007024265,0.00031220386,0.0004123467,0.00016443293,0.000041192277,0.0008092591,0.00054281903,0.0027895367,0.00013617604],"about_ca_topic_score_codex":0.00055084325,"about_ca_topic_score_gemma":0.0004432352,"teacher_disagreement_score":0.023162434,"about_ca_system_score_codex":0.0012559341,"about_ca_system_score_gemma":0.0005998163,"threshold_uncertainty_score":0.71082807},"labels":[],"label_agreement":null},{"id":"W4415459514","doi":"10.1002/hon.70144","title":"The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO)","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Observational study; Software deployment; Retrospective cohort study; Pharmacy practice; Pharmacist; MEDLINE","score_opus":0.07731557741980553,"score_gpt":0.441086529883501,"score_spread":0.36377095246369545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415459514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891926,0.001419785,0.000025015064,0.0016450499,0.00028748612,0.0013239578,0.0000062261142,0.000017328957,0.0060825297],"genre_scores_gemma":[0.9966379,0.0010063321,0.00023781406,0.0003888709,0.000028038103,0.00015671145,9.28181e-7,0.000008543253,0.001534895],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973398,0.00068010465,0.00082490535,0.00037495687,0.00040376597,0.00037645805],"domain_scores_gemma":[0.99644053,0.0022848179,0.00034698562,0.0005146696,0.00031377102,0.00009920262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083269057,0.00018874744,0.0010310189,0.000059916067,0.00014674976,0.0000045707066,0.0005096966,0.00021332897,0.0005978152],"category_scores_gemma":[0.0002792215,0.00009930185,0.0002346539,0.00056490354,0.001852251,0.000024048937,0.00052345335,0.00058294955,0.0000016083075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014390807,0.008017342,0.17161812,0.0006349144,0.0009295562,0.00012056319,0.021724734,0.0000065972813,0.7189215,0.0007487838,0.016208922,0.05962989],"study_design_scores_gemma":[0.02813104,0.011229131,0.05506806,0.00018981722,0.0007145712,0.0007660071,0.023360457,0.0016557372,0.67988944,0.0013545741,0.19725573,0.00038545343],"about_ca_topic_score_codex":0.00030014242,"about_ca_topic_score_gemma":0.00009250559,"teacher_disagreement_score":0.18104681,"about_ca_system_score_codex":0.00013931248,"about_ca_system_score_gemma":0.00055574306,"threshold_uncertainty_score":0.6824696},"labels":[],"label_agreement":null}]}